false true false true true true true false false false false 1 0.05 1 1 0001817640 3,140,000 3,140,000 --12-31 FY 2024 0.05 1 1 1 3 1.00 TX

 brzh: PublicRelationsAgreementMember
 brzh: GatewayGroupIncMember

 2024-02-29

 brzh: ConsultantMember

 us-gaap: OverAllotmentOptionMember
 brzh: RepresentativeMember

 brzh: SPACExtensionFundsMember

 brzh: DirectWorkingCapitalMember

 2023-04-01
 2023-04-01

 2023-10-01
 2023-10-01

 2023-10-01

 2023-02-23

 2023-01-25

 2022-12-26

 2022-11-26

 2022-09-26

 2022-10-26

 2023-06-26

 2023-05-25

 2023-08-28

 2023-08-02

 2023-04-25

 us-gaap: SubsequentEventMember

 2025-03-11
 2025-03-11

 us-gaap: SubsequentEventMember

 2025-03-11

 2025-03-11

 brzh: MergerProxyBusinessCombinationRateAgreementMember
 brzh: GatewayGroupIncMember

 2024-10-30

 brzh: LegalServicesEngagementLetterMember
 brzh: WooleryAndCoMember

 brzh: WooleryAndCoMember
 brzh: LegalServicesEngagementLetterMember

 2022-08-30
 2022-08-30

 brzh: MilestoneEventTwoMember
 srt: MinimumMember

 brzh: MilestoneEventTwoMember

 brzh: MilestoneEventOneMember

 2022-09-11
 2022-09-11

 brzh: MilestoneEventOneMember

 brzh: MilestoneEventPeriodMember

 2022-02-18

 2021-11-19

 brzh: IBankersAndNorthlandMember

 brzh: PubcoOrdinarySharesMember

 brzh: YDBiopharmaCommonStockMember

 brzh: BreezeCommonStocksMember

 brzh: RepresentativeFounderSharesMember

 2020-07-15

 2023-09-27
 2023-09-27

 2023-03-30
 2023-03-30

 brzh: CommonStockSubjectToPossibleRedemptionMember

 2024-12-26

 brzh: ProxySolicitationServicesAgreementMember
 brzh: DFKingAndCoIncMember

 2024-10-14

 2024-12-26
 2024-12-26

 2020-11-22
 2020-11-22

 2022-12-31

 2023-01-01

 2023-03-29
 2023-03-29

 2023-03-29

 2024-08-21

 2022-09-13
 2022-09-13

 us-gaap: AdditionalPaidInCapitalMember

 brzh: CommonStockSubjectToPossibleRedemptionMember

 us-gaap: AdditionalPaidInCapitalMember

 2022-12-31

 us-gaap: MeasurementInputExpectedDividendRateMember

 2023-01-01

 2022-10-01
 2022-10-01

 srt: DirectorMember

 2023-03-22

 2020-06-01
 2020-06-30

 2022-02-01

 us-gaap: FairValueInputsLevel2Member

 us-gaap: FairValueInputsLevel2Member

 2022-10-01

 us-gaap: MeasurementInputSharePriceMember

 us-gaap: MeasurementInputExpectedTermMember

 us-gaap: FairValueInputsLevel2Member

 us-gaap: FairValueInputsLevel2Member

 2022-12-31

 2020-07-15

 us-gaap: WarrantMember

 us-gaap: MeasurementInputRiskFreeInterestRateMember

 2023-03-30

 us-gaap: RelatedPartyMember

 brzh: RepresentativeAndConsultantMember

 2022-09-13

 srt: DirectorMember

 us-gaap: OverAllotmentOptionMember

 brzh: PrivatePlacementWarrantMember

 brzh: IPOIncludingOverAllotmentOptionMember

 brzh: RepresentativeAndConsultantMember

 us-gaap: OverAllotmentOptionMember

 us-gaap: AdditionalPaidInCapitalMember

 2022-12-31

 us-gaap: RelatedPartyMember

 brzh: CommonStockSubjectToPossibleRedemptionMember

 brzh: PrivatePlacementWarrantMember

 2024-07-01

 us-gaap: MeasurementInputExercisePriceMember

 us-gaap: RightsMember

 us-gaap: MeasurementInputPriceVolatilityMember

 2024-03-01

 2024-03-01
 2024-03-01

 2023-01-01

 2023-04-01

 2022-02-01
 2022-02-01

 2024-07-01
 2024-07-01

 2023-01-01

 2023-03-22
 2023-03-22

 2020-07-15
 2020-07-15

 brzh: Director

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2024

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to

 (Exact name of registrant as specified in its charter)

 Delaware

 001-39718

 85-1849315

 (State or other jurisdiction of
incorporation or organization)

 (Commission File Number)

 (I.R.S. Employer
Identification Number)

 955 W. John Carpenter Fwy., Suite 100-929

 Irving, TX 75039

 75039

 (Address of principal executive offices)

 (Zip Code)

 Registrant's telephone number, including area code: (888) 273-9001

 Not Applicable

 (Former name or former address, if changed since last report)

 Securities registered pursuant to Section 12(b) of the Act:

 Title of Each Class:

 Trading Symbol:

 Name of Each Exchange on Which Registered:

 Common Stock, par value $0.0001 per share

 BRZH

 OTCQX Best Market

 Rights exchangeable into one-twentieth of one share of common stock

 BRZHR

 OTCQX Best Market

 Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per whole share

 BRZHW

 OTCQX Best Market

 Securities registered pursuant to Section 12(g) of the Act: None

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer, "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 As of June 28, 2024, the last business
day of the registrant's most recently completed second fiscal quarter, the
registrant's common stock was not listed on an exchange or actively traded due
to the registrant's delisting from the NASDAQ on May 29, 2024. Due
to the delisting, we are unable to calculate the aggregate market value of the
common stock outstanding as of such date. The registrant commenced trading on
the OTCQX on August 21, 2024. The aggregate market value of the common
stock outstanding, other than shares held by persons who may be deemed
affiliates of the registrant, computed by reference to the closing sales price
for the shares of common stock on August 21, 2024, as reported on the OTCQX,
was $ 10,009,574 (based on the closing sales price of the common stock on
August 21, 2024 of $ 11.20.

 As of March 11, 2025, 3,412,103 shares of common stock, par value $0.0001, were issued and outstanding.

 Page

 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 iii

 Item 1

 Business

 Item 1.A.

 Risk Factors

 Item 1.B.

 Unresolved Staff Comments

 Item 1.C

 Cybersecurity

 Item 2.

 Properties

 Item 3.

 Legal Proceedings

 Item 4.

 Mine Safety Disclosures

 Item 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6.

 [Reserved]

 Item 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A.

 Quantitative and Qualitative Disclosures About Market Risk

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information.

 Item 9C.

 Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accountant Fees and Services

 Item 15.

 Exhibits and Financial Statement Schedules

 Item 16.

 Form 10-K Summary

 i

 CERTAIN TERMS

 Unless otherwise stated in this Annual Form 10-K (this "Report"), or the context otherwise requires, references to:

 •

 "common stock" is to our common stock;

 •

 "founder shares" are to shares of our common stock initially purchased by our sponsor in a private placement prior to our Initial Public Offering;

 •

 "Initial Public Offering" refers to the Initial Public Offering closed on November 25, 2020 (the "Closing Date")

 •

 "initial stockholders" are to our holders of our founder shares prior to our Initial Public Offering (or their permitted transferees);

 •

 "management" or our "management team" are to our officers and directors;

 •

 "private placement warrants" are to the warrants issued to our sponsor and I-Bankers Securities, Inc. ("I-Bankers") in a private placement simultaneously with the closing of our Initial Public Offering;

 •

 "public shares" are to shares of our common stock sold as part of the units in our Initial Public Offering (whether they were purchased in our Initial Public Offering or thereafter in the open market);

 •

 "public stockholders" are to the holders of our public shares, including our initial stockholders and management team to the extent our initial stockholders and/or members of our management team purchase public shares, provided that each initial stockholder's and member of our management team's status as a "public stockholder" shall only exist with respect to such public shares;

 •

 "public warrants" are to our redeemable warrants sold as part of the units in our Initial Public Offering (whether they were purchased in our Initial Public Offering or thereafter in the open market), and to any private placement warrants or warrants issued upon conversion of working capital loans that are sold to third parties that are not our sponsor or executive officers or directors (or permitted transferees) following the consummation of our initial business combination;

 •

 "sponsor" is to Breeze Sponsor, LLC, a Delaware limited liability company formed by our chairman and chief executive officer;

 •

 "warrants" are to our redeemable warrants, which includes the public warrants as well as the private placement warrants to the extent they are no longer held by the initial purchasers of the private placement warrants or their permitted transferees;

 •

 "rights" are to the rights; and

 •

 "Breeze," "we," "us," "company" or "our company" are to Breeze Holdings Acquisition Corp.

 ii

 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 This Report, including, without limitation, statements under the heading "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations," includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"). These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our ability to consummate any acquisition or other business combination and any other statements that are not statements of current or historical facts. These statements are based on management's current expectations, but actual results may differ materially due to various factors, including, but not limited to:

 •

 our ability to complete any initial business combination;

 •

 our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

 •

 our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;

 •

 our potential ability to obtain additional financing to complete our initial business combination;

 •

 our pool of prospective target businesses;

 •

 the ability of our officers and directors to generate a number of potential investment opportunities;

 •

 our public securities' potential liquidity and trading;

 •

 the lack of a market for our securities;

 •

 the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;

 •

 the trust account not being subject to claims of third parties; or

 •

 our financial performance following our Initial Public Offering.

 The forward-looking statements contained in this Amendment are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors." Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described under "Risk Factors" may not be exhaustive.

 By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Amendment. In addition, even if our results or operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods.

 iii

 ITEM 1. BUSINESS

 Overview

 We are a blank check company incorporated on June 11, 2020 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Report as our initial business combination. We have elected to pursue an acquisition in the defense technology industry.

 On October 31, 2022, Breeze Holdings Acquisition Corp. ("Breeze") entered into the Original
Merger Agreement, by and among Breeze, BH Velocity Merger Sub, Inc. ("Company
Merger Sub"), and TV Ammo, Inc., an advanced technology manufacturing and
licensing company focused on revolutionizing the global ammunition and weapons
industry through the introduction of its composite-cased ammunition, innovative
weapons systems and advanced manufacturing technology ("TV Ammo"). On
February 14, 2024, Breeze entered into an Amended and Restated Merger Agreement
and Plan of Reorganization (the "A&R Merger Agreement"), by and among
Breeze, True Velocity, Inc. ("True Velocity"), Breeze Merger Sub,
Inc. ("Parent Merger Sub"), Company Merger Sub, and TV Ammo, which
amended and restated the Original Merger Agreement in its entirety.

 On August 5, 2024, the A&R Merger Agreement was
terminated by written notice from TV Ammo. As a result of the
termination, the Company is no longer pursuing a business Combination with TV
Ammo.

 On May 24, 2024, the Company received written notice
(the "Notice Letter") from the Panel indicating that the Panel had determined
to delist our securities from The Nasdaq Stock Market LLC ("Nasdaq") and that
trading in our securities would be suspended at the open of trading on May 29,
2024, due to our failure to satisfy the terms of the Panel's Decision. Pursuant
to the terms of the Decision, amongst other things, we were required to close
our initial business combination, with the new entity demonstrating compliance
with the initial listing criteria set forth in Nasdaq Listing Rule 5500 on or before May 28, 2024. On May 24, 2024, we
notified the Panel that we would not be able to close our initial business
combination by the Panel's May 28, 2024 deadline. Accordingly, the Panel
determined to delist our securities from Nasdaq as set forth in the Notice
Letter.

 On August 21, 2024, the Company's common stock and warrants began trading, and on August 23, 2024 the Company's rights began trading on the OTCQX Best Market under the symbols "BRZH", "BRZHW" and "BRZHR".

 On September 24, 2024, Breeze Holdings Acquisition
Corp., a Delaware corporation ("Breeze" or "Parent"), entered into a
Merger Agreement and Plan of Reorganization (the "Merger Agreement"), by and
among (i) Breeze, (ii) a Cayman Islands exempted company and wholly-owned
subsidiary of Parent named "YD Bio Limited," (f/k/a True Velocity, Inc., a
wholly-owned subsidiary of Breeze) which name was changed to YD Bio Limited on
November 18, 2024, which will enter into a joinder to the Merger Agreement
("Pubco"), (iii) Breeze Merger Sub, Inc., a Delaware corporation and which
is a direct, wholly-owned subsidiary of Pubco ("Parent Merger Sub"), (iv) a
Cayman Islands exempted company which will be a wholly-owned subsidiary of
Pubco, expected to be named "BH Biopharma Merger Sub Limited," and once formed,
will enter into a joinder to the Merger Agreement ("Company Merger Sub," with
Company Merger Sub and Parent Merger Sub together referred to herein as the
"Merger Subs"), and (v) YD Biopharma Limited, a Cayman Islands exempted company
("YD Biopharma"). YD Biopharma is the operating company of the target.
Capitalized terms used herein and not defined shall have the meaning attributed
to them in the Merger Agreement. The Merger Agreement and the transactions
contemplated thereby were approved by the boards of directors of each of Breeze
and YD Biopharma.

 The aggregate
 consideration to be received by the equity holders of YD Biopharma
 is based on a pre-transaction equity value of $647,304,110. In accordance with the terms and subject
 to the conditions of the Merger Agreement, at the Company
 Merger Effective Time, each issued and outstanding ordinary share
 of YD Biopharma shall
 be cancelled and converted into a number of Pubco Ordinary Shares based on that Exchange
 Ratio described below. The Exchange
 Ratio will be equal to (i) $647,304,110, divided by (ii) the number of fully-diluted shares of YD Biopharma Common Stock outstanding as of the Closing, further divided by (iii) an assumed value of Pubco Ordinary Shares of
10.00 per share.

 Our management team has extensive experience in taking companies public, acquisitions, divestitures, corporate sales, and equity and debt capital markets transactions. Additionally, our management team has well-established banking relationships and procured several billion dollars of committed capital in connection with prior investments. Our team has experience investing across a variety of commodity price cycles and a track record of identifying high quality assets and businesses with significant resources, capital and optimization potential.

 In addition, our management team has an intense focus on cost management which we believe will translate into meaningful reductions in overall capital and operating costs. Our management team has consistently demonstrated their commitment to cost management. At EXCO Resources, Inc. ("EXCO"), for example, Dr. Ramsey and Messrs. Griffin and Ross were able to significantly improve EXCO's drilling and development costs and operating costs through renegotiated rig rates and operating efficiencies.

 Prior to our initial public offering, 13.9 % of our common stock was held by I-Bankers Securities, Inc. I-Bankers is a global provider of financial and advisory services. I-Bankers' main business focus is generating returns to investors and stockholders by providing a diversified range of services to clients. I-Bankers acts on behalf of institutional, corporate and retail clients and counterparties around the world.

 I-Bankers comprises advisory, capital raising and principal investing capabilities. The firm provides varied services to corporate, financial sponsor and government clients involved in mergers and acquisitions, debt and equity fund raising, corporate restructuring, and project finance. In the United States, I-Bankers has specialist sector expertise and a comprehensive advisory and capital markets platform.

 The past performance of the members of our management team, I-Bankers, or their affiliates is not a guarantee that we will be able to identify a suitable candidate for our initial business combination or of success with respect to any business combination we may consummate. You should not rely on the historical record of the performance of our management team, I-Bankers, or their affiliates as indicative of our future performance. None of our directors have any past experience with any blank check companies or special purpose acquisition companies. In addition, such parties may have conflicts of interest with other entities for which a conflict of interest may or does exist between such persons and the company, as well as the priority and preference that such entity has with respect to performance of obligations and presentation of business opportunities to us, please refer to the table and subsequent explanatory paragraph under "Item 10. Directors, Executive Officers and Corporate Governance—Conflicts of Interest".

 Business Operations

 As of December 31, 2024, the Company had not commenced any operations. All activity through December 31, 2024 relates to the Company's formation, the Initial Public Offering ("Initial Public Offering"), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering and from changes in the fair value of its warrant liability.

 The registration statement for the Company's Initial Public Offering was declared effective on November 23, 2020. On November 25, 2020, the Company consummated the Initial Public Offering of 11,500,000 units (the "Units" and, with respect to the shares of common stock included in the Units sold, the "Public Shares"), generating gross proceeds of $ 115,000,000.

 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,425,000 warrants (the "Private Placement Warrants") at a price of $ 1.00 per Private Placement Warrant in a private placement to Breeze Sponsor, LLC, a Delaware limited liability company (the "Sponsor") and I-Bankers Securities, Inc, generating gross proceeds of $ 5,425,000.

 Following the closing of the Initial Public Offering on November 25, 2020, an amount of $ 115,000,000 ($ 10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and $ 1,725,000 from the sale of the Private Placement Warrants was placed in a trust account (the "Trust Account") and invested in U.S. government securities, within the meaning set forth in Section 2 (a)( 16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2 a- 7 of the Investment Company Act of 1940, as amended (the "Investment Company Act"), as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account to the Company's stockholders, as described below.

 Transaction costs incurred in connection with the Initial Public Offering amounted to $ 4,099,907, consisting of $ 2,300,000 of underwriting fees, $ 1,322,350 of representative share offering costs, and $ 477,577 of other offering costs. As of December 31, 2024, cash of $ 101,674 was held outside of the Trust Account and was available for working capital purposes.

 The Company's management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete an initial Business Combination having an aggregate fair market value of at least 80 % of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable) at the time of the agreement to enter into the initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50 % or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

 The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then in the Trust Account (initially $ 10.15 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. There will be no redemption rights upon the completion of a Business Combination with respect to the Company's warrants.

 The Company will proceed with a business combination only if the Company has net tangible assets of at least $5,000,001 upon such consummation of a business combination unless a stockholder proposal to approve an amendment
to the Company's Amended and Restated Certificate of Incorporation to eliminate
the limitation is approved and, if a majority of the outstanding shares voted are voted in favor of the business combination. If a stockholder vote is not required and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission ("SEC") and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a business combination. If the Company seeks stockholder approval in connection with a business combination, the Company's Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased by it during or after the Initial Public Offering in favor of approving a business combination. Additionally, each public stockholder may elect to redeem their Public Shares, regardless of whether they vote for or against a business combination.

 If the Company seeks stockholder approval of a business combination and it does not conduct redemptions pursuant to the tender offer rules, the Company's Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a "group" (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), will be restricted from seeking redemption rights with respect to 10 % or more of the Public Shares, without the Company's prior written consent.

 The Sponsor has agreed (a) to waive its redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and (b) to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination by November 25, 2021 (which can be extended up to 6 months) and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company's obligation to allow redemption in connection with the Company's initial Business Combination or to redeem 100 % of its Public Shares if the Company does not complete a business combination or (ii) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.

 On November 22, 2021, the Company announced that its sponsor, Breeze Sponsor, LLC, timely deposited an aggregate of $ 1,150,000 (the "Extension Payment"), representing $ 0.10 per public share, into the Trust Account to extend the date by which the Company has to consummate a business combination from November 25, 2021 to February 25, 2022. On February 22, 2022, the Company announced that its sponsor, Breeze Sponsor, LLC, timely deposited an aggregate of $ 1,150,000 (the "Second Extension Payment"), representing $ 0.10 per public share, into the Trust Account to extend the date by which the Company has to consummate a business combination from February 25, 2022 to May 25, 2022. The Sponsor loaned the Extension Payment and Second Extension Payment to the Company in exchange for promissory notes in the amount of the Extension Payment and Second Extension Payment. The loans under the promissory notes are non-interest bearing and will be repaid upon the consummation of a business combination. The Company's stockholders are not entitled to vote on or redeem their shares in connection with such extensions.

 On May 5, 2022, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to September 26, 2022 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.35 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 6,732,987 shares of the Company's common stock were redeemed for $ 69,700,628 (the "Redemption") with 7,907,013 shares of common stock remaining outstanding after Redemption; 4,767,013 of the 7,907,013 shares of common stock remaining outstanding after redemption (the "Public Shares") were owned by the public stockholders. On May 10, 2022, $ 109,000 was withdrawn from the Trust Account for payment of franchise and income taxes.

 On September 13, 2022, the Company held its annual stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a business combination Agreement to March 26, 2023 was approved. The Company provided its stockholders with the opportunity to redeem all or a portion of their Public Shares at the time of this stockholders' meeting. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.35 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 3,076,817 shares of the Company's common stock were redeemed for $ 31,845,056, with 4,830,196 shares of common stock remaining outstanding after Redemption; 1,690,196 of the 4,830,196 shares of common stock remaining outstanding after redemption (the "Public Shares") are owned by the public stockholders. O n September 8, 2022, $ 122,247 was withdrawn from the Trust Account for payment of franchise and income taxes.

 Following the payment for redemptions on September 22, 2022, resulting from the Company's annual stockholders' meeting held on September 13, 2022, approximately $ 17.5 million remained on deposit in our Trust Account.

 At the annual meeting of the Company held on September 13, 2022, the Company's stockholders approved (i) a proposal to amend the Company's Amended and Restated Certificate of Incorporation (the "A&R COI") to authorize the Company to extend the date of September 26, 2022, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as March 26, 2023) by which the Company must (a) consummate a merger, capital stock exchange, asset, stock purchase, reorganization or other similar business combination, which we refer to as our initial business combination, or (b) cease its operations except for the purpose of winding up if it fails to complete such initial business combination, and redeem all of the shares of common stock of the Company included as part of the units sold in the Company's initial public offering that was consummated on November 25, 2020, and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. The amended Trust Agreement authorizes the Company's Board of Directors to extend the time to complete the Business Combination up to six ( 6) times for an additional one ( 1) month each time (for a maximum of six one -month extensions), upon the deposit into the Trust Account of $ 0.035 for each outstanding public share by the Sponsor or its designees on or prior to September 26, 2022 or such other date as may be extended. Breeze executed its first one month extension of September 26, 2022 depositing $ 59,157 in the Trust Account. On October 21, 2022, November 23, 2022 and December 20, 2022 Breeze executed the second, third and fourth one month extensions depositing $ 59,157 in the Trust Account for each monthly extension through January 26, 202 3. On January 25, 2023 and February 2 3, 2023 Breeze executed the fifth and sixth one month extensions depositing $ 59,157 in the Trust Account for each monthly extension through March 26, 202 3. The Company scheduled a meeting of its stockholders for March 22, 2023 to consider (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of March 26, 202 3, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as September 26, 2023).

 On March 22, 2023, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to September 26, 2023 was approved. The Company provided its stockholders with the opportunity to redeem all or a portion of their Public Shares at the time of this stockholders' meeting. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.56 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 509,712 shares of the Company's common stock were redeemed for $ 5,395,929, with 4,320,484 shares of common stock remaining outstanding after Redemption; 1,180,484 of the 4,320,484 shares of common stock remaining outstanding after redemption (the "Public Shares") are owned by the public stockholders.

 Following the payment for redemptions on March 29, 2023, resulting from the Company's annual stockholders' meeting held on March 22, 2023, approximately $ 12.5 million remained on deposit in our Trust Account.

 At the meeting of the Company held on March 22, 2023, the Company's stockholders approved (i) a proposal to amend the Company's Amended and Restated Certificate of Incorporation (the "A&R COI") to authorize the Company to extend the date of March 26, 2023, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as September 26, 2023) by which the Company must (a) consummate a merger, capital stock exchange, asset, stock purchase, reorganization or other similar business combination, which we refer to as our initial business combination, or (b) cease its operations except for the purpose of winding up if it fails to complete such initial business combination, and redeem all of the shares of common stock of the Company included as part of the units sold in the Company's initial public offering that was consummated on November 25, 2020, and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. The amended Trust Agreement authorizes the Company's Board of Directors to extend the time to complete the Business Combination up to six ( 6) times for an additional one ( 1) month each time (for a maximum of six one -month extensions), upon the deposit into the Trust Account of $ 0.035 for each outstanding public share by the Sponsor or its designees on or prior to September 26, 2023 or such other date as may be extended. On March 29, 2023, April 25, 2023, May 25, 2023, June 26, 2023, August 3, 2023, and August 28, 2023, Breeze executed the seventh, eighth, ninth, tenth, eleventh and twelfth one -month extensions through September 26, 2023.

 On September 22, 2023, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to June 26, 2024 was approved. The Company provided its stockholders with the opportunity to redeem all or a portion of their Public Shares at the time of this stockholders' meeting. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($10.77 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 21,208 shares of the Company's common stock were redeemed for $228,410, with 4,299,276 shares of common stock remaining outstanding after Redemption; 1,159,276 of the 4,299,276 shares of common stock remaining outstanding after redemption (the "Public Shares") are owned by the public stockholders.

 Following the payment for redemptions on September 25, 2023, resulting from the Company's stockholders' meeting held on September 22, 2023, approximately $12.5 million remained on deposit in our Trust Account.

 T he Company held a meeting of its stockholders on September 22, 2023, the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of September 26, 2023, up to nine ( 9) times for an additional one ( 1) month each time (ultimately until as late as June 26, 2024), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On September 27, 2023, October 24. 2023, November 27, 2023, December 27, 2023, January 26, 2024, February 27, 2024, March 26, 2024, May 7, 2024 and June 3, 2024 Breeze executed the thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty-first one -month extensions through June 26, 2024.

 The Company held
a meeting of its stockholders on June 21, 2024 where the Company's stockholders
approved (i) a proposal to amend the Company's A&R COI to authorize
the Company to extend the date of June 26, 2024, up to six (6) times
for an additional one (1) month each time (ultimately until as late as
December 26, 2024), and (ii) a proposal to amend the Trust Agreement to
authorize the Extension and its implementation by the Company. For each one-month extension
the Company deposited $31,280 ($0.035 per share) into the Trust Account. On June 26, 2024
and August 1, 2024, Breeze executed the twenty-second and twenty-third
extensions, and on November 22, 2024, Breeze executed (including accrued
interest) the twenty-fourth, twenty-fifth and twenty-sixth one-month extensions
for the period from September 26, 2024 through November 26, 2024.

 On December 23, 2024, the Company held a
stockholders' meeting at which a proposal to approve the extension of time to
consummate the closing of a Business Combination Agreement to June 26, 2025,
was approved. The Company, as with all previous extensions, provided its stockholders with the opportunity to
redeem all or a portion of their Public Shares at the time of this
stockholders' meeting. The stockholders who elected to redeem their shares did
so for a pro rata portion of the amount then in the Trust Account ($11.295 per
share), plus any pro rata interest earned on the funds held in the Trust
Account and not previously released to the Company to pay its tax obligations.
On January 2, 2025, $7,353,424 was paid to stockholders in
conjunction with the redemptions from our Special Shareholders Meeting held on
December 23, 2024, redeeming 621,609 shares of the Company's
common stock, with 3,412,103 shares of common
stock remaining outstanding after Redemption; 272,103 of the 3,412,103 shares
of common stock remaining outstanding after redemption (the "Public Shares")
are owned by the public stockholders. The public stockholders will continue to
have the opportunity to redeem all or a portion of their Public Shares upon the
completion of an initial business combination at a per-share price, payable in
cash, equal to the aggregate amount on deposit in the Trust Account as of two
business days prior to the consummation of the initial business combination,
including interest (which interest shall be net of taxes payable) divided by
the number of then outstanding public shares, subject to the limitations
described herein. On January 2, 2025, the Company
executed the twenty-seventh and twenty-eighth one-month extensions for the
period from November 26, 2024 to January 26, 2025.

 In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below ( 1) $ 11.505 per Public Share or ( 2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and will not apply to any claims under the Company's indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company's independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 Termination of Proposed Business Combination with TV Ammo

 On October 31, 2022, Breeze entered into the Original Merger Agreement, by and among
Breeze, BH Velocity Merger Sub, Inc. ("Company Merger Sub"), and TV Ammo, Inc.,
an advanced technology manufacturing and licensing company focused on
revolutionizing the global ammunition and weapons industry through the
introduction of its composite-cased ammunition, innovative weapons systems and
advanced manufacturing technology ("TV Ammo"). On February 14, 2024, Breeze
entered into an Amended and Restated Merger Agreement and Plan of
Reorganization (the "A&R Merger Agreement"), by and among Breeze, True
Velocity, Inc. ("True Velocity"), Breeze Merger Sub, Inc.
("Parent Merger Sub"), Company Merger Sub, and TV Ammo, which amended
and restated the Original Merger Agreement in its entirety.

 On August 5, 2024, the A&R Merger Agreement was
terminated by written notice from TV Ammo. As a result of the
termination, the Company is no longer pursuing a business Combination with TV
Ammo.

 Proposed Business Combination with YD Biopharma

 On September 24, 2024, Breeze Holdings
Acquisition Corp., a Delaware corporation ("Breeze"), entered into a Merger
Agreement and Plan of Reorganization (the "Merger Agreement"), by and among (i)
Breeze, (ii) a Cayman Islands exempted company and wholly-owned subsidiary of
Parent expected to be named "YD Bio Limited," which is in the process of being
formed, and once formed will enter into a joinder to the Merger Agreement
("Pubco"), (iii) Breeze Merger Sub, Inc., a Delaware corporation and which will
be a direct, wholly-owned subsidiary of Pubco ("Parent Merger Sub"), (iv) a
Cayman Islands exempted company which will be a wholly-owned subsidiary of
Pubco, expected to be named "BH Biopharma Merger Sub Limited," and once formed,
will enter into a joinder to the Merger Agreement ("Company Merger Sub," with
Company Merger Sub and Parent Merger Sub together referred to herein as the
"Merger Subs"), and (v) YD Biopharma Limited, a Cayman Islands exempted company
("YD Biopharma"). Capitalized terms used herein and not defined shall have the
meaning attributed to them in the Merger Agreement.

 The Merger Agreement and the
transactions contemplated thereby were approved by the boards of directors of
each of Breeze and YD Biopharma.

 Pursuant to and in accordance with
the terms set forth in the Merger Agreement, (a) Parent Merger Sub will merge
with and into Breeze, with Breeze continuing as the surviving entity (the
"Parent Merger"), as a result of which, (i) Breeze will become a wholly-owned
subsidiary of Pubco, and (ii) each issued and outstanding security of Breeze
immediately prior to the effective time of the Parent Merger (the "Parent
Merger Effective Time") (other than shares of Breeze common stock that have
been redeemed or are owned by Breeze or any of its direct or indirect
subsidiaries as treasury shares and any Dissenting Parent Shares (as defined in
the Merger Agreement)) shall no longer be outstanding and shall automatically
be cancelled in exchange for the issuance to the holder thereof of a
substantially equivalent security of Pubco (other than the Parent Rights, which
shall be automatically converted into ordinary shares of Pubco), and, (b)
immediately following the consummation of the Parent Merger but on the same day,
Company Merger Sub will merge with and into YD Biopharma, with YD Biopharma
continuing as the surviving entity (the "Company Merger" and, together with the
Parent Merger, the "Mergers"), as a result of which, (i) YD Biopharma will
become a wholly-owned subsidiary of Pubco, and (ii) each issued and outstanding
security of YD Biopharma immediately prior to the effective time of the Company
Merger (the "Company Merger Effective Time") (other than any Cancelled Shares
or Dissenting Shares) shall no longer be outstanding and shall automatically be
cancelled in exchange for the issuance to the holder thereof of a substantially
equivalent security of Pubco. The Mergers and the other transactions
contemplated by the Merger Agreement are hereinafter referred to as the
"Business Combination."

 The Business Combination is expected to
close in April 2025, subject to customary closing conditions, the receipt of
certain governmental approvals and the required approval by the stockholders of
Breeze and YD Biopharma.

 Pursuant to and in accordance with
the terms set forth in the Merger Agreement, at the Parent Merger Effective
Time, (a) each share of Breeze common stock, par value $0.0001 per share
("Breeze Common Stock") outstanding immediately prior to the Parent Merger
Effective Time that has not been redeemed, is not owned by Breeze or any of its
direct or indirect subsidiaries as treasury shares and is not a Dissenting
Parent Share will automatically convert into one ordinary share of Pubco (each,
a "Pubco Ordinary Share"), (b) each Breeze Warrant shall automatically convert
into one warrant to purchase a Pubco Ordinary Share (each, a "Pubco Warrant")
on substantially the same terms and conditions; and (c) each Breeze Right will
be automatically converted into the number of Pubco Ordinary Shares that would
have been received by the holder of such Breeze Right if it had been converted
upon the consummation of a business combination in accordance with Breeze's
organizational documents.

 The aggregate consideration to be
received by the equity holders of YD Biopharma is based on a pre-transaction
equity value of $647,304,110. In accordance with the terms and subject to the
conditions of the Merger Agreement, at the Company Merger Effective Time, each
issued and outstanding ordinary share of YD Biopharma shall be cancelled and
converted into a number of Pubco Ordinary Shares based on that Exchange Ratio
described below. The Exchange Ratio will be equal to (i) $647,304,110, divided
by (ii) the number of fully-diluted shares of YD Biopharma Common Stock
outstanding as of the Closing, further divided by (iii) an assumed value of
Pubco Ordinary Shares of 10.00 per share.

 The parties have agreed to take
actions such that, effective immediately after the Closing of the Business
Combination, Pubco's board of directors shall consist of seven directors,
consisting of two Breeze designees (at least one of whom shall be an "independent
director"), four YD Biopharma designees (at least three of whom shall be
"independent directors"). Additionally, certain current YD Biopharma management
personnel will become officers of Pubco. To qualify as an "independent
director" under the Merger Agreement, a designee shall qualify as "independent"
under the rules of the Nasdaq Stock Market.

 The Merger Agreement contains
representations, warranties and covenants of each of the parties thereto that
are customary for transactions of this type, including, among others, covenants
providing for (i) certain limitations on the operation of the parties'
respective businesses prior to consummation of the Business Combination, (ii)
the parties' efforts to satisfy conditions to consummation of the Business
Combination, including by obtaining any necessary approvals from governmental
agencies (including U.S. federal antitrust authorities and under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR
Act")), (iii) prohibitions on the parties soliciting alternative transactions,
(iv) Pubco preparing and filing a registration statement on Form F-4 with the
Securities and Exchange Commission (the "SEC") and taking certain other actions
to obtain the requisite approval of Breeze's stockholders to vote in favor of
certain matters, including the adoption of the Merger Agreement and approval of
the Business Combination, at a special meeting to be called for the approval of
such matters, and (v) the protection of, and access to, confidential
information of the parties.

 The representations, warranties
and covenants in the Merger Agreement were made solely for the benefit of the
parties to the Merger Agreement and are subject to limitations agreed upon by
the contracting parties, including being qualified by confidential disclosures
made the parties to the Merger Agreement which are not filed publicly and which
are subject to a contractual standard of materiality different from that
generally applicable to stockholders and were used for the purpose of
allocating risk among the parties rather than establishing matters as facts.
Breeze does not believe that these schedules contain information that is
material to an investment decision.

 In addition, Pubco has agreed to adopt
an equity incentive plan, as described in the Merger Agreement.

 The obligations of Breeze, Pubco,
Parent Merger Sub and Company Merger Sub (the "Breeze Parties") and YD
Biopharma to consummate the Business Combination are subject to certain closing
conditions, including, but not limited to, (i) the approval of Breeze's
stockholders, (ii) the approval of YD Biopharma's stockholders, and (iii)
Pubco's Form F-4 registration statement becoming effective.

 In addition, the obligations of
the Breeze Parties to consummate the Business Combination are also subject to
the fulfillment (or waiver) of other closing conditions, including, but not
limited to, (i) the representations and warranties of YD Biopharma being true
and correct to the standards applicable to such representations and warranties
and each of the covenants of YD Biopharma having been performed or complied
with in all material respects, (ii) delivery of certain ancillary agreements
required to be executed and delivered in connection with the Business
Combination, and (iii) no Material Adverse Effect having occurred.

 The obligation of YD Biopharma to
consummate the Business Combination is also subject to the fulfillment (or
waiver) of other closing conditions, including, but not limited to, (i) the
representations and warranties of the Breeze Parties being true and correct to
the standards applicable to such representations and warranties and each of the
covenants of the Breeze Parties having been performed or complied with in all
material respects, and (ii) the shares of Pubco Common Stock issuable in
connection with the Business Combination being listed on the Nasdaq Stock
Market.

 The Merger Agreement may be terminated
under certain customary and limited circumstances prior to the Closing of the
Business Combination, including, but not limited to, (i) by mutual written
consent of Breeze and YD Biopharma, (ii) by Breeze, on the one hand, or YD
Biopharma, on the other hand, if there is any breach of the representations,
warranties, covenant or agreement of the other party as set forth in the Merger
Agreement, in each case, such that certain conditions to closing cannot be
satisfied and the breach or breaches of such representations or warranties or
the failure to perform such covenant or agreement, as applicable, are not cured
or cannot be cured within certain specified time periods, (iii) by either
Breeze or YD Biopharma if the Business Combination is not consummated by April
30, 2025 (which date may be extended by mutual agreement of the parties to the
Merger Agreement), (iv) by either Breeze or YD Biopharma if a meeting of
Breeze's stockholders is held to vote on proposals relating to the Business
Combination and the stockholders do not approve the proposals, and (v) by
Breeze if the YD Biopharma stockholders do not approve the Merger Agreement.

 Under certain circumstances as
described further in the Merger Agreement, if the Merger Agreement is validly
terminated by Breeze, YD Biopharma will pay Breeze a fee equal to the trust
extension payments made by on behalf of Breeze to the trust in connection with
the Business Combination of up to $150,000.

 The Merger Agreement contemplates
that Breeze, Pubco and YD Biopharma shall use their commercially reasonable
efforts to enter into and consummate a subscription with investors related to a
private placement of shares in the Company, Breeze and/or Pubco (the "PIPE
Investment").

 Concurrently with the execution of
the Merger Agreement, Breeze, Pubco, YD Biopharma and the Parent Initial
Stockholders (as defined in the Merger Agreement) entered into an Sponsor
Support Agreement (the "Sponsor Support Agreement"), pursuant to which, among
other things, the Parent Initial Stockholders: (a) agreed to vote all of their
shares of Breeze Common Stock in favor of the Parent Proposals, including the
adoption of the Merger Agreement and the approval of the Transactions; (b)
agreed to vote against any other matter, action, agreement, transaction or
proposal that would reasonably be expected to result in (i) a breach of any of
the Breeze Parties' representations, warranties, covenants, agreements or
obligations under the Merger Agreement or (ii) any of the mutual or YD
Biopharma conditions to the Closing in the Merger Agreement not being
satisfied; (c) (i) waived, subject to and conditioned upon the Closing and to
the fullest extent permitted by applicable law and the Breeze organizational
documents, and (ii) agreed not to assert or perfect, any rights to adjustment
or other anti-dilution protections to which such Breeze Initial Stockholder may
be entitled in connection with the Mergers or the other Transactions; (d)
agreed to take, or cause to be taken, all actions and to do, or cause to be
done, all things reasonably necessary under applicable laws to consummate the
Mergers and the other Transactions on the terms and subject to the conditions
set forth in the Merger Agreement prior to any valid termination of the Merger
Agreement; (e) agreed not to transfer or pledge any of their shares of Breeze
Common Stock, or enter into any arrangement with respect thereto, after the
execution of the Merger Agreement and prior to the Closing Date, subject to certain
customary conditions and exceptions; and (f) waived their rights to redeem any
of their shares of Breeze Common Stock in connection with the approval of the
Parent Proposals.

 Concurrently with the execution of
the Merger Agreement, Breeze, Pubco, YD Biopharma, and certain shareholders of
YD Biopharma representing the requisite votes necessary to approve the Merger
Agreement (the "YD Biopharma Equity Holders") entered into Shareholder Support
Agreements (the "Shareholder Support Agreement"), pursuant to which the YD
Biopharma Equity Holders: (a) agreed to vote in favor of the adoption of the
Merger Agreement and approve the Mergers and the other Transactions to which YD
Biopharma is a party; (b) agreed to waive any appraisal or similar rights they
may have pursuant to Cayman law with respect to the Mergers and the other
Transactions; (d) agreed to vote against any other matter, action, agreement,
transaction or proposal that would reasonably be expected to result in (i) a
breach of any of YD Biopharma's representations, warranties, covenants,
agreements or obligations under the Merger Agreement or (ii) any of the mutual
or the Breeze Parties' conditions to the Closing in the Merger Agreement not
being satisfied; and (e) agreed not to sell, assign, transfer or pledge any of
their YD Biopharma ordinary shares (or enter into any arrangement with respect
thereto) after the execution of the Merger Agreement and prior to the Closing
Date, subject to certain customary conditions and exceptions.

 Concurrently with the execution of
the Merger Agreement, Breeze, Pubco, YD Biopharma, the Parent Initial
Stockholders and certain YD Biopharma Equity Holders entered into a Lock-Up
Agreement (the "Lock-Up Agreement"), pursuant to which the Parent Initial
Stockholders and such YD Biopharma Equity Holders agreed, among other things,
to refrain from selling or transferring their shares of Pubco Common Stock for
a period of eight (8) months following the Closing, subject to early release
(a) of 10% of their shares of Pubco Common Stock if the daily volume weighted
average closing sale price of Pubco Common Stock quoted on the Nasdaq for any
20 trading days within any 30 consecutive trading day period beginning on the
four-month anniversary of the Closing exceeds $12.50 per share, (b) of an
additional 10% of their shares of Pubco Common Stock if the daily volume
weighted average closing sale price of Pubco Common Stock quoted on the Nasdaq
for any 20 trading days within any 30 consecutive trading day period beginning
on the four-month anniversary of the Closing exceeds $15.00 per share; (c) of
all of their shares of Pubco Common Stock upon the occurrence of a Subsequent
Transaction; and (d) upon the determination of the Pubco board of directors
(including a majority of the independent directors) following the six month
anniversary of the Closing Date.

 In accordance with the Merger
Agreement, within thirty (30) days after the execution of the Merger Agreement,
Breeze, the Parent Initial Stockholders, Pubco, and certain YD Biopharma Equity
Holders are expected to enter into a registration rights agreement (the
"Registration Rights Agreement"), pursuant to which Pubco will, among other
things, be obligated to file a registration statement to register the resale of
certain securities of Pubco held by the Parent Initial Stockholders and such YD
Biopharma Equity Holders. The Registration Rights Agreement will also provide
the Parent Initial Stockholders and such YD Biopharma Equity Holders with
"piggy-back" registration rights, subject to certain requirements and customary
conditions.

 Business Strategy & Competitive Strengths

 Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, build a company in North America that complements the experience of our management team and can benefit from their operational expertise and/or executive oversight. Our acquisition strategy leverages our management team's network of potential proprietary and public transaction sources where we believe a combination of our relationships, knowledge and experience could effect a positive transformation or augmentation of existing businesses or properties to improve their overall value proposition.

 We utilized the network and industry experience of our management team and business partners in seeking an initial business combination and employing our acquisition strategy. Over the course of their careers, the members of our management team and their affiliates have developed a broad network of contacts and industry relationships that we believe will serve as a useful source of acquisition opportunities. This network has been developed through our management team's extensive experience. In addition to our industry and lending community relationships, we leverage relationships with management teams of public and private companies, capital market participants, private equity groups, investment banking firms, consultants, restructuring advisers, attorneys and accounting firms, which we believe should provide us with a number of business combination opportunities. Members of our management team are communicating with their networks of relationships to articulate the parameters for our search for a target business and a potential business combination and have identified a target and executed a Business Combination Agreement.

 Acquisition Strategy

 Consistent with this strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. We use these criteria and guidelines in evaluating acquisition opportunities, but we may decide to enter into our initial business combination with a target business that does not meet these criteria and guidelines. We intend to acquire one or more companies that we believe:

 •

 have the ability to generate significant current free cash flow;

 •

 have potential to generate significant growth in shareholder value following our initial business combination;

 •

 are at an inflection point, such as requiring additional management expertise, are able to innovate through new operational techniques and technology, or where we believe we can drive improved financial performance;

 •

 can utilize the extensive networks, operational experience and insights of our management team;

 •

 are fundamentally sound but we believe can achieve better results by leveraging the operating and financial experience of our management team and their affiliates;

 •

 exhibit unrecognized value or other characteristics, desirable returns on capital, and a need for capital to achieve the company's growth strategy, that we believe have been misevaluated by the marketplace based on our analysis and due diligence review; and

 •

 can offer attractive risk-adjusted returns on investments for our stockholders.

 We seek to acquire the target on terms and in a manner that leverage our management team's investing experience. Potential upside from growth in the target business and an improved capital structure will be weighed against any identified downside risks.

 These criteria are not intended to be exhaustive. Any evaluation relating to the merits of the initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management deems relevant. In the event that our initial business combination with a target business does not meet the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our stockholder communications related to our initial business combination, which would be in the form of tender offer documents or proxy solicitation materials that we would file with the SEC.

 In evaluating the target business, we conducted a thorough due diligence review that encompasses, among other things, meetings with incumbent management and employees, document reviews, inspection of facilities, as well as a review of financial and other information that is made available to us. In conducting our due diligence review, we leveraged the experience of members of our management team and I-Bankers on an efficient and cost-effective basis as we deployed them to review matters related to their specific areas of functional expertise.

 We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a company that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm which is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent accounting firm (exclusive of our registered independent public accounting firm) that our initial business combination is fair to our company from a financial point of view.

 Members of our management team, our sponsor and our independent directors directly or indirectly own founder shares and/or private placement warrants following our initial public offering and, accordingly, may have a conflict of interest in determining whether the target business is an appropriate business with which to effectuate our initial business combination. Further, each of our officers and directors may have a conflict of interest with respect to evaluating the particular business combination target if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination.

 Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our business combination. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue.

 Our executive officers are not required to commit any specified amount of time to our affairs, and, accordingly, will have conflicts of interest in allocating management time among various business activities, including identifying potential business combination targets and monitoring the related due diligence.

 Our sponsor and executive officers have agreed, pursuant to a written letter agreement, not to participate in the formation of, or become an officer of, any other blank check company until we have entered into a definitive agreement regarding our initial business combination or we have failed to complete our initial business combination within 18 months after the closing of our initial public offering; provided that this agreement would not prevent our executive officers from serving as directors in other blank check companies.

 Neither I-Bankers nor any of its affiliates has entered into such an agreement, and, accordingly, are not precluded from participating in any other blank check company or from underwriting an offering by any other blank check company.

 Initial Business Combination

 As required by NASDAQ rules, our initial business combination will be approved by a majority of our independent directors. NASDAQ rules also require that we must complete one or more business combinations having an aggregate fair market value of at least 80 % of the value of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable) at the time of our signing a definitive agreement in connection with our initial business combination.

 We anticipate structuring our initial business combination either (i) in such a way so that the post-transaction company in which our public stockholders own shares will own or acquire 100 % of the equity interests or assets of the target business or businesses, or (ii) in such a way so that the post-transaction company owns or acquires less than 100 % of such interests or assets of the target business in order to meet certain objectives of the target management team or stockholders, or for other reasons. However, we will only complete an initial business combination if the post-transaction company owns or acquires 50 % or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the "Investment Company Act". Even if the post-transaction company owns or acquires 50 % or more of the voting securities of the target, our stockholders prior to the initial business combination may collectively own a minority interest in the post-transaction company, depending on valuations ascribed to the target and us in the initial business combination. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock of a target. In this case, we would acquire a 100 % controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our stockholders immediately prior to our initial business combination could own less than a majority of our outstanding shares subsequent to our initial business combination. If less than 100 % of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of NASDAQ's 80 % of fair market value test. If the initial business combination involves more than one target business, the 80 % of fair market value test will be based on the aggregate value of all of the transactions and we will treat the target businesses together as the initial business combination for purposes of a tender offer or for seeking stockholder approval, as applicable.

 Our Business Combination Process

 In evaluating prospective business combinations, we expect to conduct a thorough due diligence review process that may encompass, among other things, a review of historical and projected financial and operating data, meetings with management and their advisors (if applicable), on-site inspection of facilities and assets, discussion with customers and suppliers, legal reviews and other reviews as we deem appropriate.

 We will also leverage our operational and capital allocation experience in order to:

 •

 Assemble a team of industry and financial experts: For each potential transaction, we intend to assemble a team of industry and financial experts to supplement our management's efforts to identify and resolve key issues facing the company. We intend to construct an operating and financial plan which optimizes the potential to grow shareholder value. With extensive experience investing in both healthy and underperforming businesses, we expect that our management will be able to demonstrate to the target business and its stakeholders that we have the resources and expertise to lead the combined company through complex and often turbulent market conditions and provide the strategic and operational direction necessary to grow the business in order to maximize cash flows and improve the overall strategic prospects for the business;

 •

 Conduct rigorous research and analysis: Performing disciplined, bottom-up fundamental research and analysis is core to our strategy, and we intend to conduct extensive due diligence to evaluate the impact that a transaction may have on the target business; and

 •

 Acquire the target company at an attractive price relative to our view of its intrinsic value: Combining rigorous bottom-up analysis as well as input from industry and financial experts, the management team intends to develop its view of the intrinsic value of the potential business combination. In doing so, the management team will evaluate future cash flow potential, relative industry valuation metrics and precedent transactions to inform its view of intrinsic value, with the intention of creating a business combination at an attractive price relative to such view.

 Corporate Information

 Our executive offices are located at 955 W. John Carpenter Fwy., Suite 100 - 929, Irving, TX 75039 and our telephone number is ( 888) 273 - 9001.

 We are an "emerging growth company," as defined in Section 2 (a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

 In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7 (a)( 2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.

 We will remain an emerging growth company until the earlier of ( 1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $ 1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $ 700 million as of the prior June 30, and ( 2) the date on which we have issued more than $ 1.0 billion in non-convertible debt securities during the prior three -year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.

 Status as a Public Company

 We believe our structure will make us an attractive business combination partner to target businesses. As a public company, we offer a target business an alternative to the traditional initial public offering through a merger or other business combination with us. Following an initial business combination, we believe the target business would have greater access to capital and additional means of creating management incentives that are better aligned with stockholders' interests than it would as a private company. A target business can further benefit by augmenting its profile among potential new customers and vendors and aid in attracting talented employees. In a business combination transaction with us, the owners of the target business may, for example, exchange their shares of stock in the target business for our shares of common stock (or shares of a new holding company) or for a combination of our shares of common stock and cash, allowing us to tailor the consideration to the specific needs of the sellers.

 Although there are various costs and obligations associated with being a public company, we believe target businesses will find this method a more expeditious and cost-effective method to becoming a public company than the typical initial public offering. The typical initial public offering process takes a significantly longer period of time than the typical business combination transaction process, and there are significant expenses in the initial public offering process, including underwriting discounts and commissions, marketing and road show efforts that may not be present to the same extent in connection with an initial business combination with us.

 Furthermore, once a proposed initial business combination is completed, the target business will have effectively become public, whereas an initial public offering is always subject to the underwriters' ability to complete the offering, as well as general market conditions, which could delay or prevent the offering from occurring or could have negative valuation consequences. Following an initial business combination, we believe the target business would then have greater access to capital and an additional means of providing management incentives consistent with stockholders' interests and the ability to use its shares as currency for acquisitions. Being a public company can offer further benefits by augmenting a company's profile among potential new customers and vendors and aid in attracting talented employees.

 While we believe that our structure and our management team's backgrounds will make us an attractive business partner, some potential target businesses may view our status as a blank check company, such as our lack of an operating history and our ability to seek stockholder approval of any proposed initial business combination, negatively.

 Financial Position

 As of December 31, 2024, we had approximately $10.5 million held in the trust account of which approximately $7.4 million was paid out on January 2, 2025 in conjunction with the
redemptions from our Special Shareholders Meeting held December 23, 2024. With the funds available, we offer a target business a variety of options such as creating a liquidity event for its owners, providing capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its debt or leverage ratio. Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires. However, we have not taken any steps to secure third party financing and there can be no assurance it will be available to us.

 Effecting Our Initial Business Combination

 We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering and the private placement of the private placement warrants, the proceeds of the sale of our shares in connection with our initial business combination, shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing. We may seek to complete our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.

 If our initial business combination is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination or used for redemptions of our common stock, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.

 We may seek to raise additional funds through a private offering of debt or equity securities in connection with the completion of our initial business combination, and we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts held in the trust account. In addition, we intend to target businesses larger than we could acquire with the net proceeds of our initial public offering and the sale of the private placement warrants, and may as a result be required to seek additional financing to complete such proposed initial business combination. Subject to compliance with applicable securities laws, we would expect to complete such financing only simultaneously with the completion of our initial business combination. In the case of an initial business combination funded with assets other than the trust account assets, our proxy materials or tender offer documents disclosing the initial business combination would disclose the terms of the financing and, only if required by law, we would seek stockholder approval of such financing. There are no prohibitions on our ability to raise funds privately or through loans in connection with our initial business combination. At this time, we are not a party to any arrangement or understanding with any third party with respect to raising any additional funds through the sale of securities or otherwise.

 Sources of Target Businesses

 We anticipate that target business candidates will continue to be brought to our attention from various unaffiliated sources, including investment bankers and investment professionals. Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us by calls or mailings. These sources may also introduce us to target businesses in which they think we may be interested on an unsolicited basis, since many of these sources will have read this Report or the final prospectus relating to our initial public offering and know what types of businesses we are targeting. Our officers and directors, as well as our sponsor and their affiliates, may also bring to our attention target business candidates that they become aware of through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending trade shows or conventions. In addition, we expect to receive a number of proprietary deal flow opportunities that would not otherwise necessarily be available to us as a result of the business relationships of our officers and directors and our sponsor and their respective industry and business contacts as well as their affiliates. While we do not presently anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal basis, we may engage these firms or other individuals in the future, in which event we may pay a finder's fee, consulting fee, advisory fee or other compensation to be determined in an arms-length negotiation based on the terms of the transaction. We will engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management determines is in our best interest to pursue. Payment of finder's fees is customarily tied to completion of a transaction; in which case any such fee will be paid out of the funds held in the trust account. In no event will our sponsor or any of our existing officers or directors, or any entity with which our sponsor or officers are affiliated, be paid any finder's fee, reimbursement, consulting fee, monies in respect of any payment of a loan or other compensation by the company prior to, or in connection with any services rendered for any services they render in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is). Although none of our sponsor, executive officers or directors, or any of their respective affiliates, will be allowed to receive any compensation, finder's fees or consulting fees from a prospective business combination target in connection with a contemplated initial business combination, we do not have a policy that prohibits our sponsor, executive officers or directors, or any of their respective affiliates, from negotiating for the reimbursement of out-of-pocket expenses by a target business. We have agreed to pay an affiliate of our sponsor a total of $ 5,000 per month for office space, utilities and secretarial and administrative support and to reimburse our sponsor for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination. Some of our officers and directors may enter into employment or consulting agreements with the post-transaction company following our initial business combination. The presence or absence of any such fees or arrangements will not be used as a criterion in our selection process of an initial business combination candidate.

 If any of our officers or directors becomes aware of an initial business combination opportunity that falls within the line of business of any entity to which he or she has pre-existing fiduciary or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior to presenting such business combination opportunity to us. Our officers and directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us.

 Lack of Business Diversification

 For an indefinite period of time after the completion of our initial business combination, the prospects for our success may depend entirely on the future performance of a single business. Unlike other entities that have the resources to complete business combinations with multiple entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate the risks of being in a single line of business. In addition, we focus our search for an initial business combination in a single industry. By completing our initial business combination with only a single entity, our lack of diversification may:

 •

 subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and

 •

 cause us to depend on the marketing and sale of a single product or limited number of products or services.

 Limited Ability to Evaluate the Target's Management Team

 Although we intend to closely scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial business combination with that business, our assessment of the target business' management may not prove to be correct. In addition, the future management may not have the necessary skills, qualifications or abilities to manage a public company.

 Furthermore, the future role of members of our management team, if any, in the target business cannot presently be stated with any certainty. The determination as to whether any of the members of our management team will remain with the combined company will be made at the time of our initial business combination. While it is possible that one or more of our directors will remain associated in some capacity with us following our initial business combination, it is unlikely that any of them will devote their full efforts to our affairs subsequent to our initial business combination. Moreover, we cannot assure you that members of our management team will have significant experience or knowledge relating to the operations of the particular target business.

 We cannot assure you that any of our key personnel will remain in senior management or advisory positions with the combined company. The determination as to whether any of our key personnel will remain with the combined company will be made at the time of our initial business combination.

 Following an initial business combination, we may seek to recruit additional managers to supplement the incumbent management of the target business. We cannot assure you that we will have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge or experience necessary to enhance the incumbent management.

 Stockholders May Not Have the Ability to Approve Our Initial Business Combination

 We may conduct redemptions without a stockholder vote pursuant to the tender offer rules of the SEC. However, we will seek stockholder approval if it is required by law or applicable stock exchange rule, or we may decide to seek stockholder approval for business or other legal reasons. Presented in the table below is a graphic explanation of the types of initial business combinations we may consider and whether stockholder approval is currently required under Delaware law for each such transaction.

 Type of Transaction

 Whether Stockholder
Approval Is Required

 Purchase of assets

 No

 Purchase of stock of target not involving a merger with the company

 No

 Merger of target into a subsidiary of the company

 No

 Merger of the company with a target

 Yes

 Under NASDAQ's listing rules, stockholder approval would be required for our initial business combination if, for example:

 •

 we issue shares of common stock that will be equal to or in excess of 20% of the number of shares of our common stock then outstanding (other than in a public offering);

 •

 any of our directors, officers or substantial security holders (as defined by NASDAQ rules) has a 5% or greater interest (or such persons collectively have a 10% or greater), directly or indirectly, in the target business or assets to be acquired or otherwise and the present potential issuance of common stock could result in an increase in outstanding common shares or voting power of 5% or more; or

 •

 the issuance or potential issuance of common stock will result in our undergoing a change of control.

 Permitted Purchases of our Securities

 If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial stockholders, directors, officers, advisors or their affiliates may purchase shares or public warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. There is no limit on the number of shares our initial stockholders, directors, officers, advisors or their affiliates may purchase in such transactions, subject to compliance with applicable law and NASDAQ rules. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material nonpublic information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules.

 Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements. None of the funds held in the trust account will be used to purchase shares or public warrants in such transactions prior to completion of our initial business combination.

 The purpose of any such purchases of shares could be to vote such shares in favor of the initial business combination and thereby increase the likelihood of obtaining stockholder approval of the initial business combination or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. The purpose of any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with our initial business combination. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible. In addition, if such purchases are made, the public "float" of our shares of common stock or warrants may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.

 Our sponsor, officers, directors and/or their affiliates anticipate that they may identify the stockholders with whom our sponsor, officers, directors or their affiliates may pursue privately negotiated purchases by either the stockholders contacting us directly or by our receipt of redemption requests submitted by stockholders following our mailing of proxy materials in connection with our initial business combination. To the extent that our sponsor, officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling stockholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against our initial business combination, whether or not such stockholder has already submitted a proxy with respect to our initial business combination. Our sponsor, officers, directors, advisors or their affiliates will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.

 Any purchases by our sponsor, officers, directors and/or their affiliates who are affiliated purchasers under Rule 10 b- 18 under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule 10 b- 18, which is a safe harbor from liability for manipulation under Section 9 (a)( 2) and Rule 10 b- 5 of the Exchange Act. Rule 10 b- 18 has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. Our sponsor, officers, directors and/or their affiliates will not make purchases of common stock if the purchases would violate Section 9 (a)( 2) or Rule 10 b- 5 of the Exchange Act. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchases are subject to such reporting requirements.

 Redemption Rights for Public Stockholders upon Completion of our Initial Business Combination

 We will provide our public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of the initial business combination including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes, divided by the number of then outstanding public shares, subject to the limitations described herein. As of March 11, 2025, the approximate per share amount in the trust account (excluding interest income) is $ 11.33 per public share. The per-share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to any founder shares and any public shares held by them in connection with the completion of our initial business combination.

 Ability to Extend Time to Complete Business Combination

 We had until 12 months from the closing of our initial public offering to consummate our initial business combination. However, by resolution of our board and at the request by our sponsor, we extended the period of time to 18 months to consummate a business combination exercising two 3 -month extensions. Pursuant to the terms of the trust agreement entered into between us and Continental Stock Transfer & Trust Company, LLC on the date of our initial public offering, in order to extend the time available for us to consummate our initial business combination, our initial stockholders or their affiliates or designees, upon five days advance notice prior to the applicable deadlines, deposited into the trust account for each three -month extension, $ 1,150,000, or $ 0.10 per share, on or prior to the date of the applicable deadline, up to an aggregate of $ 2,300,000, or $ 0.20 per share. At the annual meeting of the Company held on September 13, 2022, the Company's stockholders approved a proposal to amend the Company's Amended and Restated Certificate of Incorporation (the "A&R COI") to authorize the Company to extend the date of September 26, 2022, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as March 26, 2023) upon the deposit into the Trust Account of $ 0.035 for each outstanding public share by the Sponsor or its designees on or prior to September 26, 2022 or such other date as may be extended. Any such payments were made in the form of a loan. Any such loans are non-interest bearing and payable upon the consummation of our initial business combination. If we complete our initial business combination, we will repay such loaned amounts out of the proceeds of the trust account released to us. If we do not complete a business combination, we will not repay such loans. Furthermore, the letter agreement with our initial stockholders contains a provision pursuant to which our sponsor has agreed to waive its right to be repaid for such loans out of the funds held in the trust account in the event that we do not complete a business combination. We issued a press release announcing our intention to extend in both cases at least three days prior to the applicable deadline. In addition, for each extension we issued a press release the day after the applicable deadline announcing that the funds had been timely deposited. Investors do not have the ability to vote or redeem their shares of common stock in connection with either of the three -month extensions. However, if we seek to complete a business combination during an extension period, investors will still be able to vote and redeem their shares of common stock in connection with that business combination.

 Pursuant to the terms and subject to the conditions of the Merger Agreement, Breeze filed with the SEC the Extension Proxy Statement, for the purpose of amending the Breeze organizational documents and the Trust Agreement, in each case, to extend the time period for Breeze to consummate a Business Combination from March 26, 2023 up to September 26, 2023 (the "Extension Proposal"). Breeze filed and distributed the Extension Proxy Statement to solicit proxies thereunder and held a meeting of the stockholders of Breeze to consider, vote on and approve the Extension Proposal on March 22, 2023. Breeze stockholders approved the Extension Proposal and extended the time period for Breeze to consummate a Business Combination from March 26, 2023 up to September 26, 2023.

 Breeze prepared and filed with the SEC the Extension Proxy Statement, for the purpose of amending the Breeze organizational documents and the Trust Agreement, in each case, to extend the time period for Breeze to consummate a Business Combination from September 26, 2023 up to June 26, 2024 (the "Extension Proposal"). Breeze filed and distributed the Extension Proxy Statement to solicit proxies thereunder and held a meeting of the stockholders of Breeze to consider, vote on and approve the Extension Proposal on September 22, 2023. Breeze stockholders approved the Extension Proposal and extended the time period for Breeze to consummate a Business Combination from September 26, 2023 up to June 26, 2024.

 The Company held a meeting of its stockholders
on June 21, 2024 where the Company's stockholders approved (i) a proposal
to amend the Company's A&R COI to authorize the Company to extend the date
of June 26, 2024, up to six (6) times for an additional one (1) month
each time (ultimately until as late as December 26, 2024), and (ii) a proposal
to amend the Trust Agreement to authorize the Extension and its implementation
by the Company.

 Pursuant to the terms and subject to the conditions of the Merger Agreement, on December 23, 2024, the Company held a meeting of its
stockholders on December 23, 2024 where they approved (i) a proposal to amend
the Company's A&R COI to authorize the Company, and (ii) a proposal to
amend the Trust Agreement to authorize and implement by the Company, an
extension in one-month intervals up to June 26, 2025.

 Manner of Conducting Redemptions

 We will provide our public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon the completion of our initial business combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether we will seek stockholder approval of a proposed initial business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek stockholder approval under the law or stock exchange listing requirement. Under NASDAQ rules, asset acquisitions and stock purchases would not typically require stockholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than 20 % of our outstanding common stock or seek to amend our amended and restated certificate of incorporation would require stockholder approval. If we structure an initial business combination with a target company in a manner that requires stockholder approval, we will not have discretion as to whether to seek a stockholder vote to approve the proposed initial business combination. We may conduct redemptions without a stockholder vote pursuant to the tender offer rules of the SEC unless stockholder approval is required by law or stock exchange listing requirements or we choose to seek stockholder approval for business or other legal reasons. So long as we obtain and maintain a listing for our securities on NASDAQ, we are required to comply with such rules.

 If a stockholder vote is not required and we do not decide to hold a stockholder vote for business or other legal reasons, we will, pursuant to our amended and restated certificate of incorporation:

 •

 conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and

 •

 file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.

 Upon the public announcement of our initial business combination, we or our sponsor will terminate any plan established in accordance with Rule 10 b 5 - 1 to purchase shares of our common stock in the open market if we elect to redeem our public shares through a tender offer, to comply with Rule 14 e- 5 under the Exchange Act.

 In the event we conduct redemptions pursuant to the
tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the
Exchange Act, and we will not be permitted to complete our initial business
combination until the expiration of the tender offer period. In addition, unless
a stockholder proposal to approve an amendment to the Company's Amended and
Restated Certificate of Incorporation to eliminate the limitation is approved, the
tender offer will be conditioned on public stockholders not tendering more than
a specified number of public shares which are not purchased by our sponsor,
which number will be based on the requirement that we may not redeem public
shares in an amount that would cause our net tangible assets to be less than $5,000,001 upon consummation of our initial business
combination and after payment of underwriters' fees and commissions (so that we
are not subject to the SEC's "penny stock" rules) or any greater net tangible
asset or cash requirement which may be contained in the agreement relating to
our initial business combination. If public stockholders tender more shares
than we have offered to purchase, we will withdraw the tender offer and not
complete the initial business combination.

 If, however, stockholder approval of the transaction is required by law or stock exchange listing requirement, or we decide to obtain stockholder approval for business or other legal reasons, we will, pursuant to our amended and restated certificate of incorporation:

 •

 conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and

 •

 file proxy materials with the SEC.

 In the event that we seek stockholder approval of our initial business combination, we will distribute proxy materials and, in connection therewith, provide our public stockholders with the redemption rights described above upon completion of the initial business combination.

 If we seek stockholder approval, we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the initial business combination. A quorum for such meeting will consist of the holders present in person or by proxy of shares of outstanding capital stock of the company representing a majority of the voting power of all outstanding shares of capital stock of the company entitled to vote at such meeting. Our initial stockholders will count toward this quorum and pursuant to the letter agreement, our sponsor, officers and directors have agreed to vote their founder shares and any public shares purchased during or after our initial public offering (including in open market and privately negotiated transactions) in favor of our initial business combination. For purposes of seeking approval of the majority of our outstanding shares of common stock voted, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. As a result, in addition to our initial stockholders' founder shares and representative shares, initially we needed to have only 4,187,501, or 36.4 %, of the 11,500,000 public shares sold in our initial public offering to be voted in favor of an initial business combination (assuming all outstanding shares are voted) in order to have our initial business combination approved. As of April 1, 2024, no public shares are required to approve the business combination. We intend to give approximately 30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which a vote shall be taken to approve our initial business combination. These quorum and voting thresholds, and the voting agreements of our initial stockholders, may make it more likely that we will consummate our initial business combination. Each public stockholder may elect to redeem its public shares irrespective of whether they vote for or against the proposed transaction. In addition, our initial stockholders have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of a business combination.

 U nless a stockholder proposal to approve an amendment
to the Company's Amended and Restated Certificate of Incorporation to eliminate
the limitation is approved, o ur amended and restated certificate of incorporation provides that in no event will we redeem our public shares in an amount that would cause our net tangible assets to be less than $ 5,000,001 upon consummation of our initial business combination and after payment of underwriters' fees and commissions (so that we are not subject to the SEC's "penny stock" rules) or any greater net tangible asset or cash requirement which may be contained in the agreement relating to our initial business combination. For example, the proposed initial business combination may require: (i) cash consideration to be paid to the target or its owners, (ii) cash to be transferred to the target for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions in accordance with the terms of the proposed initial business combination. In the event the aggregate cash consideration we would be required to pay for all shares of common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, and all shares of common stock submitted for redemption will be returned to the holders thereof.

 Limitation on Redemption upon Completion of our Initial Business Combination if we Seek Stockholder Approval

 Notwithstanding the foregoing, if we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 10 % of the shares sold in our initial public offering, which we refer to as the "Excess Shares." Such restriction shall also be applicable to our affiliates. We believe this restriction will discourage stockholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to exercise their redemption rights against a proposed initial business combination as a means to force us or our management to purchase their shares at a significant premium to the then-current market price or on other undesirable terms. Absent this provision, a public stockholder holding more than an aggregate of 10 % of the shares sold in our initial public offering could threaten to exercise its redemption rights if such holder's shares are not purchased by us or our management at a premium to the then-current market price or on other undesirable terms. By limiting our stockholders' ability to redeem no more than 10 % of the shares sold in our initial public offering without our prior consent, we believe we will limit the ability of a small group of stockholders to unreasonably attempt to block our ability to complete our initial business combination, particularly in connection with an initial business combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash. However, we would not be restricting our stockholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination.

 Tendering Stock Certificates in Connection with a Tender Offer or Redemption Rights

 We may require our public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to either tender their certificates to our transfer agent prior to the date set forth in the tender offer documents or proxy materials mailed to such holders, or up to two business days prior to the initial vote on the proposal to approve the initial business combination in the event we distribute proxy materials, or to deliver their shares to the transfer agent electronically using the Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) System, at the holder's option. The tender offer or proxy materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public stockholders to satisfy such delivery requirements, which will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. Accordingly, a public stockholder would have from the time we send out our tender offer materials until the close of the tender offer period, or up to two days prior to the vote on the initial business combination if we distribute proxy materials, as applicable, to tender its shares if it wishes to seek to exercise its redemption rights. Given the relatively short exercise period, it is advisable for stockholders to use electronic delivery of their public shares.

 There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge the tendering broker and it would be up to the broker whether or not to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether or not we require holders seeking to exercise redemption rights to tender their shares. The need to deliver shares is a requirement of exercising redemption rights regardless of the timing of when such delivery must be effectuated.

 The foregoing is different from the procedures used by many blank check companies. In order to perfect redemption rights in connection with their business combinations, many blank check companies would distribute proxy materials for the stockholders' vote on an initial business combination, and a holder could simply vote against a proposed initial business combination and check a box on the proxy card indicating such holder was seeking to exercise his or her redemption rights. After the initial business combination was approved, the company would contact such stockholder to arrange for him or her to deliver his or her certificate to verify ownership. As a result, the stockholder then had an "option window" after the completion of the initial business combination during which he or she could monitor the price of the company's stock in the market. If the price rose above the redemption price, he or she could sell his or her shares in the open market before actually delivering his or her shares to the company for cancellation. As a result, the redemption rights, to which stockholders were aware they needed to commit before the stockholder meeting, would become "option" rights surviving past the completion of the initial business combination until the redeeming holder delivered its certificate. The requirement for physical or electronic delivery prior to the meeting ensures that a redeeming holder's election to redeem is irrevocable once the initial business combination is approved.

 Any request to redeem such shares, once made, may be withdrawn at any time up to the date set forth in the tender offer materials or the date of the stockholder meeting set forth in our proxy materials, as applicable. Furthermore, if a holder of a public share delivered its certificate in connection with an election of redemption rights and subsequently decides prior to the applicable date not to elect to exercise such rights, such holder may simply request that the transfer agent return the certificate (physically or electronically). It is anticipated that the funds to be distributed to holders of our public shares electing to redeem their shares will be distributed promptly after the completion of our initial business combination.

 If our initial business combination is not approved or completed for any reason, then our public stockholders who elected to exercise their redemption rights would not be entitled to redeem their shares for the applicable pro rata share of the trust account. In such case, we will promptly return any certificates delivered by public holders who elected to redeem their shares.

 If our proposed initial business combination is not completed, we may continue to try to complete another initial business combination with a different target until 18 months from the closing of our initial public offering.

 Redemption of Public Shares and Liquidation if no Initial Business Combination

 Prior to our proxy extensions voted on May 5, 2022, September 13, 2022, March 22, 2023, September 22, 2023, June 21, 2024 and December 23, 2024, we had only 18 months from the closing of our initial public offering to complete our initial business combination. If we are unable to complete our initial business combination within such 18 -month period, we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $ 100,000 of interest to pay dissolution expenses which interest shall be net of taxes payable), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to our rights or warrants, which will expire worthless if we fail to complete our initial business combination within the 18 -month time period.

 Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares held by them if we fail to complete our initial business combination within 18 months from the closing of our initial public offering. However, if our sponsor, officers or directors acquire public shares in or after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the allotted 18 -month time period.

 Our sponsor, officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering or (ii) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity, unless we provide our public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes divided by the number of then outstanding public shares. However, we may not redeem our public shares in an
amount that would cause our net tangible assets to be less than $ 5,000,001 upon consummation of our initial business
combination and after payment of underwriters' fees and commissions (so that we
are not subject to the SEC's "penny stock" rules) and unless a stockholder proposal to approve an
amendment to the Company's Amended and Restated Certificate of Incorporation to
eliminate the limitation is approved. If this optional redemption
right is exercised with respect to an excessive number of public shares such
that we cannot satisfy the net tangible asset requirement (described above), we
would not proceed with the amendment or the related redemption of our public
shares at such time.

 We expect that all costs and expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining out of the $ 101,674 of proceeds held outside the trust account (as of December 31, 2024), and amounts raised after December 31, 2024, if any, although we cannot assure you that there will be sufficient funds for such purpose. We will depend on sufficient interest being earned on the proceeds held in the trust account to pay any tax obligations we may owe. However, if those funds are not sufficient to cover the costs and expenses associated with implementing our plan of dissolution, to the extent that there is any interest accrued in the trust account not required to pay taxes on interest income earned on the trust account balance, we may request the trustee to release to us an additional amount of up to $ 100,000 of such accrued interest to pay those costs and expenses.

 If we were to expend all of the net proceeds of our initial public offering and the sale of the private placement warrants, other than the proceeds deposited in the trust account, and without taking into account interest, if any, earned on the trust account, the per-share redemption amount received by stockholders upon our dissolution as of June 26, 2025, would be approximately $ 11.505. The proceeds deposited in the trust account could, however, become subject to the claims of our creditors, which would have higher priority than the claims of our public stockholders. We cannot assure you that the actual per-share redemption amount received by stockholders will not be substantially less than $ 11.505. Under Section 281 (b) of the General Corporation Law of Delaware, as amended (the "DGCL"), our plan of dissolution must provide for all claims against us to be paid in full or make provision for payments to be made in full, as applicable, if there are sufficient assets. These claims must be paid or provided for before we make any distribution of our remaining assets to our stockholders. While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors' claims.

 Although we will seek to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account including but not limited to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the trust account. If any third-party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party's engagement would be significantly more beneficial to us than any alternative. Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. Marcum LLP, our independent registered public accounting firm, and the underwriters of our initial public offering will not execute agreements with us waiving such claims to the monies held in the trust account.

 In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ 11.505 per public share and (ii) such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account and except as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then our sponsor will not be responsible to the extent of any liability for such third-party claims. We have not asked our sponsor to reserve for such indemnification obligations, and our sponsor's only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. We believe the likelihood of our sponsor having to indemnify the trust account is limited because we will endeavor to have all vendors and prospective target businesses as well as other entities execute agreements with us waiving any right, title, interest or claim of any kind in or to monies held in the trust account.

 In the event that the proceeds in the trust account are reduced below (i) $ 11.505 per public share or (ii) such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, and our sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so if, for example, the cost of such legal action is deemed by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not likely. We have not asked our sponsor to reserve for such indemnification obligations and we cannot assure you that our sponsor would be able to satisfy those obligations. Accordingly, we cannot assure you that due to claims of creditors the actual value of the per-share redemption price will not be less than $ 11.505 per public share.

 We will seek to reduce the possibility that our sponsor will have to indemnify the trust account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to monies held in the trust account. Our sponsor will also not be liable as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. We will have access to up to $ 101,674 of proceeds held outside the trust account (as of December 31, 2024), and amounts raised after December 31, 2024, if any, with which to pay any such potential claims (including costs and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $ 100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, stockholders who received funds from our trust account could be liable for claims made by creditors.

 Under the DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by them in a dissolution. The pro rata portion of our trust account distributed to our public stockholders upon the redemption of our public shares in the event we do not complete our initial business combination within 18 months from the closing of our initial public offering may be considered a liquidating distribution under Delaware law. If the corporation complies with certain procedures set forth in Section 280 of the DGCL intended to ensure that it makes reasonable provision for all claims against it, including a 60 -day notice period during which any third-party claims can be brought against the corporation, a 90 -day period during which the corporation may reject any claims brought, and an additional 150 -day waiting period before any liquidating distributions are made to stockholders, any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder's pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third anniversary of the dissolution.

 Furthermore, if the pro rata portion of our trust account distributed to our public stockholders upon the redemption of our public shares in the event we do not complete our initial business combination within 18 months from the closing of our initial public offering, is not considered a liquidating distribution under Delaware law and such redemption distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may bring or due to other circumstances that are currently unknown), then pursuant to Section 174 of the DGCL, the statute of limitations for claims of creditors could then be six years after the unlawful redemption distribution, instead of three years, as in the case of a liquidating distribution. If we are unable to complete our initial business combination within 1 8 months from the closing of our initial public offering, we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $ 100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Accordingly, it is our intention to redeem our public shares as soon as reasonably possible following our 18 th month and, therefore, we do not intend to comply with those procedures. As such, our stockholders could potentially be liable for any claims to the extent of distributions received by them (but no more) and any liability of our stockholders may extend well beyond the third anniversary of such date.

 Because we will not be complying with Section 280, Section 281 (b) of the DGCL requires us to adopt a plan, based on facts known to us at such time that will provide for our payment of all existing and pending claims or claims that may be potentially brought against us within the subsequent 10 years. However, because we are a blank check company, rather than an operating company, and our operations will be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, etc.) or prospective target businesses. As described above, pursuant to the obligation contained in our underwriting agreement, we will seek to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account. As a result of this obligation, the claims that could be made against us are significantly limited and the likelihood that any claim that would result in any liability extending to the trust account is remote. Further, our sponsor may be liable only to the extent necessary to ensure that the amounts in the trust account are not reduced below (i) $ 11.505 per public share or (ii) such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case net of the amount of interest withdrawn to pay taxes and will not be liable as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, our sponsor will not be responsible to the extent of any liability for such third-party claims.

 If we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to return $ 11.505 per share to our public stockholders. Additionally, if we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a "preferential transfer" or a "fraudulent conveyance." As a result, a bankruptcy court could seek to recover some or all amounts received by our stockholders. Furthermore, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or may have acted in bad faith, thereby exposing itself and our company to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.

 Our public stockholders will be entitled to receive funds from the trust account only upon the earlier to occur of: (i) the completion of our initial business combination, (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend any provisions of our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity, and (iii) the redemption of all of our public shares if we are unable to complete our business combination within 18 months from the closing of our initial public offering, subject to applicable law. In no other circumstances will a stockholder have any right or interest of any kind to or in the trust account. In the event we seek stockholder approval in connection with our initial business combination, a stockholder's voting in connection with the initial business combination alone will not result in a stockholder's redeeming its shares to us for an applicable pro rata share of the trust account. Such stockholder must have also exercised its redemption rights as described above. These provisions of our amended and restated certificate of incorporation, like all provisions of our amended and restated certificate of incorporation, may be amended with a stockholder vote.

 Competition

 In identifying, evaluating and selecting a target business for our initial business combination, we may encounter competition from other entities having a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout funds, and operating businesses seeking strategic business combinations. Many of these entities are well established and have extensive experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors possess greater financial, technical, human and other resources than we do. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the initial business combination of a target business. Furthermore, our obligation to pay cash in connection with our public stockholders who exercise their redemption rights may reduce the resources available to us for our initial business combination and our outstanding warrants, and the future dilution they potentially represent, may not be viewed favorably by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating an initial business combination.

 Facilities

 Our executive offices are located at 955 W. John Carpenter Fwy., Suite 100 - 929, Irving, TX 75039 and our telephone number is ( 888) 273 - 9001. Our executive offices are provided to us by our sponsor. Commencing on the date our securities were first listed on NASDAQ, we have agreed to pay an affiliate of our sponsor a total of $ 5,000 per month for office space, utilities and secretarial and administrative support. We consider our current office space adequate for our current operations.

 Employees

 We currently have four executive officers. Members of our management team are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the initial business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination.

 Periodic Reporting and Financial Information

 Our common stock, rights and warrants are registered under the Exchange Act and have reporting obligations, including the requirement that we file annual, quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual reports will contain financial statements audited and reported on by our independent registered public accountants.

 We will provide stockholders with audited financial statements of the prospective target business as part of the tender offer materials or proxy solicitation materials sent to stockholders to assist them in assessing the target business. In all likelihood, these financial statements will need to be prepared in accordance with, or reconciled to, GAAP, or IFRS, depending on the circumstances, and the historical financial statements may be required to be audited in accordance with the standards of the PCAOB. These financial statement requirements may limit the pool of potential targets we may conduct an initial business combination with because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy rules and complete our initial business combination within the prescribed time frame. We cannot assure you that any particular target business identified by us as a potential business combination candidate will have financial statements prepared in accordance with GAAP or that the potential target business will be able to prepare its financial statements in accordance with the requirements outlined above. To the extent that these requirements cannot be met, we may not be able to acquire the proposed target business. While this may limit the pool of potential business combination candidates, we do not believe that this limitation will be material.

 We were required to evaluate our internal control procedures for the fiscal years ending December 31, 2024 and 2023 as required by the Sarbanes-Oxley Act. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to have our internal control procedures audited. A target company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business combination.

 We are an "emerging growth company," as defined in Section 2 (a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

 In addition, Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7 (a)( 2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.

 We will remain an emerging growth company until the earlier of ( 1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $ 1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our shares of common stock that are held by non-affiliates exceeds $ 700 million as of the prior June 30, and ( 2) the date on which we have issued more than $ 1.0 billion in non-convertible debt during the prior three -year period.

 Additionally, we are a "smaller reporting company" as defined in Item 10 (f)( 1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which ( 1) the market value of our shares of common stock held by non-affiliates exceeds $ 250 million as of the prior June 30, or ( 2) our annual revenues exceeded $ 100 million during such completed fiscal year and the market value of our shares of common stock held by non-affiliates exceeds $ 700 million as of the prior June 30.

 ITEM 1 A.

 RISK FACTORS

 An investment in our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the other information contained in this Report, before making a decision to invest in our units. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all or part of your investment.

 Summary of Risk Factors

 •

 We may not be able to complete the Business Combination pursuant to the Combination Agreement. If we are unable to do so, we will incur substantial costs associated with withdrawing from the transaction and may not be able to find additional sources of financing to cover those costs.

 •

 We are a newly formed company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.

 •

 Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination.

 •

 If we seek stockholder approval of our initial business combination, our initial stockholders have agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote.

 •

 The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure.

 •

 The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your stock.

 •

 The requirement that we complete our initial business combination within the prescribed time frame may give potential target businesses leverage over us in negotiating an initial business combination and may decrease our ability to conduct due diligence on potential business combination targets as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our stockholders.

 •

 If a stockholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed.

 •

 You will not be entitled to protections normally afforded to investors of many other blank check companies.

 •

 Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on our redemption of our public shares, or less than such amount in certain circumstances, and our warrants will expire worthless.

 •

 If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share.

 •

 Our directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public stockholders.

 •

 We may not hold an annual meeting of stockholders until after the consummation of our initial business combination, which could delay the opportunity for our stockholders to elect directors.

 •

 Because we are neither limited to evaluating a target business in a particular industry sector, you will be unable to ascertain the merits or risks of any particular target business's operations.

 •

 Although we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.

 •

 We are not required to obtain an opinion on the price we are paying for the business we are completing our initial business combination with from an independent investment banking firm or from an independent accounting firm, and consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our company or the stockholders from a financial point of view.

 •

 We may issue additional common stock or preferred stock to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. Any such issuances would dilute the interest of our stockholders and likely present other risks.

 •

 Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.

 •

 Since our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.

 •

 In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and other governing instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated certificate of incorporation or governing instruments in a manner that will make it easier for us to complete our initial business combination that our stockholders may not support.

 •

 Our initial stockholders may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support.

 •

 Because each unit contains one -twentieth of one right, the units may be worth less than units of other blank check companies.

 •

 Our warrant agreement and rights agreement designate the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants or rights, which could limit the ability of warrant or right holders to obtain a favorable judicial forum for disputes with our company.

 Risks Related to the Business Combination

 We may not be able to complete the Business Combination pursuant to the Combination Agreement. If we are unable to do so, we will incur substantial costs associated with withdrawing from the transaction and may not be able to find additional sources of financing to cover those costs.

 In connection with the Combination Agreement, we have incurred substantial costs researching, planning and negotiating the transaction. These costs include, but are not limited to, costs associated with securing sources of financing, costs associated with employing and retaining third-party advisors who performed the financial, auditing and legal services required to complete the transaction, and the expenses generated by our officers, executives, and employees in connection with the transaction. If, for whatever reason, the transactions contemplated by the Combination Agreement fail to close, we will be responsible for these costs, but will have no source of revenue with which to pay them. We may need to obtain additional sources of financing in order to meet our obligations, which we may not be able to secure on the same terms as our existing financing or at all. If we are unable to secure new sources of financing and do not have sufficient funds to meet our obligations, we will be forced to cease operations and liquidate the trust account.

 Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination

 We are a company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.

 We are a company with no operating results, and we will not commence operations until obtaining funding through our initial public offering. Because we lack an operating history, you have no basis upon which to evaluate our ability to achieve our business objective of completing our initial business combination with one or more target businesses. We have no plans, arrangements or understandings with any prospective target business concerning an initial business combination and may be unable to complete our initial business combination. If we fail to complete our initial business combination, we will never generate any operating revenues.

 Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination.

 We may choose not to hold a stockholder vote to approve our initial business combination unless the initial business combination would require stockholder approval under applicable law or stock exchange listing requirements or if we decide to hold a stockholder vote for business or other legal reasons. Except as required by law, the decision as to whether we will seek stockholder approval of a proposed initial business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors, such as the timing of the transaction and whether the terms of the transaction would otherwise require us to seek stockholder approval. Accordingly, we may complete our initial business combination even if holders of a majority of our public shares do not approve of the initial business combination we complete.

 If we seek stockholder approval of our initial business combination, our initial stockholders have agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote.

 Pursuant to the letter agreement, our sponsor, officers and directors have agreed to vote their founder shares, as well as any public shares purchased during or after our initial public offering (including in open market and privately negotiated transactions), in favor of our initial business combination. As of March 11, 2025, in addition to our initial stockholders' founder shares and representative shares, we would not require any of the 272,103 public shares sold in our initial public offering to be voted in favor of an initial business combination (assuming all outstanding shares are voted) in order to have our initial business combination approved. Our initial stockholders own shares representing 92 % of our outstanding shares of common stock immediately following the completion of our initial public offering. Accordingly, if we seek stockholder approval of our initial business combination, the agreement by our initial stockholders to vote in favor of our initial business combination will increase the likelihood that we will receive the requisite stockholder approval for such initial business combination.

 Your only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of the initial business combination.

 At the time of your investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of our initial business combination. Since our board of directors may complete an initial business combination without seeking stockholder approval, public stockholders may not have the right or opportunity to vote on the initial business combination, unless we seek such stockholder vote.

 Accordingly, if we do not seek stockholder approval, your only opportunity to affect the investment decision regarding a potential business combination may be limited to exercising your redemption rights within the period of time (which will be at least 20 business days) set forth in our tender offer documents mailed to our public stockholders in which we describe our initial business combination.

 The
ability of our public stockholders to redeem their shares for cash may make our
financial condition unattractive to potential business combination targets,
which may make it difficult for us to enter into an initial business
combination with a target.

 We may seek to enter into an initial business
combination agreement with a prospective target that requires as a closing
condition that we have a minimum net worth or a certain amount of cash. If too
many public stockholders exercise their redemption rights, we would not be able
to meet such closing condition and, as a result, would not be able to proceed
with the initial business combination. Furthermore, unless a stockholder proposal to approve an
amendment to the Company's Amended and Restated Certificate of Incorporation to
eliminate the limitation is approved, in no event will we redeem
our public shares in an amount that would cause our net tangible assets to be
less than $ 5,000,001 upon consummation of our
initial business combination and after payment of underwriters' fees and
commissions (so that we are not subject to the SEC's "penny stock" rules) or
any greater net tangible asset or cash requirement which may be contained in the
agreement relating to our initial business combination. Consequently, if
accepting all properly submitted redemption requests would cause our net
tangible assets to be less than $ 5,000,001 upon
consummation of our initial business combination and after payment of
underwriters' fees and commissions or such greater amount necessary to satisfy
a closing condition as described above unless a stockholder proposal to approve
amendment to the Company's Amended and Restated Certificate of Incorporation to
eliminate the limitation is approved, we would not proceed with such
redemption and the related business combination and may instead search for an
alternate business combination. Prospective targets will be aware of these
risks and, thus, may be reluctant to enter into an initial business combination
with us.

 The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure.

 At the time we enter into an agreement for our initial business combination, we will not know how many stockholders may exercise their redemption rights, and therefore will need to structure the transaction based on our expectations as to the number of shares that will be submitted for redemption. If our initial business combination agreement requires us to use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash at closing, we will need to reserve a portion of the cash in the trust account to meet such requirements, or arrange for third party financing. In addition, if a larger number of shares are submitted for redemption than we initially expected, we may need to restructure the transaction to reserve a greater portion of the cash in the trust account or arrange for third party financing. Raising additional third-party financing may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. The above considerations may limit our ability to complete the most desirable business combination available to us or optimize our capital structure. The amount of the deferred underwriting commissions payable to the underwriters will not be adjusted for any shares that are redeemed in connection with an initial business combination. The per-share amount we will distribute to stockholders who properly exercise their redemption rights will not be reduced by the deferred underwriting commission and after such redemptions, the per-share value of shares held by non- redeeming stockholders will reflect our obligation to pay the deferred underwriting commissions.

 The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your stock.

 If our initial business combination agreement requires us to use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash at closing, the probability that our initial business combination would be unsuccessful is increased. If our initial business combination is unsuccessful, you would not receive your pro rata portion of the trust account until we liquidate the trust account. If you are in need of immediate liquidity, you could attempt to sell your stock in the open market; however, at such time our stock may trade at a discount to the pro rata amount per share in the trust account. In either situation, you may suffer a material loss on your investment or lose the benefit of funds expected in connection with our redemption until we liquidate or you are able to sell your stock in the open market.

 The requirement that we complete our initial business combination within the prescribed time frame may give potential target businesses leverage over us in negotiating an initial business combination and may decrease our ability to conduct due diligence on potential business combination targets as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our stockholders.

 Any potential target business with which we enter into negotiations concerning an initial business combination will be aware that we must complete our initial business combination within 18 months from the closing of our initial public offering. Consequently, such target business may obtain leverage over us in negotiating an initial business combination, knowing that if we do not complete our initial business combination with that particular target business, we may be unable to complete our initial business combination with any target business. This risk will increase as we get closer to the timeframe described above. In addition, we may have limited time to conduct due diligence and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive investigation.

 We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate, in which case our public stockholders may only receive $ 11.505 per share, or less than such amount in certain circumstances, and our warrants will expire worthless.

 We must complete our initial business combination within 18 months from the closing of our initial public offering. We may not be able to find a suitable target business and complete our initial business combination within such time period. If we have not completed our initial business combination within such time period, we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $ 100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In such case, our public stockholders may only receive $ 11.505 per share, and our warrants will expire worthless. In certain circumstances, our public stockholders may receive less than $ 11.505 per share on the redemption of their shares. See "— If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share" and other risk factors below.

 If we seek stockholder approval of our initial business combination, our sponsor, directors, officers, advisors and their affiliates may elect to purchase shares or warrants from public stockholders, which may influence a vote on a proposed initial business combination and reduce the public "float" of our common stock.

 If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, directors, officers, advisors or their affiliates may purchase shares or public warrants or a combination thereof in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination, although they are under no obligation to do so. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or public warrants in such transactions.

 Such a purchase may include a contractual acknowledgement that such stockholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our sponsor, directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. The purpose of such purchases could be to vote such shares in favor of the initial business combination and thereby increase the likelihood of obtaining stockholder approval of the initial business combination, or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. The purpose of any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with our initial business combination. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements.

 In addition, if such purchases are made, the public "float" of our common stock or public warrants and the number of beneficial holders of our securities may be reduced, possibly making it difficult to obtain or maintain the quotation, listing or trading of our securities on a national securities exchange.

 If a stockholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed.

 We will comply with the tender offer rules or proxy rules, as applicable, when conducting redemptions in connection with our initial business combination. Despite our compliance with these rules, if a stockholder fails to receive our tender offer or proxy materials, as applicable, such stockholder may not become aware of the opportunity to redeem its shares. In addition, proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will describe the various procedures that must be complied with in order to validly tender or redeem public shares, which will include the requirement that a beneficial holder must identify itself. For example, we may require our public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to either tender their certificates to our transfer agent prior to the date set forth in the tender offer documents mailed to such holders, or up to two business days prior to the initial vote on the proposal to approve the initial business combination in the event we distribute proxy materials, or to deliver their shares to the transfer agent electronically. In the event that a stockholder fails to comply with these or any other procedures, its shares may not be redeemed. See the section of this Report entitled "Item 1. Business — Redemption Rights for Public Stockholders upon Completion of our Initial Business Combination — Tendering Stock Certificates in Connection with a Tender Offer or Redemption Rights."

 You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares or warrants, potentially at a loss.

 Our public stockholders will be entitled to receive funds from the trust account only upon the earliest to occur of: (i) our completion of an initial business combination, (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity and (iii) the redemption of our public shares if we are unable to complete an initial business combination within 18 months from the closing of our initial public offering, subject to applicable law and as further described herein. In no other circumstances will a public stockholder have any right or interest of any kind in the trust account. Holders of warrants will not have any right to the proceeds held in the trust account with respect to the warrants. Accordingly, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.

 Because we are not limited to evaluating a target business in a particular industry sector, you will be unable to ascertain the merits or risks of any particular target business's operations.

 We may seek to complete a business combination with an operating company in any industry or sector. However, we will not, under our amended and restated certificate of incorporation, be permitted to effectuate our business combination with another blank check company or similar company with nominal operations. To the extent we complete our initial business combination, we may be affected by numerous risks inherent in the business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially unstable or a development stage entity. Although our officers and directors will endeavor to evaluate the risks inherent in a particular target business, we cannot assure you that we will properly ascertain or assess all of the significant risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a target business. We also cannot assure you that an investment in our securities will ultimately prove to be more favorable to investors than a direct investment, if such opportunity were available, in a business combination target. Accordingly, any stockholders who choose to remain stockholders following our initial business combination could suffer a reduction in the value of their securities. Such stockholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.

 Past performance by our management team, may not be indicative of future performance of an investment in the Company.

 Information regarding performance by, or businesses associated with our management team and their affiliates is presented for informational purposes only. Past performance by our management team is not a guarantee either (i) of success with respect to any business combination we may consummate or (ii) that we will be able to locate a suitable candidate for our initial business combination. You should not rely on the historical record of our management team's or their affiliates' performance as indicative of the future performance of an investment in the company or the returns the company will, or is likely to, generate going forward. Our officers and directors have not had experience with blank check companies or special purpose acquisition companies in the past.

 We may seek business combination opportunities in industries or sectors which may or may not be outside of our management's area of expertise.

 We will consider an initial business combination outside of our management's area of expertise if an initial business combination candidate is presented to us and we determine that such candidate offers an attractive business combination opportunity for our company or we are unable to identify a suitable candidate in this sector after having expanded a reasonable amount of time and effort in an attempt to do so. Although our management will endeavor to evaluate the risks inherent in any particular business combination candidate, we cannot assure you that we will adequately ascertain or assess all of the significant risk factors. We also cannot assure you that an investment in our securities will not ultimately prove to be less favorable to investors in our initial public offering than a direct investment, if an opportunity were available, in an initial business combination candidate. In the event we elect to pursue a business combination outside of the areas of our management's expertise, our management's expertise may not be directly applicable to its evaluation or operation, and the information contained in this Report regarding the areas of our management's expertise would not be relevant to an understanding of the business that we elect to acquire. As a result, our management may not be able to adequately ascertain or assess all of the significant risk factors. Accordingly, any stockholders who choose to remain stockholders following our initial business combination could suffer a reduction in the value of their shares. Such stockholders are unlikely to have a remedy for such reduction in value.

 Although we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.

 Although we have identified general criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which we enter into our initial business combination will not have all of these positive attributes. If we complete our initial business combination with a target that does not meet some or all of these guidelines, such combination may not be as successful as a combination with a business that does meet all of our general criteria and guidelines. In addition, if we announce a prospective business combination with a target that does not meet our general criteria and guidelines, a greater number of stockholders may exercise their redemption rights, which may make it difficult for us to meet any closing condition with a target business that requires us to have a minimum net worth or a certain amount of cash. In addition, if stockholder approval of the transaction is required by law, or we decide to obtain stockholder approval for business or other legal reasons, it may be more difficult for us to attain stockholder approval of our initial business combination if the target business does not meet our general criteria and guidelines. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on the liquidation of our trust account and our warrants will expire worthless. In certain circumstances, our public stockholders may receive less than $ 11.505 per share on the redemption of their shares. See "— If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share" and other risk factors below.

 Resources could be wasted in researching business combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share, or less than such amount in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.

 We anticipate that the investigation of each specific target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial costs for accountants, attorneys, consultants and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to complete our initial business combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on the liquidation of our trust account and our warrants will expire worthless. In certain circumstances, our public stockholders may receive less than $ 11.505 per share on the redemption of their shares. See "— If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share" and other risk factors below.

 Our key personnel may negotiate employment or consulting agreements as well as reimbursement of out-of-pocket expenses, if any, with a target business in connection with a particular business combination. These agreements may provide for them to receive compensation or reimbursement for out-of-pocket expenses, if any, following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous.

 Our key personnel may be able to remain with the company after the completion of our initial business combination only if they are able to negotiate employment or consulting agreements in connection with the initial business combination. Additionally, they may negotiate reimbursement of any out-of-pocket expenses incurred on our behalf prior to the consummation of our initial business combination, should they choose to do so. Such negotiations would take place simultaneously with the negotiation of the initial business combination and could provide for such individuals to receive compensation in the form of cash payments and/or our securities for services they would render to us after the completion of the initial business combination, or as reimbursement for such out-of-pocket expenses. The personal and financial interests of such individuals may influence their motivation in identifying and selecting a target business. However, we believe the ability of such individuals to remain with us after the completion of our initial business combination will not be the determining factor in our decision as to whether or not we will proceed with any potential business combination. There is no certainty, however, that any of our key personnel will remain with us after the completion of our initial business combination. We cannot assure you that any of our key personnel will remain in senior management or advisory positions with us. The determination as to whether any of our key personnel will remain with us will be made at the time of our initial business combination.

 Since our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.

 Our sponsor and I-Bankers hold 2,875,000 founder shares. The founder shares will be worthless if we do not complete an initial business combination. In addition, our sponsor and I-Bankers purchased an aggregate of 5,425,000 private placement warrants, each exercisable for one share of our common stock at $ 11.50 per share, for a purchase price of $ 5,425,000, or $ 1.00 per warrant, that will also be worthless if we do not complete a business combination.

 The personal and financial interests of our executive officers and directors may influence their motivation in identifying and selecting a target business combination, completing an initial business combination and influencing the operation of the business following the initial business combination. This risk may become more acute as the 18 -month anniversary of the closing of our initial public offering nears, which is the deadline for our completion of an initial business combination.

 Since our sponsor, executive officers and directors will not be eligible to be reimbursed for their out-of-pocket expenses if our business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.

 At the closing of our initial business combination, our sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred in connection with activities on our behalf. These financial interests of our sponsor, executive officers and directors may influence their motivation in identifying and selecting a target business combination and completing an initial business combination.

 The excise tax included in the Inflation Reduction Act of 2022 may decrease the value of our securities following our initial Business Combination, hinder our ability to consummate an initial Business Combination, and decrease the amount of funds available for distribution in connection with a liquidation.

 On August 16, 2022, the Inflation Reduction Act of 2022 (the "Inflation Reduction Act") was signed into law, which, among other things, imposes a 1 % excise tax on the fair market value of stock repurchased by a domestic corporation beginning in 2023, with certain exceptions. Because we are a Delaware corporation and our securities trade on the Nasdaq Stock Market, we are a "covered corporation" within the meaning of the Inflation Reduction Act, and while not free from doubt, it is possible that the excise tax will apply to any redemptions of our common stock after December 31, 2022, including redemptions in connection with an initial Business Combination and any amendment to our certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. Consequently, the value of your investment in our securities may decrease as a result of the excise tax. In addition, the excise tax may make a transaction with us less appealing to potential Business Combination targets, and thus, potentially hinder our ability to enter into and consummate an initial Business Combination. Further, the application of the excise tax in the event of a liquidation is uncertain absent further guidance.

 Risks Relating to Our Securities

 NASDAQ delisted our securities from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.

 Our securities are no longer listed on NASDAQ. As a result, we could face significant material adverse consequences, including:

 •

 a limited availability of market quotations for our securities;

 •

 reduced liquidity for our securities;

 •

 a determination that our common stock is a "penny stock" which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

 •

 a limited amount of news and analyst coverage; and

 •

 a decreased ability to issue additional securities or obtain additional financing in the future.

 On November 27, 2023, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel"), the Company's securities (shares, warrants, and rights) would be subject to suspension and delisting from The Nasdaq Capital Market at the opening of business on December 6, 2023 due to the Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. The Company timely requested a hearing before the Panel to request additional time to complete its business combination. The hearing request resulted in a stay of any suspension or delisting action pending the hearing which was held on February 27, 2024. On March 15, 2024, the Company received the Panel's determination
granting the Company an exception until May 28, 2024 to complete its initial
business combination. O n May 24, 2024, we notified the Panel
that we would not be able to close our initial business combination by the
Panel's May 28, 2024 deadline. Accordingly, the Panel determined to delist our
securities from Nasdaq as set forth in the Notice Letter.

 On August 21, 2024, the Company's common stock
and warrants began trading, and on August 23, 2024 the Company's rights began
trading on the OTCQX Best Market under the symbol "BRZH", "BRZHW" and "BRZHR".

 You will not be entitled to protections normally afforded to investors of many other blank check companies.

 Since the net proceeds of our initial public offering and the sale of the private placement warrants are intended to be used to complete an initial business combination with a target business that has not been identified, we may be deemed to be a "blank check" company under the United States securities laws. However, because we had net tangible assets in excess of $ 5,000,000 upon the successful completion of our initial public offering and the sale of the private placement warrants and filed a Current Report on Form 8-K, including an audited balance sheet demonstrating this fact, we are exempt from rules promulgated by the SEC to protect investors in blank check companies, such as Rule 419. Accordingly, investors will not be afforded the benefits or protections of those rules. Among other things, this means our units will have a longer period of time to complete our initial business combination than do companies subject to Rule 419. Moreover, if our initial public offering were subject to Rule 419, that rule would prohibit the release of any interest earned on funds held in the trust account to us unless and until the funds in the trust account were released to us in connection with our completion of an initial business combination.

 If we seek stockholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a "group" of stockholders are deemed to hold in excess of 10 % of our common stock, you will lose the ability to redeem all such shares in excess of 10 % of our common stock.

 If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 10 % of the shares sold in our initial public offering without our prior consent, which we refer to as the "Excess Shares."

 However, we would not be restricting our stockholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Your inability to redeem the Excess Shares will reduce your influence over our ability to complete our initial business combination and you could suffer a material loss on your investment in us if you sell Excess Shares in open market transactions. Additionally, you will not receive redemption distributions with respect to the Excess Shares if we complete our initial business combination. And as a result, you will continue to hold that number of shares exceeding 10 % and, in order to dispose of such shares, would be required to sell your stock in open market transactions, potentially at a loss.

 Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on our redemption of our public shares, or less than such amount in certain circumstances, and our warrants will expire worthless.

 We have encountered and continue to expect to encounter competition from other entities having a business objective similar to ours, including private investors (which may be individuals or investment partnerships), other blank check companies and other entities competing for the types of businesses we intend to acquire. Many of these individuals and entities are well-established and have extensive experience in identifying and effecting, directly or indirectly, acquisitions of companies operating in or providing services to various industries. Many of these competitors possess similar technical, human and other resources to ours, and our financial resources are relatively limited when contrasted with those of many of these competitors. While we believe there are numerous target businesses we could potentially acquire with the net proceeds of our initial public offering and the sale of the private placement warrants, our ability to compete with respect to the acquisition of certain target businesses that are sizable are limited by our available financial resources. This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses. Furthermore, if we are obligated to pay cash for the shares of common stock which our public stockholders redeem in connection with our initial business combination, target companies will be aware that this may reduce the resources available to us for our initial business combination. This may place us at a competitive disadvantage in successfully negotiating an initial business combination. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on the liquidation of our trust account and our warrants will expire worthless.

 If the net proceeds of our initial public offering, the sale of the private placement warrants not being held in the trust account and loans from our sponsor or management team are insufficient, we may be unable to complete our initial business combination.

 The funds available to us outside of the trust account may not be sufficient to allow us to complete our initial business combination. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on the liquidation of our trust account and our warrants will expire worthless. In certain circumstances, our public stockholders may receive less than $ 11.505 per share upon our liquidation. See "— If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share" and other risk factors below.

 If the net proceeds of our initial public offering and the sale of the private placement warrants not being held in the trust account are insufficient, it could limit the amount available to complete our initial business combination and we will depend on loans from our sponsor or management team to pay our franchise and income taxes and to complete our initial business combination. If we are unable to obtain these loans, we may be unable to complete our initial business combination.

 Of the net proceeds of our initial public offering and the sale of the private placement warrants, $ 947,443 was available to us initially outside the trust account to fund our working capital requirements. If we are required to seek additional capital, we would need to borrow funds from our sponsor, management team or other third parties to operate or may be forced to liquidate. None of our sponsor, members of our management team or any of their affiliates is under any obligation to advance funds to us in such circumstances. Any such advances would be repaid only from funds held outside the trust account or from funds released to us upon completion of our initial business combination. We do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. Consequently, our public stockholders may only receive approximately $ 11.505 per share on our redemption of our public shares, and our rights and warrants will expire worthless.

 If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $ 11.505 per share.

 Our placing of funds in the trust account may not protect those funds from third-party claims against us. Although we will seek to have all vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders, such parties may not execute such agreements, or even if they execute such agreements they may not be prevented from bringing claims against the trust account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust account. If any third-party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party's engagement would be significantly more beneficial to us than any alternative.

 Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we are unable to complete our initial business combination within the prescribed timeframe, or upon the exercise of a redemption right in connection with our initial business combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the 10 years following redemption. Accordingly, the per-share redemption amount received by public stockholders could be less than the $ 11.505 per share initially held in the trust account, due to claims of such creditors. Our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ 11.505 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $ 11.505 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and believe that our sponsor's only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. None of our officers, directors or members of our sponsor will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

 Our directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public stockholders.

 In the event that the proceeds in the trust account are reduced below the lesser of (i) $ 11.505 per share and (ii) the actual amount per share held in the trust account as of the date of the liquidation of the trust account if less than $ 11.505 per share due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, and our sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations.

 While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment and subject to their fiduciary duties may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not likely. If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the trust account available for distribution to our public stockholders may be reduced below $ 11.505 per share.

 We may not have sufficient funds to satisfy indemnification claims of our directors and executive officers.

 We have agreed to indemnify our officers and directors to the fullest extent permitted by law. However, our officers and directors have agreed to waive (and any other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest or claim of any kind in or to any monies in the trust account and not to seek recourse against the trust account for any reason whatsoever. Accordingly, any indemnification provided will be able to be satisfied by us only if (i) we have sufficient funds outside of the trust account or (ii) we consummate an initial business combination. Our obligation to indemnify our officers and directors may discourage stockholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.

 If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, a bankruptcy court may seek to recover such proceeds, and we and our board may be exposed to claims of punitive damages.

 If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a "preferential transfer" or a "fraudulent conveyance." As a result, a bankruptcy court could seek to recover all amounts received by our stockholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors.

 If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our stockholders and the per-share amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced.

 If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, the per-share amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced. Our stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares.

 Under the DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by them in a dissolution. The pro rata portion of our trust account distributed to our public stockholders upon the redemption of our public shares in the event we do not complete our initial business combination within 18 months from the closing of our initial public offering may be considered a liquidating distribution under Delaware law. If a corporation complies with certain procedures set forth in Section 280 of the DGCL intended to ensure that it makes reasonable provision for all claims against it, including a 60 -day notice period during which any third-party claims can be brought against the corporation, a 90 -day period during which the corporation may reject any claims brought, and an additional 150 -day waiting period before any liquidating distributions are made to stockholders, any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder's pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third anniversary of the dissolution. However, it is our intention to redeem our public shares as soon as reasonably possible following the 18 th month from the closing of our initial public offering in the event we do not complete our initial business combination and, therefore, we do not intend to comply with the foregoing procedures.

 Because we will not be complying with Section 280, Section 281 (b) of the DGCL requires us to adopt a plan, based on facts known to us at such time that will provide for our payment of all existing and pending claims or claims that may be potentially brought against us within the 10 years following our dissolution. However, because we are a blank check company, rather than an operating company, and our operations will be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, etc.) or prospective target businesses. If our plan of distribution complies with Section 281 (b) of the DGCL, any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder's pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would likely be barred after the third anniversary of the dissolution. We cannot assure you that we will properly assess all claims that may be potentially brought against us. As such, our stockholders could potentially be liable for any claims to the extent of distributions received by them (but no more) and any liability of our stockholders may extend beyond the third anniversary of such date. Furthermore, if the pro rata portion of our trust account distributed to our public stockholders upon the redemption of our public shares in the event we do not complete our initial business combination within 1 8 months from the closing of our initial public offering is not considered a liquidating distribution under Delaware law and such redemption distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may bring or due to other circumstances that are currently unknown), then pursuant to Section 174 of the DGCL, the statute of limitations for claims of creditors could then be six years after the unlawful redemption distribution, instead of three years, as in the case of a liquidating distribution.

 We may not hold an annual meeting of stockholders until after the consummation of our initial business combination, which could delay the opportunity for our stockholders to elect directors.

 We may not hold an annual meeting of stockholders until after we consummate a business combination, and thus may not be in compliance with Section 211 (b) of the DGCL, which requires an annual meeting of stockholders be held for the purposes of electing directors in accordance with a company's bylaws unless such election is made by written consent in lieu of such a meeting. Therefore, if our stockholders want us to hold an annual meeting prior to our consummation of a business combination, they may attempt to force us to hold one by submitting an application to the Delaware Court of Chancery in accordance with Section 211 (c) of the DGCL.

 We have not registered the shares of common stock issuable upon exercise of the warrants under the Securities Act or any state securities laws at this time, and such registration may not be in place when an investor desires to exercise warrants, thus precluding such investor from being able to exercise its warrants except on a cashless basis. If the issuance of the shares upon exercise of warrants is not registered, qualified or exempt from registration or qualification, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless.

 We have not registered the shares of common stock issuable upon exercise of the warrants under the Securities Act or any state securities laws at this time. However, under the terms of the warrant agreement, we have agreed that as soon as practicable, but in no event later than 15 business days after the closing of our initial business combination, we will use our best efforts to file with the SEC a registration statement for the registration under the Securities Act of the shares of common stock issuable upon exercise of the warrants and thereafter will use our best efforts to cause the same to become effective within 60 business days following our initial business combination and to maintain a current prospectus relating to the common stock issuable upon exercise of the warrants, until the expiration of the warrants in accordance with the provisions of the warrant agreement. We cannot assure you that we will be able to do so if, for example, any facts or events arise which represent a fundamental change in the information set forth in the registration statement or prospectus, the financial statements contained or incorporated by reference therein are not current or correct or the SEC issues a stop order. If the shares issuable upon exercise of the warrants are not registered under the Securities Act, we will be required to permit holders to exercise their warrants on a cashless basis. However, no warrant will be exercisable for cash or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In no event will we be required to net cash settle any warrant, or issue securities or other compensation in exchange for the warrants in the event that we are unable to register or qualify the shares underlying the warrants under applicable state securities laws and there is no exemption available. If the issuance of the shares upon exercise of the warrants is not so registered or qualified or exempt from registration or qualification, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In such event, holders who acquired their warrants as part of a purchase of units will have paid the full unit purchase price solely for the shares of common stock included in the units. If and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. We will use our best efforts to register or qualify such shares of common stock under the blue sky laws of the state of residence in those states in which the warrants were offered by us in our initial public offering. However, there may be instances in which holders of our public warrants may be unable to exercise such public warrants but holders of our private warrants may be able to exercise such private warrants.

 The grant of registration rights to our initial stockholders and holders of our private placement warrants may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our common stock.

 Pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in our initial public offering, our initial stockholders and their permitted transferees can demand that we register their shares of our common stock at the time of our initial business combination. In addition, holders of our private placement warrants and their permitted transferees can demand that we register the private placement warrants and the shares of common stock issuable upon exercise of the private placement warrants, and holders of warrants that may be issued upon conversion of working capital loans may demand that we register such warrants or the common stock issuable upon exercise of such warrants. We will bear the cost of registering these securities. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our common stock. In addition, the existence of the registration rights may make our initial business combination more costly or difficult to conclude. This is because the stockholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration to offset the negative impact on the market price of our common stock that is expected when the common stock owned by our initial stockholders, holders of our private placement warrants or holders of our working capital loans or their respective permitted transferees are registered.

 We may issue additional common stock or preferred stock to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. Any such issuances would dilute the interest of our stockholders and likely present other risks.

 Our amended and restated certificate of incorporation authorizes the issuance of up to 100,000,000 shares of common stock, par value $ 0.0001 per share and 1,000,000 shares of undesignated preferred stock, par value $ 0.0001 per share. Immediately after our initial public offering, there were 67,875,000 authorized but unissued shares of common stock available for issuance, which amount takes into account shares of common stock reserved for issuance upon exercise of outstanding warrants and the conversion of the rights. There are no shares of preferred stock issued and outstanding.

 We may issue a substantial number of additional shares of common or preferred stock to complete our initial business combination or under an employee incentive plan after completion of our initial business combination (although our amended and restated certificate of incorporation provides that we may not issue securities that can vote with common stockholders on matters related to our pre-initial business combination activity). However, our amended and restated certificate of incorporation provides, among other things, that prior to our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on any initial business combination. These provisions of our amended and restated certificate of incorporation, like all provisions of our amended and restated certificate of incorporation, may be amended with the approval of our stockholders. However, our executive officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering (or up to 18 months from the closing of our initial public offering if we extend the period of time to consummate a business combination) or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity, unless we provide our public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (which interest shall be net of taxes payable), divided by the number of then outstanding public shares.

 The issuance of additional shares of common or preferred stock:

 •

 may significantly dilute the equity interest of investors in our initial public offering;

 •

 may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;

 •

 could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and

 •

 may adversely affect prevailing market prices for our units, common stock, rights and/or warrants.

 Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.

 Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for an initial business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in other business endeavors for which he may be entitled to substantial compensation and our officers are not obligated to contribute any specific number of hours per week to our affairs. Our independent directors may also serve as officers or board members for other entities. If our officers' and directors' other business affairs require them to devote substantial amounts of time to such affairs in excess of their current commitment levels, it could limit their ability to devote time to our affairs which may have a negative impact on our ability to complete our initial business combination. For a complete discussion of our officers' and directors' other business affairs, please see the section of this Report entitled "Item 10. Directors, Executive Officers and Corporate Governance — Directors and Executive Officers."

 Certain of our officers and directors are now, and all of them may in the future become, affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly, may have conflicts of interest in allocating their time and determining to which entity a particular business opportunity should be presented.

 Following the completion of our initial public offering and until we consummate our initial business combination, we intend to engage in the business of identifying and combining with one or more businesses. Our officers and directors are, and may in the future become, affiliated with entities that are engaged in business activities similar to those intended to be conducted by us following our initial business combination.

 Our officers and directors also may become aware of business opportunities which may be appropriate for presentation to us and the other entities to which they owe certain fiduciary or contractual duties. Any such companies may present additional conflicts of interest in pursuing an acquisition target.

 Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in our favor and a potential target business may be presented to another entity prior to its presentation to us. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.

 For a complete discussion of our officers' and directors' business affiliations and the potential conflicts of interest that you should be aware of, please see the sections of this Report entitled "Item 10. Directors, Executive Officers and Corporate Governance— Directors and Executive Officers," "Item 10. Directors, Executive Officers and Corporate Governance — Conflicts of Interest" and "Item 13. Certain Relationships and Related Transactions, and Director Independence."

 Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.

 We have not adopted a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into an initial business combination with a target business that is affiliated with our sponsor, our directors or officers, although we do not intend to do so. We do not have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours.

 In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and other governing instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated certificate of incorporation or governing instruments in a manner that will make it easier for us to complete our initial business combination that our stockholders may not support.

 In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and modified governing instruments, including their warrant agreements. For example, blank check companies have amended the definition of business combination, increased redemption thresholds and extended the time to consummate an initial business combination. And, with respect to their warrants, amended their warrant agreements to require the warrants to be exchanged for cash and/or other securities. Amending our amended and restated certificate of incorporation requires the approval of holders of 65 % of our common stock, and amending our warrant agreement requires a vote of holders of at least 65 % of the public warrants and, solely with respect to any amendment to the terms of the private placement warrants or any provision of the warrant agreement with respect to the private placement warrants, 50 % of the number of the then outstanding private placement warrants. In addition, our amended and restated certificate of incorporation requires us to provide our public stockholders with the opportunity to redeem their public shares for cash if we propose an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 1 8 months or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity. To the extent any such amendments would be deemed to fundamentally change the nature of any securities offered through this registration statement, we would register, or seek an exemption from registration for, the affected securities. We cannot assure you that we will not seek to amend our charter or governing instruments or extend the time to consummate an initial business combination in order to effectuate our initial business combination.

 Certain agreements related to our initial public offering may be amended without stockholder approval.

 Certain agreements, including the underwriting agreement relating to our initial public offering, the investment management trust agreement between us and Continental Stock Transfer & Trust Company, the letter agreement among us and our sponsor, executive officers and directors, the registration rights agreement among us and our initial stockholders, the administrative services agreement between us and our sponsor, and the business combination marketing agreement may be amended without stockholder approval. These agreements contain various provisions that our public stockholders might deem to be material. While we do not expect our board to approve any amendment to any of these agreements prior to our initial business combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to any such agreement in connection with the consummation of our initial business combination. Any such amendment may have an adverse effect on the value of an investment in our securities.

 We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.

 We have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $ 0.01 per warrant, provided that the last reported sales price of our common stock equals or exceeds $ 18.00 per share for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders. We may not redeem the warrants when a holder may not exercise such warrants. Redemption of the outstanding warrants could force you (i) to exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) to sell your warrants at the then-current market price when you might otherwise wish to hold your warrants or (iii) to accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your warrants. None of the private placement warrants will be redeemable by us so long as they are held by their initial purchasers or their permitted transferees.

 Our warrants and founder shares may have an adverse effect on the market price of our common stock and make it more difficult to effectuate our initial business combination.

 We issued warrants to purchase 11,500,000 shares of our common stock as part of the units offered in our initial public offering and, simultaneously with the closing of our initial public offering, we issued in a private placement warrants to purchase an aggregate of 5,425,000 shares of common stock at $ 11.50 per share. Our initial stockholders currently own an aggregate of 2,875,000 founder shares. The founder shares are convertible into shares of common stock on a one -for- one basis, subject to adjustment as set forth herein.

 To the extent we issue shares of common stock to effectuate an initial business combination, the potential for the issuance of a substantial number of additional shares of common stock upon exercise of these warrants and conversion rights could make us a less attractive business combination vehicle to a target business. Any such issuance will increase the number of issued and outstanding shares of our common stock and reduce the value of the shares of common stock issued to complete the initial business combination. Therefore, our warrants and founder shares may make it more difficult to effectuate an initial business combination or increase the cost of acquiring the target business.

 The private placement warrants are identical to the warrants sold as part of the units in our initial public offering except that, so long as they are held by our sponsor or its permitted transferees, (i) they will not be redeemable by us, (ii) they (including the common stock issuable upon exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by our sponsor until 30 days after the completion of our initial business combination and (iii) they may be exercised by the holders on a cashless basis.

 Because each unit contains one -twentieth of one right, the units may be worth less than units of other blank check companies.

 Each unit contains one -twentieth of one right. Pursuant to the rights agreement, the rights may only be exercised for a whole number of shares, which means you must hold 20 rights in order to receive one share of common stock. We have established the components of the units in this way in order to reduce the dilutive effect of the rights upon completion of our initial business combination. While we believe this makes us a more attractive merger partner for target businesses, this unit structure may nevertheless cause our units to be worth less than if they included a right to purchase one whole share.

 General Risks

 The target business with which we ultimately consummate a business combination may be materially adversely affected by geopolitical conflicts and wars.

 With rising tensions around the world based on the current conflict between Ukraine and Russia, and between Israel and Hamas, we may be unable to complete a business combination if concerns related to these and other potential conflicts impact global capital markets, the ability to transfer money, currency exchange rates, cyber attacks and infrastructure including power generation and transmission, communications, and travel. Escalating conflicts could also have an impact on global demands for health care, international trade including vendor supply chains, and energy. In addition, there have been recent threats to infrastructure and equipment including cyber attacks, physical facility destruction and equipment destruction. The outcome of these conflicts or their impact cannot be predicted and may have an adverse impact in a material way on our ability to consummate a business combination, or to operate a target business with which we ultimately consummate a business combination.

 Our operations and financial performance may also be
subject to significant risks arising from geopolitical tensions, particularly
in relation to China, South Korea and Taiwan. As a major global economic power,
China's political policies, trade practices, and regulatory environment may
directly impact our business. Additionally, rising political tensions and
potential conflicts in the Asia-Pacific region, such as territorial disputes,
trade disagreements, or military confrontations, could disrupt supply chains,
increase costs, or adversely affect market demand. These risks are compounded
by the potential for government interventions, such as trade restrictions,
tariffs, sanctions, export controls or blockades, which may affect our ability
to operate or source products from Taiwan and/or other affected regions.
Moreover, changes in laws and regulations, including those relating to
technology, intellectual property, labor practices, and environmental
regulations, may also introduce additional uncertainty and operational
challenges.

 The outcome of these conflicts or their impact cannot
be predicted and may have an adverse impact in a material way on our ability to
consummate a business combination, or to operate a target business with which
we ultimately consummate a business combination.

 If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination.

 If we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including:

 •

 restrictions on the nature of our investments; and

 •

 restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination.

 •

 In addition, we may have imposed upon us burdensome requirements, including:

 •

 registration as an investment company;

 •

 adoption of a specific form of corporate structure; and

 •

 reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations.

 In order not to be regulated as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must ensure that we are engaged primarily in a business other than investing, reinvesting or trading in securities and that our activities do not include investing, reinvesting, owning, holding or trading "investment securities" constituting more than 40 % of our total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Our business is to identify and complete an initial business combination and thereafter to operate the post-transaction business or assets for the long term. We do not plan to buy businesses or assets with a view to resale or profit from their resale. We do not plan to buy unrelated businesses or assets or to be a passive investor.

 We do not believe that our anticipated principal activities will subject us to the Investment Company Act. To this end, the proceeds held in the trust account may only be invested in United States "government securities" within the meaning of Section 2 (a)( 16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2 a- 7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an "investment company" within the meaning of the Investment Company Act. Our securities are not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of our initial business combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to redeem 100 % of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity; or (iii) absent an initial business combination within 1 8 months from the closing of our initial public offering, our return of the funds held in the trust account to our public stockholders as part of our redemption of the public shares. If we do not invest the proceeds as discussed above, we may be deemed to be subject to the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete an initial business combination or may result in our liquidation. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $ 11.505 per share on the liquidation of our trust account and our rights and warrants will expire worthless.

 We are dependent upon our executive officers and directors and their departure could adversely affect our ability to operate.

 Our operations are dependent upon a relatively small group of individuals and, in particular, our executive officers and directors. We believe that our success depends on the continued service of our executive officers and directors, at least until we have completed our initial business combination. We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or executive officers. The unexpected loss of the services of one or more of our directors or executive officers could have a detrimental effect on us.

 The requirements of being a public company may strain our resources and divert management's attention.

 As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of OTCQX Best Market and other applicable securities rules and regulations. Compliance with these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an "emerging growth company." The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management's attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to comply with these requirements, which will increase our costs and expenses.

 Delays in causing extension payments to be funded
to the Trust Account may contradict our governing documents.

 The monthly extension payments were and are
required to be made in order to extend the business combination period monthly,
and the failure to complete the liquidation of our Trust Account following a
late payment may violate the terms of the Trust Agreement. As of the date of
this Form10-K filing, the Board has not taken steps to commence
liquidation of the Trust Account, nor discussed the commencement of a
liquidation with the Trustee, however, the Company has caused additional
amounts, as calculated by the Trustee, to be contributed to the Trust Account
to offset any unearned interest as a result of any late payments. Any violation
of the Trust Agreement could be the basis for a stockholder lawsuit against us,
though all monies owed to prior redeeming stockholders have been funded by the
Company including extension payments and unearned interest.

 We are an emerging growth company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.

 We are an "emerging growth company" within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $ 700 million as of any June 30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.

 Further, Section 102 (b)( 1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an initial business combination.

 Section 404 of the Sarbanes-Oxley Act requires that we evaluate and report on our system of internal controls beginning with our Annual Report on Form 10-K for the year ending December 31, 2024. Only in the event we are deemed to be a large accelerated filer or an accelerated filer will we be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. Further, for as long as we remain an emerging growth company, we will not be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to other public companies because a target company with which we seek to complete our initial business combination may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal control of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business combination.

 Provisions in our amended and restated certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management.

 Our amended and restated certificate of incorporation contains provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. These provisions include a staggered board of directors and the ability of the board of directors to designate the terms of and issue new series of preferred shares, which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.

 We are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control. Together these provisions may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.

 Our amended and restated certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder's counsel, which may have the effect of discouraging lawsuits against our directors, officers, other employees or stockholders.

 Our amended and restated certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder's counsel except any action (A) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, (C) for which the Court of Chancery does not have subject matter jurisdiction, or (D) any action arising under the Securities Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall have concurrent jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our amended and restated certificate of incorporation. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.

 Our amended and restated certificate of incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

 The determination of the offering price of our units and the size of our initial public offering was more arbitrary than the pricing of securities and size of an offering of an operating company in a particular industry. You may have less assurance, therefore, that the offering price of our units properly reflects the value of such units than you would have in a typical offering of an operating company.

 Prior to our public offering there has been no public market for any of our securities. The public offering price of the units and the terms of the rights and warrants were negotiated between us and the underwriters. In determining the size of our initial public offering, management held customary organizational meetings with representatives of the underwriters, both prior to our inception and thereafter, with respect to the state of capital markets, generally, and the amount the underwriters believed they reasonably could raise on our behalf. Factors considered in determining the size of our initial public offering, prices and terms of the units, including the common stock, rights and warrants underlying the units, included:

 •

 the history and prospects of companies whose principal business is the acquisition of other companies;

 •

 prior offerings of those companies;

 •

 our prospects for acquiring an operating business at attractive values;

 •

 a review of debt-to-equity ratios in leveraged transactions;

 •

 our capital structure;

 •

 an assessment of our management and their experience in identifying operating companies;

 •

 general conditions of the securities markets at the time of our initial public offering; and

 •

 other factors as were deemed relevant.

 Although these factors were considered, the determination of our offering price was more arbitrary than the pricing of securities of an operating company in a particular industry since we have no historical operations or financial results.

 Our warrant agreement and rights agreement designate the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants or rights, which could limit the ability of warrant or right holders to obtain a favorable judicial forum for disputes with our company.

 Our warrant agreement and right agreement provide that, subject to applicable law, (i) any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.

 Notwithstanding the foregoing, these provisions of the warrant agreement and rights agreement do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants or rights shall be deemed to have notice of and to have consented to the forum provisions in our warrant agreement or rights agreement, as applicable. If any action, the subject matter of which is within the scope the forum provisions of the warrant agreement or rights agreement, is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York (a "foreign action") in the name of any holder of our warrants or rights, such holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an "enforcement action"), and (y) having service of process made upon such warrant holder or right holder in any such enforcement action by service upon such warrant or right holder's counsel in the foreign action as agent for such warrant or right holder.

 This choice-of-forum provision may limit a warrant or right holder's ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our warrant agreement or rights agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors.

 Our warrants are accounted for as liabilities and changes in the value of our warrants could have a material effect on our financial results.

 Under
the guidance in Accounting Standards Codification ("ASC") 815-40, certain warrants do not meet the criteria for
equity treatment. These warrants include a clause whereby the warrant holder
may be entitled to receive a net cash settlement upon the acceptance by the
holders of the Company's common stock of a tender, exchange or redemption
offer. Upon such a qualifying tender cash offer (an event which could be
outside the control of the Company), all Warrant holders would be entitled to
cash. This factor precludes the Company
from applying equity accounting as the warrant holder could receive a net cash
settlement value that is greater than a holder of the Company's common stock.
Accordingly, the Company has concluded that liability accounting is required.
As such, these warrants are recorded at fair value as of each reporting date
with the change in fair value reported within other income in the accompanying
consolidated statements of operations as "Change in fair value of warrant
liability" until the warrants are exercised, expired or other facts and
circumstances lead the warrant liability to be reclassified to stockholders'
equity. The Company utilized a Modified Black Scholes Model to estimate the
fair values of the warrants, which incorporates significant inputs that are not
observable in the market, and thus represents a Level 3 measurement as defined
in ASC 820. The unobservable inputs utilized for measuring the fair value of
the contingent consideration reflect management's own assumptions about the
assumptions that market participants would use in valuing the contingent
consideration. The Company determined the fair value by using the below key
inputs to the Modified Black Scholes Model.

 As a result, included on our balance sheets as of December 31, 2024 and 2023, contained elsewhere in this Report are derivative liabilities related to embedded features contained within our warrants. Accounting Standards Codification ASC 815 - 40 provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring fair value measurement, our financial statements and results of operations may fluctuate quarterly based on factors which are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our warrants each reporting period and that the amount of such gains or losses could be material.

 We
identified a material weakness in our internal control over financial
reporting. This material weakness could continue to adversely affect our
ability to report our results of operations and financial condition accurately
and in a timely manner.

 Breeze's management is responsible for establishing and maintaining adequate internal
control over financial reporting designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with GAAP. Our
management also evaluates the effectiveness of our internal controls and we
will disclose any changes and material weaknesses in those internal controls identified
through such evaluation. A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of our annual or
interim financial statements will not be prevented or detected on a timely
basis.

 Breeze's management identified a material weakness
in our internal control over financial reporting. The material weakness
primarily related to the preparation and presentation of our 2023 income tax
provision and accounting for income tax expense. Management concluded that a
deficiency in internal control over financial reporting existed relating to the
recognition of transaction costs related to income taxes which constituted a
material weakness as defined in the SEC regulations. The material weakness resulted
in an increase in the net operating loss carryforward balance, and also
impacted Breeze's income tax expense and related balance sheet accounts.

 We have implemented a
remediation plan, described under Item 9A, Evaluation of Disclosure Controls
and Procedures to remedy the material weakness surrounding the preparation and review of our tax provision, but can give no assurance that the measures we have taken
will prevent any future material weaknesses or deficiencies in internal control
over financial reporting. Even though we have strengthened our controls and
procedures, in the future those controls and procedures may not be adequate to
prevent or identify irregularities or errors or to facilitate the fair
presentation of our financial statements.

 If Breeze is unable to successfully maintain effective internal control over financial reporting, investors may lose confidence in Breeze's reported financial information and its stock price and business may be adversely impacted.

 As a public company, Breeze is required to maintain internal control over financial reporting and Breeze's management is required to evaluate the effectiveness of its internal control over financial reporting as of the end of each fiscal year. If the company is not successful in maintaining effective internal control over financial reporting, there could be inaccuracies or omissions in the financial information Breeze is required to file with the SEC. Additionally, even if there are no inaccuracies or omissions, Breeze will be required to publicly disclose the conclusion of its management that the company's internal control over financial reporting or disclosure controls and procedures are not effective. These events could cause investors to lose confidence in Breeze's reported financial information, adversely impact Breeze's stock price, result in increased costs to remediate any deficiencies, attract regulatory scrutiny or lawsuits that could be costly to resolve and distract management's attention, limit the company's ability to access the capital markets or cause its stock to be delisted from The Nasdaq Stock Market or any other securities exchange on which it is then listed.

 ITEM 1 B. UNRESOLVED STAFF COMMENTS

 None.

 ITEM 1 C. CYBERSECURITY

 On July 26, 2023, the SEC adopted rules
requiring registrants to disclose material cybersecurity incidents they
experience and to disclose on an annual basis material information regarding
their cybersecurity risk management, strategy and governance. The final rules
became effective 30 days following publication of the adopting release in
the Federal Register. The Form 10-K disclosures are
due beginning with annual reports for fiscal years ending on or after December 15, 2023.

 Our board of directors is
generally responsible for the oversight of risks from cybersecurity threats, if
any.

 Breeze maintains a cyber risk
management program designed to identify, assess, manage, mitigate, and respond
to cybersecurity threats as appropriate for a Special Purpose Acquisition
Company ("SPAC"). Breeze's cybersecurity risk profile will significantly change
upon completion of the pending Business Combination transaction with YD Biopharma Limited. described in Item 1. Business within this Report. The
cyber risk management program will be re-evaluated upon the close of the Business
Combination.

 Breeze has a periodic assessment of the Company's cyber risk management program performed by a third-party specialist. The cyber risk
management assessment incorporates recognized best practices and standards for
cybersecurity and information technology of the National Institute of Standards
and Technology Cybersecurity Framework. The annual risk assessment identifies,
quantifies, and categorizes material cyber risks. In addition, the
Company, in conjunction with the third-party cyber risk management specialists, develops a risk mitigation plan to address such risks, and where necessary,
remediate potential vulnerabilities identified through the annual assessment
process.

 Breeze
employs additional measures within the cybersecurity risk management program
including identity access management controls such as restricted access of
privileged accounts, periodic reviews of user access, and segregation of duties
and anti-malware/anti-virus tools.

 Cybersecurity partners to the Company,
including consultants are
a key part of the Company's cybersecurity risk management strategy and infrastructure and provide
services including, cyber risk advisory. Breeze partners with industry recognized cybersecurity providers leveraging
third-party technology and expertise.

 Breeze currently does not have significant
operations. The Company is focused on effecting an initial business combination with one or more businesses. Upon completion of the
pending Business Combination with YD Biopharma, Breeze will face risks
 from cybersecurity threats that
could have a material adverse effect on its business, financial condition,
results of operations, cash flows or reputation. Breeze acknowledges that the risk of a cyber
incident is prevalent in the current threat landscape and that a future cyber
incident may occur in the normal course of its business. No prior cybersecurity
incidents have been identified by the Company. The Company proactively
seeks to detect and investigate unauthorized attempts and attacks against Company
IT assets and data, and to prevent
their occurrence and recurrence where practicable, however, potential vulnerabilities
to known or unknown threats will remain. Further,
there is increasi ng regulation regarding responses
to cybersecurity incidents, including reporting to regulators, investors, and additional
stakeholders, which could subject us to additional liability and reputational
harm. In response to such risks, the Company plans to implement initiatives
such as implementation of the cybersecurity risk assessment process and development
of an incident response plan. See Item 1A. "Risk
Factors" for more information on cybersecurity risks.

 ITEM 2. PROPERTIES

 We maintain our principal executive offices at 955 W. John Carpenter Fwy., Suite 100 - 929, Irving, TX 75039. The cost of our use of this space is included in the $ 5,000 per month fee we currently pay to an affiliate of our sponsor for office space, administrative and support services. We consider our current office space adequate for our current operations.

 ITEM 3. LEGAL PROCEEDINGS

 To the knowledge of our management, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.

 ITEM 4. MINE SAFETY DISCLOSURES

 Not applicable.

 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 (a) Market Information

 Our units commenced public trading on November 23, 2020, on the NASDAQ under the symbol "BREZU" until December 23, 2020, at which time our common stock, rights and warrants began separate trading, and units ceased trading. Our common stock, rights and redeemable warrants were each traded on the NASDAQ until May 29, 2024, under the symbol "BREZ", "BREZR" and "BREZW", respectively. On August 21, 2024, the Company's common stock and warrants began trading, and on August 23, 2024 the Company's rights began trading on the OTCQX Best Market under the symbol
"BRZH", "BRZHW" and "BRZHR".

 (b) Holders

 On March 11, 2025, there were 10 holders of record for our shares of common stock, 1 holder of our rights and 3 holders of our warrants. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our shares of common stock whose shares are held in the names of various security brokers, dealers and registered clearing agencies.

 (c) Dividends

 We have not paid any cash dividends on our common stock to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions subsequent to completion of an initial business combination. The payment of any cash dividends subsequent to an initial business combination will be within the discretion of our board of directors at such time. In addition, our board of directors is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.

 (d) Securities Authorized for Issuance Under Equity Compensation Plans

 None.

 (e) Performance Graph

 Not applicable.

 (f) Recent Sales of Unregistered Securities; Use of Proceeds from Registered Offerings

 Unregistered Sales

 On June 11, 2020, our sponsor, purchased an aggregate of 2,875,000 founder shares, for an aggregate offering price of $ 25,000 at an average purchase price of approximately $ 0.0001 per share. Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4 (a)( 2) of the Securities Act. Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D.

 In addition, our sponsor and I-Bankers purchased an aggregate of 5,425,000 warrants at a price of $ 1.00 per warrant, $ 5,425,000 in the aggregate. This purchase took place on a private placement basis simultaneously with the completion of our initial public offering. This issuance was made pursuant to the exemption from registration contained in Section 4 (a)( 2) of the Securities Act.

 Use of Proceeds

 In connection with the initial public offering, we incurred offering costs of $ 4,099,907 (including underwriting commissions of approximately $ 2.3 million). Other incurred offering costs consisted principally of preparation fees related to the initial public offering. After deducting the underwriting discounts and commissions and the initial public offering expenses, $ 116,725,000 of the net proceeds from our initial public offering and certain of the proceeds from the private placement of the private placement warrants (or $ 10.15 per Unit sold in the initial public offering) was placed in the trust account. The net proceeds of the initial public offering and certain proceeds from the sale of the private placement warrants are held in the trust account and invested as described elsewhere in this Report.

 There has been no material change in the planned use of the proceeds from our initial public offering and the sale of the private placement warrants as is described in our final prospectus related to our initial public offering. Other than as described above, no payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates.

 (g) Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 None.

 ITEM 6. [RESERVED]

 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 References in this report (the "Annual Report") to "we," "us" or the "Company" refer to Breeze Holdings Acquisition Corp. References to our "management" or our "management team" refer to our officers and directors, and references to the "Sponsor" refer to Breeze Sponsor, LLC.

 Special Note Regarding Forward-Looking Statements

 This Annual Report includes "forward-looking statements" within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-K including, without limitation, statements in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding the Company's financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as "expect," "believe," "anticipate," "intend," "estimate," "seek" and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management's current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements.

 The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Annual Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Annual Report.

 Overview

 We are a blank check company formed under the laws of the State of Delaware on June 11, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. We intend to effectuate our business combination using cash from the proceeds of the Initial Public Offering and the sale of the private placement warrants, our capital stock, debt or a combination of cash, stock and debt.

 As indicated in the accompanying financial statements, at December 31, 2024 and 2023, we had $ 101,674 and $ 4,228 in cash, respectively, and working capital deficits of $ 17,358,530 and $ 7,849,292, respectively (excluding prepaid income tax, franchise tax payable and excise tax payable). We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete our initial business combination will be successful.

 Results of Operations

 We have neither engaged in any operations nor generated any revenues to date. Our only activities from June 11, 2020 (inception) through December 31, 2024 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for a business combination. We do not expect to generate any operating revenues until after the completion of our business combination. We generate non-operating income in the form of interest income on marketable securities held in the trust account, and changes in the fair value of warrant liabilities. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

 For the year ended December 31, 2024, we had net loss of $ 2,304,638, which consisted of a loss of $ 677,000 in the fair value of warrant liabilities and operating costs of $ 2,225,820, offset by interest income from our trust account of $ 598,182.

 For the year ended December 31, 2023, we had net loss of $ 2,549,111, which consisted of a loss of $ 1,015,500 in the fair value of warrant liabilities, interest income from our trust account of $ 554,701, offset by operating and formation costs of $ 2,070,143 and a tax credit of $18,169.

 Liquidity and Capital Resources

 On November 25, 2020, we consummated the Initial Public Offering of 11,500,000 units at a price of $ 10.00 per unit (including 1,500,000 units from the full exercise of the underwriters' over-allotment option), generating gross proceeds of $ 115,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 5,425,000 private placement warrants to the Sponsor at a price of $ 1.00 per warrant, generating gross proceeds of $ 5,425,000.

 Following the Initial Public Offering, the exercise of the over-allotment option and the sale of the private placement warrants, a total of $ 116,725,000 was placed in the trust account. We incurred $ 4,099,907 in transaction costs, including $ 2,300,000 of underwriting fees, $ 1,322,350 of representative share offering costs, and $ 477,557 of other offering costs.

 As of December 31, 2024, we had cash held in the interest-bearing trust account of $ 10,532,045 of which $7,353,424 was disbursed January 2, 2025
in conjunction with the redemptions from our Special Shareholders Meeting held
on December 23, 2024.

 On May 5, 2022, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to September 26, 2022 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.35 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 6,732,987 shares of the Company's common stock were redeemed for $ 69,700,628, (the "Redemption"). On May 10, 2022, $ 109,000 was withdrawn from the Trust Account for payment of franchise and income taxes.

 On September 13, 2022, the Company held its annual stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to March 26, 2023 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.35 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 3,076,817 shares of the Company's common stock were redeemed for $ 31,845,056 with 1,690,196 shares remaining. On September 8, 2022, $ 122,247 was withdrawn from the Trust Account for payment of franchise and income taxes.

 At the annual meeting of the Company held on September 13, 2022, the Company's stockholders approved (i) a proposal to amend the Company's Amended and Restated Certificate of Incorporation (the "A&R COI") to authorize the Company to extend the date of September 26, 2022, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as March 26, 2023) by which the Company must (a) consummate a merger, capital stock exchange, asset, stock purchase, reorganization or other similar business combination, which we refer to as our initial business combination, or (b) cease its operations except for the purpose of winding up if it fails to complete such initial business combination, and redeem all of the shares of common stock of the Company included as part of the units sold in the Company's initial public offering that was consummated on November 25, 2020, and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. The amended Trust Agreement authorizes the Company's Board of Directors to extend the time to complete the Business Combination up to six ( 6) times for an additional one ( 1) month each time (for a maximum of six one -month extensions), upon the deposit into the Trust Account of $ 0.035 for each outstanding public share by the Sponsor or its designees on or prior to September 26, 2022 or such other date as may be extended. Breeze executed its first one month extension of September 26, 2022 depositing $ 59,157 in the Trust Account. On October 21, November 23, December 20, 2022, January 25, 2023 and February 23, 2023 Breeze executed the second, third, fourth, fifth and sixth one -month extensions through March 26, 2023.

 The Company held a meeting of its stockholders on March 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of March 26, 2023, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as September 26, 2023), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On March 29, 2023, Breeze executed the seventh one -month extension through April 26, 2023. On April 25, 2023, May 25, 2023, and June 26, 2023 Breeze executed the eighth, ninth and tenth one -month extensions through July 26, 2023. On August 3, 2023 and August 28, 2023, Breeze executed the eleventh and twelfth one -month extensions through September 26, 2023.

 The Company held a meeting of its stockholders on September 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of September 26, 2023, up to nine ( 9) times for an additional one ( 1) month each time (ultimately until as late as June 26, 2024), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On September 27, 2023 Breeze executed the thirteenth one -month extension through October 26, 2023. On October 25, 2023, November 27, 2023, December 27, 2023, January 26, 2024, February 27, 2024, March 26, 2024, May 7, 2024 and June 3, 2024 Breeze executed the fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty-first one -month extensions through June 26, 2024. On June 26, 2024 and August 1, 2024, Breeze
executed the twenty-second and twenty-third one -month
extensions through August 26, 2024. On November 22, 2024, Breeze executed
(including accrued interest) the twenty-fourth, twenty-fifth and twenty-sixth
one-month extensions for the period from August 26, 2024 through November
26, 2024, and on December 31, 2024 the Company executed the twenty-seventh and
twenty-eighth one-month extension for the period from November 26, 2024 to
January 26, 2025.

 As of December 31, 2024, we had cash held in the trust account of $ 10,532,045, including $598,182 of interest. Interest income on the balance in the trust account may be used by us to pay taxes. On May 10, 2022, $ 109,000 was withdrawn from the Trust Account for payment of franchise and income taxes on September 8, 2022, $ 122,247 was withdrawn from the Trust Account for payment of franchise and income taxes, and on September 27, 2023, $ 209,650 was withdrawn of interest income from the Trust Account for payment of franchise and income taxes, and on June 24, 2024 and December 30, 2024, $59,000
and $262,226 was withdrawn for franchise and income taxes, respectively.

 For the year ended December 31, 2024, cash used in operating activities was $ 1,609,475 which was due to a net loss of $ 2,304,638 a non-cash decrease in fair value of warrant liabilities of $ 677,000, interest income of $ 598,182 on the Trust Account, and an increase in working capital of $ 616,345. For the same period cash provided by investing activities was $ 3,043,665 which was due to extension payments paid into the Trust Account of $ 359,273, a redemption of common stock of $ 3,081,712, and a withdrawal of interest income from the Trust Account of $ 321,226. For the same period net cash used in financing activities was $ 1,336,744 which was due to proceeds from a related party working capital loan of $ 1,385,695, proceeds from a related party promissory note of $ 359,273 and, a redemption of common stock of $ 3,081,712.

 For the year ended December 31, 2023, cash used in operating activities was $ 2,024,603 which was due to a net loss of $ 2,549,111 a non-cash decrease in fair value of warrant liabilities of $ 1,015,500, interest income of $ 554,701 on the Trust Account, and an increase in working capital of $ 63,709. For the same period cash used in investing activities was $ 5,308,141 which was due to extension payments paid into the Trust Account of $ 528,514, a redemption of common stock of $ 5,627,005, and a withdrawal of interest income from the Trust Account of $ 209,650. F or the same period net cash used in financing activities was $ 3,293,439 which was due to proceeds from a related party working capital loan of $ 1,811,900, proceeds from a related party promissory note of $ 521,666 and, a redemption of common stock of $ 5,627,005.

 We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account (less deferred cash underwriting commissions, and income and franchise taxes payable), to complete our business combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our business combination, the remaining proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 As of December 31, 2024 and 2023, the Company had $ 101,674 and $ 4,228, respectively, in cash held outside of the Trust Account and working capital deficits of $ 17,358,530 and $ 7,849,292, respectively, (excluding franchise tax, prepaid income tax, and excise tax payable).

 In order to fund working capital deficiencies or finance transaction costs in connection with a business combination, the initial stockholders or their affiliates may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we would repay such loaned amounts. In the event that a business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. We do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

 On November 19, 2021, the Sponsor loaned the Company an aggregate of $ 1,150,000 pursuant to an unsecured promissory note to extend the date by which the Company has to consummate a business combination from November 25, 2021 to February 25, 2022. This unsecured promissory note, as amended for the maturity date, is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025. On February 18, 2022, the Sponsor loaned the Company an aggregate of $ 1,150,000 pursuant to an unsecured promissory note to extend the date by which the Company has to consummate a business combination from February 25, 2022 to May 25, 2022. This unsecured promissory note, as amended for the maturity date, is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025.

 On February 1, 2022, the Company signed a Promissory Note with Sponsor, with a Maturity Date of March 26, 2023, for a total of up to $ 1,500,000. On October 1, 2022, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 4,000,000. On April 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 5,000,000. On October 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of June 26, 2024 for a total of up to $ 6,000,000. On March 1, 2024, the Company signed an Amended
Promissory Note with Sponsor, with a Maturity Date of June
26, 2024 for a total of up to $ 7,000,000. On
July 1, 2024, the Company signed an Amended Promissory Note with Sponsor, with
a Maturity Date of December 26, 2024 for a total
of up to $ 7,500,000. On December 26, 2024, the
Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of
June 26, 2025 for a total of up to $ 7,500,000. As of December 31, 2024, the amount outstanding under this Promissory Note was $ 5,997,804 for direct working capital, and $ 1,083,097 for monthly SPAC extension funds for the months of September, 2022 through December, 2024 for a total of $ 7,080,901 from Sponsor. The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025. Breeze additionally owes Sponsor
$202,556 for expenses paid by Sponsor on behalf of the Company. The total
amount owed Sponsor as of December 31, 2024 is $9,583,457.

 We believe we will need to raise additional funds in order to meet the expenditures required for operating our business. If our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a business combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our business combination. Moreover, we may need to obtain additional financing either to complete our business combination or because we become obligated to redeem a significant number of our public shares upon consummation of our business combination, in which case we may issue additional securities or incur debt in connection with such business combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our business combination. If we are unable to complete our business combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. In addition, following our business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

 Going Concern

 Management determined that the above conditions and/or events indicate that it may be probable that the Company would be unable to meet its obligations as they become due within one year from the date that the financial statements are available to be issued. Although Management plans to address this uncertainty through a Business Combination or through obtaining loans, there is no assurance that the Company's plans to consummate the Business Combination or obtain the loans will be successful. The Company has until
June 26, 2025 to consummate a business combination, and we intend to do so
within this time period.

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company's business plan is dependent on the completion of a business combination and the Company's cash and working capital as of December 31, 2024 are not sufficient to complete its planned activities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any
adjustments relating to the recovery of the recorded assets or the
classification of the liabilities that might be necessary should we be unable
to continue as a going concern.

 Off-balance Sheet Financing Arrangements

 We have no obligations, assets, or liabilities, which would be considered off-balance sheet arrangements as of December 31, 2024 and 2023.

 Contractual Obligations

 On November 19, 2021, the Sponsor loaned the Company an aggregate of $ 1,150,000 pursuant to an unsecured promissory note to extend the date by which the Company has to consummate a business combination from November 25, 2021 to February 25, 2022. This unsecured promissory note, as amended for the maturity date, is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025. On February 18, 2022, the Sponsor loaned the Company an aggregate of $ 1,150,000 pursuant to an unsecured promissory note to extend the date by which the Company has to consummate a business combination from February 25, 2022 to May 25, 2022. This unsecured promissory note, as amended for the maturity date, is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025.

 On February 1, 2022, the Company signed a Promissory Note with Sponsor, with a Maturity Date of March 26, 2023, for a total of up to $ 1,500,000. On October 1, 2022, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 4,000,000. On April 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 5,000,000. On October 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of June 26, 2024 for a total of up to $ 6,000,000. On March 1, 2024, the Company signed an Amended
Promissory Note with Sponsor, with a Maturity Date of June
26, 2024 for a total of up to $ 7,000,000. On
July 1, 2024, the Company signed an Amended Promissory Note with Sponsor, with
a Maturity Date of December 26, 2024 for a total
of up to $ 7,500,000. On December 26, 2024, the
Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of
June 26, 2025 for a total of up to $ 7,500,000. As of December 31, 2024, the amount outstanding under this Promissory Note was $ 5,997,804 for direct working capital, and $ 1,083,097 for monthly SPAC extension funds for the month of September, 2022 through December, 2024 for a total of $ 7,080,901 from Sponsor. The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025. The Company additionally owes Sponsor $ 202,556 for expenses paid by Sponsor on behalf of the Company. The total amount owed Sponsor as of December 31, 2024 is $ 9,583,457.

 We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay B r eeze Financial, Inc. a monthly fee of $ 5,000 for office space, administrative and support services to the Company.

 On November 23, 2020, t he Company entered into a business combination marketing agreement with I-Bankers on November 23, 2020, as an advisor in connection with a
Business Combination to assist the Company in holding meetings with its
stockholders to discuss the potential Business Combination and the target
business' attributes, introduce the Company to potential investors that are
interested in purchasing the Company's securities in connection with a Business
Combination, assist the Company in obtaining stockholder approval for the
Business Combination and assist the Company with its press releases and public
filings in connection with the Business Combination. Per the terms of the agreement, the Company will pay
I-Bankers a cash fee for such services upon the consummation of a Business
Combination in an amount equal to 2.75 % of the
gross proceeds of Initial Public Offering, or $ 3,162,500.
As of December 31, 2024, there were no unbilled or accrued amounts for services that had
been performed pursuant to this agreement.

 On
March 24, 2021, as supplemented on August 30, 2022, the Company signed a Legal
Services Engagement Letter with Woolery & Co. ("Woolery") for
services in connection with completing a business combination or a similar transaction. Services include, but are not limited to, strategic legal advice on a business combination and associated corporate matters, introductions to financial institutions to facilitate business combination financing requirements, domestic and international transaction structuring, and preparation of any required Nasdaq listing application. As of December 31, 2024, there were no unbilled or accrued amounts for services that had been performed pursuant to this
agreement. Pursuant to the engagement letter, Breeze paid a non-refundable retainer of $100,000, and upon the
completion of a business combination or similar transaction, Breeze is
obligated to pay Woolery a fee of $2.0 million, however, Sponsor has agreed to assume $1.2 million of the obligation, and any discretionary performance
fee, if warranted, and mutually and reasonably agreed upon by Breeze and
Woolery. At the closing of a business combination, Breeze will pay Woolery the balance of $800,000.

 On February 29, 2024, the Company signed a Public
Relations Agreement, as amended, with Gateway Group, Inc.("Gateway"), for public relations services for
a business combination. As of December 31, 2024, Gateway has not provided the Company with any services pursuant to this agreement. The agreement includes an obligation to pay a
Transaction Success Fee of $100,000 upon
the successful completion of a business combination.

 On October 17, 2024, Breeze signed a Proxy
Solicitation Services Agreement with D.F. King & Co., Inc. ("D.F.
King"), for proxy solicitation services associated with the business
combination with YD Biopharma. As of December 31, 2024, D.F. King has not provided the Company with any services pursuant to this agreement. The agreement includes an obligation to pay a
Service Fee of $25,000 and a discretionary fee, if warranted, at the sole
discretion of the Breeze based, upon the campaign and D.F. King's performance.

 On October 30, 2024, Breeze signed a Merger
Proxy/Business Combination Rate Agreement with Edgar Agents LLC, for SEC
document preparation, printing and filing for the merger with YD Biopharma. As of December 31, 2024, there were no unbilled or pending amounts to be invoiced for services that had been performed through December 31, 2024, pursuant to this
agreement. The
agreement includes an obligation to pay a Transaction Success Fee of $50,000
upon successful completion and filing of the documents with the SEC.

 Critical Accounting Estimates

 The preparation of the financial statements included in this Report under "Item 15. Exhibits, Financial Statements Schedules" and related disclosures in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

 We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. The critical accounting estimates, assumptions, judgements and the related policies that we believe have the most significant impact on our consolidated financial statements are described below.

 Warrant Liabilities

 The Company
evaluated the Public Warrants and Private Placement Warrants (collectively,
"Warrants", see Note 7) in accordance with ASC 815-40, "Derivatives and Hedging
— Contracts in Entity's Own Equity", and concluded that a provision in the
warrant agreement related to certain tender or exchange offers precludes the
Warrants from being accounted for as components of equity. As the Warrants meet
the definition of a derivative as contemplated in ASC 815, the Warrants are
recorded as derivative liabilities on the consolidated balance sheet and
measured at fair value at inception (on the date of the Initial Public
Offering) and at each reporting date thereafter in accordance with ASC 820,
"Fair Value Measurement" ("ASC 820"), with changes in fair value recognized in
the consolidated statement of operations in the period of change.

 In determining the fair value of the Company's
Public Warrants and Private Placement Warrants our third-party valuation firm
uses the most observable inputs available. At
December 31, 2023, the fair value of the Company's Private Placement Warrants
was based on a Modified Black-Scholes model, and the Public
Warrants utilized the trading price of the Company's Public Warrants. At
December 31, 2024, the fair value of both the Company's Private Placement
Warrants and Public Warrants utilized the Company's trading price of the Public
Warrants. As of December 31, 2024, the Company determined that utilizing the
Modified Black-Scholes model to value the Private Placement Warrants deviated
too far from what would be expected if the Private Placement Warrants were
publicly traded as the terms of the Public Warrants and Private Placement
Warrants are similar. Some of
the inputs used in the models include the dividend yield on the Company's common
stock, expected common stock price volatility, risk-free interest rate,
expected business combination date and probability of completing the business
combination. Several of these inputs are known and several use judgments. For
instance, the probability of completing the business combination is derived by
taking a sample of other special purpose acquisition companies and calculating
the implied probability of completion for each company in the sample set. The
average and 1st and 3rd
quartiles of the implied probability of completion then formulates the basis
for the probability utilized for the Company in the models. Changes in any or
all of these estimates and assumptions, or the relationships between these
assumptions, impact the Company's valuation of its Public Warrants and Private
Placement Warrants for valuation dates where the trading price of the Public Warrants was not used, and may have a material impact on
the valuation of these warrants.

 Recent Accounting Pronouncements

 For a detailed discussion of our significant accounting policies and related judgements, see Note 2 —Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements included in "Item 15. Exhibits, Financial Statements Schedules" of this Report.

 ITEM 7 A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 We are a smaller reporting company as defined by Rule 12 b- 2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 This information appears following Item 16 of this Report and is included herein by reference.

 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 None.

 ITEM 9 A. CONTROLS AND PROCEDURES

 Evaluation of Disclosure Controls and Procedures

 Our management,
including our Chief Executive Officer, who serves as our principal executive
officer and our principal financial officer, carried out an evaluation of the
effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act). Based on that evaluation, our management concluded that our disclosure
controls and procedures were not effective as
of December 31, 2024, because of the identified material weakness in our
internal control over financial reporting, described below.

 We do not expect that
our disclosure controls and procedures will prevent all errors and all
instances of fraud. Disclosure controls and procedures, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the disclosure controls and procedures are met. Further,
the design of disclosure controls and procedures must reflect the fact that
there are resource constraints, and the benefits must be considered relative to
their costs. Because of the inherent limitations in all disclosure controls and
procedures, no evaluation of disclosure controls and procedures can provide
absolute assurance that we have detected all our control deficiencies and
instances of fraud, if any. The design of disclosure controls and procedures
also is based partly on certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed in achieving
its stated goals under all potential future conditions.

 Management's
Report on Internal Control Over Financial Reporting

 Our management is
responsible for establishing and maintaining adequate internal control over
financial reporting. Internal control over financial reporting is defined in
Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process
designed by, or under the supervision of, the Company's Chief Executive
Officer, who serves as the Company's principal executive officer and principal
financial officer, and effected by the Company's Board, management and other
personnel, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and
includes those policies and procedures that:

 Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

 Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

 Because of its
inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Therefore, even those systems determined to be
effective can provide only reasonable assurance with respect to financial
statement preparation and presentation. Projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.

 Under the
supervision, and with the participation of, our management, including our Chief
Executive Officer, we conducted an evaluation of the effectiveness of our
internal control over financial reporting based on the criteria established
in Internal Control — Integrated Framework issued by the
Committee of Sponsoring Organizations ("COSO") of the Treadway Commission
("2013 Framework"). Based on our evaluation under the COSO 2013 Framework, our
management concluded that our internal control over financial reporting was not effective as of December 31, 2024 as a result of the material weakness
discussed below.

 We identified a
material weakness in our internal control over financial reporting. A material
weakness is a deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a
material misstatement of the Company's annual or interim financial statements
will not be prevented or detected on a timely basis. The material weakness
primarily related to the preparation and presentation of our 2023 income tax
provision and accounting for income tax expense. Management concluded that a
deficiency in internal control over financial reporting existed relating to the
recognition of transaction costs related to income taxes which constituted a
material weakness as defined in the SEC regulations. The material weakness
resulted in an increase in the net operating loss carryforward balance, and
also impacted our income tax expense and related balance sheet accounts.

 In light of this
material weakness, we have implemented a remediation plan to enhance our
processes to identify and appropriately apply applicable accounting
requirements to better evaluate and understand the nuances of the transaction
costs standards that apply to our financial statements. Our remediation plan
includes providing enhanced access to accounting literature, research materials
and documents and increased communication among our personnel and third-party
professionals with whom we consult regarding income tax applications. The
elements of our remediation plan can only be accomplished over time, and we can
offer no assurance that these initiatives will ultimately have the intended
effects.

 Attestation Report
of the Registered Public Accounting Firm

 This Annual Report
on Form 10-K does not include an attestation report on internal control over
financial reporting from our independent registered public accounting firm due
to our status as an emerging growth company under the JOBS Act.

 Changes in Internal Control over Financial Reporting

 Except as set forth above, during the most recently
completed fiscal year, there has been no change in our internal control over
financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.

 ITEM 9 B. OTHER INFORMATION.

 None.

 ITEM 9 C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 Not applicable.

 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Directors and Executive Officers

 As of the date of this Report our directors and officers are as follows:

 Name

 Age

 Title

 J. Douglas Ramsey, Ph. D.

 Chairman, Chief Executive Officer and Chief Financial Officer

 Russell D. Griffin

 President and Director

 Charles C. Ross, P.E.

 Chief Operating Officer

 James L. Williams

 Independent Director

 Albert McLelland

 Independent Director

 Robert Lee Thomas

 Independent Director

 Bill Stark

 Independent Director

 J. Douglas Ramsey, Ph. D. has served as our Chairman, Chief Executive Officer and Chief Financial Officer since June 2020. Dr. Ramsey was the President and Chief Financial Officer of Saddle Operating and served in that role from May 2014 until February 2019. Prior to joining Saddle Operating, Dr. Ramsey served as the Director of Strategic Planning and Special Projects of EXCO from June 2013 until April 2014, Vice President – Finance and Special Assistant to the Chairman of EXCO Resources from August 2009 until May 2013 and as Treasurer of EXCO Resources from December 1997 until May 2013. From December 1997 until July 2009, Dr. Ramsey served as EXCO Resources' Chief Financial Officer during which time EXCO Resources completed over 160 transactions and its assets grew from $3 million to over $6 billion with over 15,000 wells and more than 1,400 employees and contractors. Dr. Ramsey also played a key role in EXCO Resources' $698 million IPO in February 2006 after EXCO Resources had gone private in July 2003. Other key financing transactions in which Dr. Ramsey was involved included a $2 billion mandatory convertible preferred stock offering, a $2.4 billion line of credit with 34 banks in the syndicate, and two bond offerings totaling $750 million. Dr. Ramsey also served as a director of EXCO Resources from March 1998 until July 2003. From March 1992 until December 1997, Dr. Ramsey worked for Coda Energy as the Financial Analyst and Assistant to the President and then as the Financial Planning Manager. Dr. Ramsey also taught finance at various universities including Southern Methodist University in its undergraduate and professional MBA programs and Baylor University in its Executive MBA program. Dr. Ramsey was named the 1996 Distinguished Alumnus of the College of Business Administration at Cal Poly Pomona. Dr. Ramsey earned his BS in Finance from Cal Poly Pomona, an MBA from the University of Chicago Booth School of Business and an MA and Ph. D. in Business and Financial Economics from the Claremont Graduate University. Dr. Ramsey is National Association of Corporate Directors (NACD) Directorship Certified.

 Russell D. Griffin has served as our President and as a director since June 2020. Mr. Griffin was the Chief Operating Officer of Saddle Operating and served in that role from November 2015 until June 2019. Prior to joining Saddle Operating, Mr. Griffin served as the Vice President of Environmental, Health and Safety of EXCO Resources from June 2010 until November 2015, and as the Vice President of Environmental, Health and Safety of TGGT Holdings, an independent midstream oil and gas company, from 2012 until 2013. Prior to joining EXCO Resources, Mr. Griffin was the Senior Regulatory Representative for Hunt Oil Company, an independent international oil and natural gas company, from August 2005 until January 2008 and held positions in exploration and production operations from August 1984 until August 2005. His areas of expertise include onshore U.S conventional and non-conventional, offshore Gulf of Mexico Outer Continental Shelf (OCS) as well as State waters of both Louisiana and Texas. Mr. Griffin has also led or participated in multiple acquisitions and divestitures, both domestic and international. He is a member of the American Association of Drilling Engineers, Society of Petroleum Engineers and American Association of Safety Professionals. Mr. Griffin received his BS degree in Petroleum Engineering Technology and an AS degree in Safety Management from Nicholls State University. Mr. Griffin is National Association of Corporate Directors (NACD) Directorship Certified.

 Charles C. Ross, P.E. has served as our Chief Operating Officer since June 2020. Mr. Ross was the Vice President of Regulatory Affairs and EHS of Saddle Operating and served in that role from December 2015 until June 2019. In January 2010 until December 2013, Mr. Ross was the Director of Regulatory Affairs of TGGT Midstream. In August 2012, Mr. Ross was named Director of Regulatory Affairs for EXCO Resources, as well, until November 2015. Mr. Ross began his career in 1982 working for the Railroad Commission of Texas Oil and Gas Division as a New Field Discovery Examiner. Mr. Ross continued working for the RRC for 27 more years in various positions including Engineering Supervisor of the Underground Injection Control Section, District Engineer, Assistant District Director, and Director of Field Operations. As Director of Field Operations, Mr. Ross oversaw nine currently serves as the Chair of the Regulatory Practice Committees at both TXOGA (Texas Oil and Gas Association) and TIPRO (Texas Independent Producers and Royalty Association) district offices and 247 employees. Mr. Ross is an expert witness at Railroad Commission hearings, civil trials, legislative committee meetings, and legislative hearings on various issues related to oil and gas regulatory and technical matters. Mr. Ross has been a registered Professional Engineer (Petroleum) since 1988, and currently serves as the Chair of the TIPRO (Texas Independent Producers and Royalty Association) Regulatory Committee. Mr. Ross received his BS in Architectural Engineering and a BS in Petroleum Engineering both from the University of Texas at Austin.

 James L. Williams began serving as a director in August 2022. General Williams served in the
United States Marine Corps for over 35 years, most recently as a
Major General, 4 th Marine Division, where he commanded Marines at
every level in combat operations and readiness until he retired from military
service in 2010. During the Global War on Terrorism, General Williams held
positions as Assistant Division Commander, 2 nd Marine Division, in
combat operations at Camp Blue Diamond, Al-Ramadi, Iraq and as Deputy
Commanding General, 1 st Marine Expeditionary Force in Fallujah,
Iraq. General Williams also served on the Secretary of Defense's Reserve Force
Policy Board, and included in his military decorations are the Defense
Meritorious Service Medal, Legion of Merit, Bronze Star Medal, Meritorious
Service Medal, and the National Defense Medal, to name a few. General Williams
currently serves as Managing Senior Partner of Lotus Tiger International, LLC.
General Williams previously served as Chief Executive Officer and Chairman of
Zenneck Power LLC. General Williams received a Bachelor of Science Degree
from Slippery Rock University, PA and reported to Officer Candidate School,
receiving his commission in 1976. His education includes Master's Degrees from
Georgetown University in Government and National Affairs and from Yale University
in Hospital Management and Public Health. He has completed program studies at
Harvard's JFK School of Government in the National and International Studies
Program. General Williams has completed the LOGTECH Program, Center of
Excellence in Logistics and Technology, University of North Carolina,
Kenan-Flagler Business School, Chapel Hill, North Carolina and a Master of
Science in Strategic Studies, U.S. Army War College, Carlisle Barracks,
Carlisle, Pennsylvania. General Williams has served on boards of directors
and/or boards of advisors of for-profit companies, including Zenneck Power,
LLC, Rewards.com/RewardToken. IO, PayFor All, LLC, Mobile Equity Corporation
(d.b.a. Qruz), and DCG International. In the non-profit sector, General
Williams served with the Board of International Learning of Texas Public
Charter School District, the Tower Center at Southern Methodist University,
Cybercrime Committee of the North Texas Crime Commission, the Tarleton State
Criminal Justice Program, the Admiral Nimitz Foundation and National Museum of
the Pacific War, the American Board of Physician Specialties and Disaster
Medicine Committee, the Veterans Coalition of North Central Texas, the VA
Medical Center of North Texas, the World Craniofacial Foundation, and the Bridge-Homeless
Program. General Williams also spends time helping Veterans and surviving
spouses fight for the benefits and services they so rightfully deserve.

 Albert McLelland has served as a director since November 2020. Since 2002, Mr. McLelland has served as
the Managing Director of AmPac Strategic Capital LLC, an advisory firm and
investment holding company that creates value across the investment process
from deal origination and execution to management, oversight and exit. Before
founding AmPac, from 1998 until 2002, Mr. McLelland was the Director of
the Chairman's Asian Cross-Border Transactions Initiative for
PricewaterhouseCoopers ("PwC") Financial Advisory Services. As Director, Mr.
McLelland assisted PwC's largest clients to complete cross-border transactions
in Asia. Between 1993 and 1998, Mr. McLelland founded and sold Pearl Delta
Capital Corp. in Taiwan. From 1991 until 1993, Mr. McLelland was Senior
Manager for Corporate Finance at CEF Taiwan Limited, a large Hong Kong based
merchant bank. In 1990, Mr. McLelland assisted in the formation of
Riddell*Tseng where he worked until 1993. Mr. McLelland started his career
as an Associate in Public Finance at Shearson Lehman from 1987 until 1990. Mr. McLelland
has served as an adjunct professor and guest lecturer at leading business
schools in the US and China. He currently serves on the Advisory Board at the
Institute for Excellence in Corporate Governance at the University of Texas
(Dallas), where he is also the Chairman of the Steering Committee for the North
Texas Private Equity Council. Mr. McLelland received his BA in Political
Science and History from the University of South Florida, an MBA from the
University of Chicago Booth School of Business and an MA in International
Affairs from Columbia University. Mr. McLelland is National Association of
Corporate Directors (NACD) Directorship Certified. In his public board
capacity, he has also served as the Chairman of the Special Committee for the
sale of China Fire & Security Group, Inc. (CFSG) to Bain Capital.

 Robert Lee Thomas has served as a director since November 2020. Mr. Thomas was Vice President and Chief Information Officer at Kosmos Energy from 2015 until May 2020. In this role, Mr. Thomas had corporate information systems oversight, as well as geotechnical systems strategy responsibility. Prior to Kosmos, Mr. Thomas was a corporate officer and Chief Information Officer at EXCO Resources from 2008 until 2015. In addition to corporate information systems oversight, Prior to Kosmos, Mr. Thomas was a corporate officer and Chief Information Officer at EXCO Resources from 2008 until 2015. In addition to corporate information systems oversight, Mr. Thomas had responsibility for the geoscience personnel and technology. From 1994 until 2006, Mr. Thomas held a series of roles, from geotechnical systems leadership to international business management to Chief Information Officer at Burlington Resources Canada with Burlington Resources Oil and Gas. Following the acquisition of Burlington Resources by ConocoPhillips in 2006, Mr. Thomas co-led the integration of systems into ConocoPhillips, earning a President's Award, and was Director of IT Strategy and Architecture at ConocoPhillips until 2008. From 1981 until 1994, Mr. Thomas held a series of roles from geophysical seismic acquisition and processing to exploration system development in the exploration technology groups with Sun Oil Company and the Oryx Energy spinoff. Mr. Thomas earned his BS in Economics and Finance from The University of Texas at Dallas. Mr. Thomas was elected and served on the City Council in Murphy, Texas, was a former member of the Advisory Board at the University of North Texas School of Information Technology Decision Sciences and has been an active member of the Society of Exploration Geophysicists for over 25 years. Mr. Thomas is National Association of Corporate Directors (NACD) Directorship Certified.

 Bill Stark has served as a director since November 2020. Mr. Stark currently serves as Senior Vice President of the Americas, and previous served as the Vice President—Western U.S. Operations of Ulterra from August 2017 to March 2021. Mr. Stark has operated in different executive positions over the Permian since joining Ulterra. In December 2009, Mr. Stark became the District Manager over the Permian. In January 2012, Mr. Stark was promoted to Area Manager for Ulterra—Permian. Prior to this, he was an agent for Halliburton—Security DBS, as well as President/Owner of Permian Bit Service Inc. and Permian Equipment Rentals Inc. Mr. Stark was one of the first to successfully introduce and continually market PDC bits in the Spraberry Trend. He has over 40 years of experience in the oil industry, all of which were with Halliburton before joining Ulterra. Mr. Stark led a team in the Permian that became one of the largest revenue districts in the U.S. for Halliburton-Security DBS. From 2012 to 2017, Mr. Stark operated as the Director of National Sales which grew Ulterra into becoming number one in market share in the U.S. In addition to his success with Ulterra, in 2012, Mr. Stark also became President and CEO of Cactus Fuel, LLC while continuously maintaining his role at Ulterra. Mr. Stark lives in Midland, Texas.

 Number and Terms of Office of Officers and Directors

 Our board of directors is divided into two classes with only one class of directors being elected in each year and each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a two-year term. The class I directors consist of Messrs. Griffin, Stark and Williams. The class II directors consist of Messrs. Ramsey, McLelland and Thomas.

 Our officers are elected by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our officers may consist of a Chief Executive Officer, President, Chief Financial Officer, Vice Presidents, Secretary, Assistant Secretaries, Treasurer and such other offices as may be determined by the board of directors.

 Involvement in Certain Legal Proceedings

 There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.

 Director Independence

 OTCQX and NASDAQ listing standards require that a majority of our board of directors be independent. An "independent director" is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company's board of directors, would interfere with the director's exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that each of Mr. McLelland, Mr. Thomas, Mr. Stark, and Gen. Williams are "independent directors" as defined in OTCQX and NASDAQ listing standards and applicable SEC rules. Our independent directors have regularly scheduled meetings at which only independent directors are present.

 Committees of the Board of Directors

 Our board of directors has three standing committees: an audit committee, a compensation committee, and a nominating and corporate governance committee. Each committee operates under a charter that has been approved by our board and has the composition and responsibilities described below. Our audit committee, compensation committee and nominating and corporate governance committee are composed solely of independent directors.

 Audit Committee

 Messrs. McLelland, Thomas and Williams serve as members of our audit committee, and Mr. McLelland serves as its chairman. Under the OTCQX and NASDAQ listing standards and applicable SEC rules, we were required to and still have at least three members on the audit committee. The rules of OTCQX, NASDAQ and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Messrs. McLelland, Thomas and Williams qualify as independent directors under applicable rules. Each member of the audit committee is financially literate and our board of directors has determined that Mr. McLelland qualifies as an "audit committee financial expert" as defined in applicable SEC rules.

 We adopted an audit committee charter, which details the principal functions of the audit committee, including:

 •

 the appointment, compensation, retention, replacement, and oversight of the work of the independent registered accounting firm and any other independent registered public accounting firm engaged by us;

 •

 pre-approving all audit and non-audit services to be provided by the independent registered accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;

 •

 reviewing and discussing with the independent registered accounting firm all relationships the auditors have with us in order to evaluate their continued independence;

 •

 setting clear hiring policies for employees or former employees of the independent registered accounting firm;

 •

 setting clear policies for audit partner rotation in compliance with applicable laws and regulations; (i) obtaining and reviewing a report, at least annually, from the independent registered accounting firm describing (ii) the independent registered accounting firm's internal quality-control procedures and (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;

 •

 reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and

 •

 reviewing with management, the independent registered accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.

 Compensation Committee

 Messrs. McLelland, Thomas and Stark serve as members of our compensation committee, and Mr. Thomas serves as its chairman. Under the OTCQX and NASDAQ listing standards and applicable SEC rules, we were required to and still have at least two members on the compensation committee, all of whom must be independent.

 We adopted a compensation committee charter, which details the principal functions of the compensation committee, including:

 •

 reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer's compensation, evaluating our Chief Executive Officer's performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer's based on such evaluation;

 •

 reviewing and approving the compensation of all of our other executive officers;

 •

 reviewing our executive compensation policies and plans;

 •

 implementing and administering our incentive compensation equity-based remuneration plans;

 •

 assisting management in complying with our proxy statement and annual report disclosure requirements;

 •

 approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;

 •

 producing a report on executive compensation to be included in our annual proxy statement; and

 •

 reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

 The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by OTCQX, NASDAQ and the SEC.

 Nominating and Corporate Governance Committee

 Messrs. Williams, Thomas and Stark serve as members of our nominating and corporate governance committee, and Mr. Williams serves as its chairman.

 The primary purposes of our nominating and corporate governance committee is to assist the board in:

 •

 identifying, screening and reviewing individuals qualified to serve as directors and recommending to the board of directors candidates for nomination for election at the annual meeting of stockholders or to fill vacancies on the board of directors;

 •

 developing, recommending to the board of directors and overseeing implementation of our corporate governance guidelines;

 •

 coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and

 •

 reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary.

 The nominating and corporate governance committee is governed by a charter that complies with the rules of OTCQX and NASDAQ.

 Code of Ethics

 We have adopted a code of ethics that applies to our officers and directors. We have filed copies of our code of ethics, our audit committee charter, our compensation committee charter, and our nominating and corporate governance committee as exhibits to our registration statement in connection with our initial public offering. You may review these documents by accessing our public filings at the Commission's website at www.sec.gov. In addition, a copy of the code of ethics will be provided without charge upon request to us.

 Conflicts of Interest

 I-Bankers and its affiliates engage in a broad spectrum of activities including principal investing, specialized investment vehicle management, asset management, financial advisory, securities underwriting, sales and trading, investment research, lending and other activities. In the ordinary course of business, they engage in activities where their interests or the interests of their clients may conflict with our interests. Accordingly, there may be situations in which I-Bankers or an affiliate has an obligation or an interest that actually or potentially conflicts with our interests. You should assume that these conflicts will not be resolved in our favor and, as a result, we may be denied certain acquisition opportunities or otherwise disadvantaged in certain situations by our relationship with I-Bankers.

 I-Bankers, its affiliates and their clients make investments in a variety of different businesses and may directly compete with us for acquisition opportunities provided or created by I-Bankers or its affiliates that meet our initial business combination objectives. Neither I-Bankers nor any of its affiliates has an obligation to offer potential acquisition opportunities to us and may allocate them at its discretion to us or other parties. We will not have any priority in respect of acquisition opportunities provided or created by I-Bankers or its affiliates. You should assume that I-Bankers and its affiliates and clients will have priority over us in terms of access to acquisition opportunities and, as a result, we may be denied certain acquisition opportunities or otherwise disadvantaged in certain situations by our relationship with I-Bankers.

 Clients of I-Bankers and its affiliates may also compete with us for investment opportunities meeting our initial business combination objectives. If I-Bankers or any of its affiliates is engaged to act for any such clients, we may be precluded from pursuing opportunities that would conflict with I-Bankers' or its affiliates' obligations to such client. In addition, investment ideas generated within I-Bankers or its affiliates may be suitable for our company or a client of I-Bankers or its affiliates, and may be directed to any of such persons or entities rather than to us. I-Bankers or its affiliates may also be engaged to advise the seller of a company, business or assets that would qualify as an acquisition opportunity for us. In such cases, we may be precluded from participating in the sale process or from purchasing the company, business or assets. If, however, we are permitted to pursue the opportunity, the interests of I-Bankers or its affiliates, or their obligations to the seller, may diverge from our interests.

 Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to another entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then- current fiduciary or contractual obligations, he or she will honor these fiduciary obligations under applicable law. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our business combination. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue.

 Our sponsor and executive officers have agreed, pursuant to a written letter agreement, not to participate in the formation of, or become an officer of, any other blank check company until we have entered into a definitive agreement regarding our initial business combination or we have failed to complete our initial business combination within 18 months after the closing of our initial public offering; provided that this agreement would not prevent our executive officers from serving as directors in other blank check companies. Neither Bankers nor any of its affiliates has entered into such an agreement, and, accordingly, are not precluded from participating in any other blank check company or from underwriting an offering by any other blank check company. Potential investors should also be aware of the following other potential conflicts of interest:

 •

 None of our officers or directors is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest in allocating his or her time among various business activities.

 •

 In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to us as well as the other entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented. For a complete description of our management's other affiliations, see "— Directors and Executive Officers."

 •

 Our initial stockholders have agreed to waive their redemption rights with respect to their founder shares and public shares in connection with the consummation of our initial business combination. Additionally, our initial stockholders have agreed to waive their redemption rights with respect to their founder shares if we fail to consummate our initial business combination within 18 months after the closing of our initial public offering. If we do not complete our initial business combination within such applicable time period, the proceeds of the sale of the private placement warrants will be used to fund the redemption of our public shares, and the private placement warrants will expire worthless. With certain limited exceptions, the founder shares will not be transferable, assignable or salable by the holder of such shares until the earlier of (1) one year after the completion of our initial business combination and (2) the date on which we consummate a liquidation, merger, capital stock exchange, reorganization, or other similar transaction after our initial business combination that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, if the last sale price of our common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 90 days after our initial business combination, the founder shares will be released from the lock-up. With certain limited exceptions, the private placement warrants and the common stock underlying such warrants, will not be transferable, assignable or salable by our sponsor until 30 days after the completion of our initial business combination. Since our sponsor and officers and directors directly or indirectly own common stock and warrants following our initial public offering, our officers and directors may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination.

 •

 Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination.

 •

 Our sponsor, officers or directors may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our sponsor or an affiliate of our sponsor or any of our officers or directors to finance transaction costs in connection with an intended initial business combination. Up to $1,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. However, all working
capital promissory notes specifically state that the Sponsor has elected not to
convert. S uch warrants would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period.

 •

 We have engaged certain I-Bankers as advisors in connection with our business combination to assist us in holding meetings with our stockholders to discuss the potential business combination and the target business's attributes, introduce us to potential investors that are interested in purchasing our securities in connection with the potential business combination, assist us in obtaining stockholder approval for the business combination and assist us with our press releases and public filings in connection with the business combination. We will pay the I-Bankers a cash fee for such services upon the consummation of our initial business combination in an amount equal to, in the aggregate, 2.75% of the gross proceeds of our initial public offering, including any proceeds from the full or partial exercise of the over- allotment option.

 The conflicts described above may not be resolved in our favor.

 In general, officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if:

 •

 the corporation could financially undertake the opportunity;

 •

 the opportunity is within the corporation's line of business; and

 •

 it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

 Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. Furthermore, our amended and restated certificate of incorporation provides that the doctrine of corporate opportunity will not apply with respect to any of our officers or directors in circumstances where the application of the doctrine would conflict with any fiduciary duties or contractual obligations they may have. We do not believe that these contractual obligations will materially affect our ability to complete our business combination. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue.

 We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm which is a member of FINRA, or from an independent accounting firm other than our registered independent public accounting firm, that such an initial business combination is fair to our company from a financial point of view.

 In the event that we submit our initial business combination to our public stockholders for a vote, our initial stockholders have agreed to vote their founder shares and any public shares purchased during or after our initial public offering in favor of our initial business combination and our officers and directors have also agreed to vote any public shares purchased during or after our initial public offering in favor of our initial business combination.

 Limitation on Liability and Indemnification of Officers and Directors

 Our amended and restated certificate of incorporation provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. In addition, our amended and restated certificate of incorporation provides that our directors will not be personally liable for monetary damages to us or our stockholders for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors.

 We entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our amended and restated certificate of incorporation. Our bylaws also will permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We will purchase a policy of directors' and officers' liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. Except with respect to any public shares they may acquire after our initial public offering (in the event we do not consummate an initial business combination), our officers and directors have agreed to waive (and any other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for any reason whatsoever, including with respect to such indemnification.

 These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

 We believe that these provisions, the directors' and officers' liability insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

 ITEM 11. EXECUTIVE COMPENSATION

 Officer and Director Compensation

 None of our executive officers or directors have received any cash compensation for services rendered to us. Until the earlier of consummation of our initial business combination and our liquidation, beginning on the effective date of this registration statement, we will pay Breeze Financial, an affiliate of our sponsor, a total of $5,000 per month for office space, utilities, secretarial support and other administrative and consulting services. Our sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates.

 After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting, management or other fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined by a compensation committee constituted solely by independent directors.

 We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after the initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management's motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment.

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 The following table sets forth information regarding the beneficial ownership of our common stock as of March 11, 2025 based on information obtained from the persons named below, with respect to the beneficial ownership of our shares of common stock, by:

 •

 each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;

 •

 each of our executive officers and directors that beneficially owns shares of our common stock; and

 •

 all our executive officers and directors as a group.

 Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them.

 The beneficial ownership of our shares of common stock is based on 3,412,103 shares of common stock issued and outstanding as of March 11, 2025.

 Common Stock

 Name of Beneficial Owner (1)

 Approximate

 Percentage of

 Number of Shares

 Outstanding

 Beneficially Owned

 Common Stock

 Breeze Sponsor, LLC

 2,475,000

 72.5

 %

 J. Douglas Ramsey, Ph. D. (2)

 2,475,000

 72.5

 %

 Russell D. Griffin (3)

 —

 *

 Charles C. Ross (3)

 —

 *

 Albert McLelland

 25,000

 *

 Bill Stark

 25,000

 *

 Robert Lee Thomas

 25,000

 *

 James L. Williams

 —

 *

 All directors and executive officers as a group (7 individuals)

 2,550,000

 74.7

 %

 I-Bankers Securities, Inc.

 512,500

 12.7

 %

 *

 Less than one percent.

 (1)

 Unless otherwise noted, the business address of each of the following entities or individuals is c/o Breeze Holdings Acquisition Corp., 955 W. John Carpenter Fwy., Suite 100-929, Irving, TX 75039.

 (2)

 Represents shares of common stock owned by our sponsor, Breeze Sponsor, LLC. Dr. Ramsey is the manager of the Sponsor and has voting and dispositive control over all such shares. Dr. Ramsey disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. Our Sponsor has agreed to transfer 15,000 shares of its common stock to each independent director upon the closing of an initial business combination by the Company, with such shares currently beneficially owned by Sponsor. There are no signed agreements associated with these transfers.

 (3)

 Does not include any securities held by our sponsor, Breeze Sponsor, LLC, of which each person is a direct or indirect member.

 Our sponsor, officers and directors are deemed to be our "promoter" as such term is defined under the federal securities laws.

 Changes in Control

 None.

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 On June 11, 2020, our initial shareholders purchased 100 founder shares for an aggregate purchase price of $25,000. On July 15, 2020, we effected a 28,750-for-1 forward stock split and, as a result, our initial shareholders held 2,875,000 founder shares as of the date of our initial public offering. The number of founder shares issued was determined based on the expectation that such founder shares would represent 20% of the outstanding shares upon completion of our initial public offering. The founder shares may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder.

 Our sponsor and I-Bankers purchased an aggregate of 5,425,000 warrants at a price of $1.00 per warrant in a private placement that occurred simultaneously with the closing of our initial public offering. Of such amount, 4,325,000 warrants were purchased by our sponsor, and 1,100,000 warrants were purchased by I-Bankers. The private placement warrants (including the common stock issuable upon exercise of the private placement warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder until 30 days after the completion of our initial business combination.

 If any of our officers or directors becomes aware of a business combination opportunity that falls within the line of business of any entity to which he or she has then-current fiduciary or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior to presenting such business combination opportunity to us. Our executive officers and directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us.

 Commencing on the date our securities were first listed on NASDAQ, we have agreed to pay an affiliate of our sponsor a total of $5,000 per month for office space, utilities and secretarial and administrative support. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

 Our sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on our behalf.

 Our sponsor agreed to loan us up to $300,000 to be used for a portion of the expenses of our initial public offering. On November 25, 2020, the outstanding balance under the promissory note in the aggregate amount of $145,617 was repaid.

 On November 19, 2021, the sponsor loaned the Company an aggregate of $1,150,000 pursuant to an unsecured promissory note (the "Note"), as amended for the maturity date, to extend the date by which the Company has to consummate a business combination from November 25, 2021 to February 25, 2022. The Note is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025.

 On February 18, 2022, the Sponsor loaned the Company an aggregate of $1,150,000 pursuant to an unsecured promissory note, as amended for the maturity date, to extend the date by which the Company has to consummate a business combination from February 25, 2022 to May 25, 2022. This unsecured promissory note is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2025.

 The amended Trust Agreement, approved on September 13, 2022, authorizes the Company's Board of Directors to extend the time to complete the Business Combination up to six (6) times for an additional one (1) month each time (for a maximum of six one-month extensions), upon the deposit into the Trust Account of $0.035 for each outstanding public share by the Sponsor or its designees on or prior to September 26, 2022 or such other date as may be extended. Breeze executed its first one-month extension of September 26, 2022 depositing $59,157 in the Trust Account. On October 21, November 23, December 20, 2022, January 25, 2023 and February 23, 2023 Breeze executed the second, third, fourth fifth and sixth one-month extensions depositing $59,157 in the Trust Account for each monthly extension through March 26, 2023.

 The Company held a meeting of its stockholders on March 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of March 26, 2023, up to six (6) times for an additional one (1) month each time (ultimately until as late as September 26, 2023), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On March 29, 2023, Breeze executed the seventh one-month extension through April 26, 2023. On April 25, 2023, May 25, 2023, and June 26, 2023 Breeze executed the eighth, ninth and tenth one-month extensions through July 26, 2023. On August 3, 2023 and August 28, 2023, Breeze executed the eleventh and twelfth one-month extensions through September 26, 2023.

 The Company held a meeting of its stockholders on September 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of September 26, 2023, up to nine (9) times for an additional one (1) month each time (ultimately until as late as June 26, 2024), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On September 27, 2023 Breeze executed the thirteenth one-month extension through October 26, 2023. On October 25, 2023, November 27, 2023, December 27, 2023, January 26, 2024, February 27, 2024, March 26, 2024, May 7, 2024 and June 3, 2024 Breeze executed the fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty-first one-month extensions through June 26, 2024.

 The Company held a meeting of its stockholders on June
21, 2024 where the Company's stockholders approved (i) a proposal to amend
the Company's A&R COI to authorize the Company to extend the date of June
26, 2024, up to six (6) times for an additional one (1) month each
time (ultimately until as late as December 26, 2024), and (ii) a proposal to
amend the Trust Agreement to authorize the Extension and its implementation by
the Company. For each one-month extension the Company deposited $31,280 ($0.035
per share) into the Trust Account. On June 26, 2024 and
August 1, 2024, Breeze executed the twenty-second and twenty-third extensions,
and on November 22, 2024, Breeze executed (including accrued interest) the
twenty-fourth, twenty-fifth and twenty-sixth one-month extensions for the
period from September 26, 2024 through November 26, 2024.

 On December 23, 2024, the Company held a stockholders'
meeting at which a proposal to approve the extension of time to consummate the
closing of a Business Combination Agreement to June 26, 2025, was approved. The
Company provided its stockholders with the opportunity to redeem all or a
portion of their Public Shares at the time of this stockholders' meeting. On December 31, 2024 the company executed the twenty-seventh
and twenty-eighth one-month extension for the period from November 26, 2024 to
January 26, 2025.

 In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete an initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. We do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

 After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our stockholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a stockholder meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive officer and director compensation.

 We entered into a registration rights agreement with respect to the founder shares and the private placement warrants.

 Policy for Approval of Related Party Transactions

 Our audit committee must review and approve any related person transaction we propose to enter into. Our audit committee charter details the policies and procedures relating to transactions that may present actual, potential or perceived conflicts of interest and may raise questions as to whether such transactions are consistent with the best interest of our company and our stockholders. A summary of such policies and procedures is set forth below.

 Any potential related party transaction that is brought to the audit committee's attention will be analyzed by the audit committee, in consultation with outside counsel or members of management, as appropriate, to determine whether the transaction or relationship does, in fact, constitute a related party transaction. At its meetings, the audit committee will be provided with the details of each new, existing or proposed related party transaction, including the terms of the transaction, the business purpose of the transaction and the benefits to us and to the relevant related party.

 In determining whether to approve a related party transaction, the audit committee must consider, among other factors, the following factors to the extent relevant:

 •

 whether the terms of the transaction are fair to us and on the same basis as would apply if the transaction did not involve a related party;

 •

 whether there are business reasons for us to enter into the transaction;

 •

 whether the transaction would impair the independence of an outside director;

 •

 whether the transaction would present an improper conflict of interest for any director or executive officer; and

 •

 any pre-existing contractual obligations.

 Any member of the audit committee who has an interest in the transaction under discussion must abstain from any voting regarding the transaction, but may, if so requested by the chairman of the audit committee, participate in some or all of the audit committee's discussions of the transaction. Upon completion of its review of the transaction, the audit committee may determine to permit or to prohibit the transaction.

 Our sponsor, officers and directors are deemed to be our "promoter" as such term is defined under the federal securities laws.

 To further minimize conflicts of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated with any of our sponsor, officers or directors unless we, or a committee of independent directors, have obtained an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions that our initial business combination is fair to our company and our stockholders from a financial point of view. No finder's fees, reimbursements, consulting fee, monies in respect of any payment of a loan or other compensation will be paid by us to our sponsor, officers or directors, or any affiliate of our sponsor or officers, for services rendered to us prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is). However, the following payments have been or will be made to our sponsor, officers or directors, or our or their affiliates, none of which will be made from the proceeds of our initial public offering held in the trust account prior to the completion of our initial business combination:

 •

 Repayment of up to an aggregate of $145,617 in loans made to us by our sponsor to cover offering related and organizational expenses;

 •

 Payment to an affiliate of our sponsor of $5,000 per month, for up to 18 months, for office space, utilities and secretarial and administrative support;

 •

 Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination; and

 •

 Repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination, the terms of which have not been determined nor have any written agreements been executed with respect thereto.

 Our audit committee reviews on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or their affiliates.

 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 The following is a summary of fees paid or to be paid to Marcum LLP, or Marcum, for services rendered.

 Audit Fees. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and services that are normally provided by Marcum in connection with regulatory filings. The aggregate fees billed by Marcum for professional services rendered for the audit of our annual financial statements, review of the financial information for the respective periods and other required filings with the SEC for the years ended December 31, 2024 and December 31, 2023 totaled $ 391,370 and $ 321,154, respectively. The above amounts include interim procedures and audit fees.

 Audit-Related Fees. Audit-related services consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our financial statements and are not reported under "Audit Fees." These services include attest services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards. We did not pay Marcum for consultations concerning financial accounting and reporting standards for the years ended December 31, 2024 and December 31, 2023, respectively.

 Tax Fees. We paid Marcum $ 21,887 and $ 19,055 for tax planning and tax advice for the years ended December 31, 2024 and December 31, 2023, respectively.

 All Other Fees. We did not pay Marcum for other services for the years ended December 31, 2024 and December 31, 2023, respectively.

 Pre-Approval Policy

 Our audit committee was formed upon the consummation of our Initial Public Offering. As a result, the audit committee did not pre-approve all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee, and on a going-forward basis, the audit committee has and will pre-approve all auditing services and permitted non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described in the Exchange Act which are approved by the audit committee prior to the completion of the audit).

 ITEM 15.

 EXHIBITS, FINANCIAL STATEMENTS SCHEDULES

 (a)

 The following documents are filed as part of this Report:

 (1)

 Financial Statements:

 Page

 Report of Independent Registered Public Accounting Firm (Marcum LLP; New York, NY; PCAOB ID# 688)

 Consolidated Balance Sheets as of December 31, 2024 and 2023

 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023

 Consolidated Statements of Changes in Stockholders' Deficit for the years ended December 31, 2024 and 2023

 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023

 Notes to Financial Statements

 (2)

 Financial Statement Schedules:

 None.

 (3)

 Exhibits

 We hereby file as part of this Report the exhibits listed in the attached Exhibit Index. Exhibits which are incorporated herein by reference can be inspected and copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of such material can also be obtained from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates or on the SEC website at www.sec.gov.

 Exhibit No.

 Description

 2.1

 Merger Agreement and Plan of Reorganization, dated as of September 24, 2024, by and among Breeze, Breeze Merger Sub and YD Biopharma (filed as Exhibit 2.1 to the form 8-K filed as of September 25, 2024).

 3.1

 Amended and Restated Certificate of Incorporation (incorporated by reference to exhibit 3.3 of the registrant's Form S-1 (file no. 333-249677).

 3.2

 Amendment to Amended and Restated Certificate of Incorporation of Breeze Holdings Acquisition Corp., dated May 9, 2022 (filed as exhibit 3.1 to the Form 8-K filed May 9, 2022).

 3.3

 Amendment to Amended and Restated Certificate of Incorporation of Breeze Holdings Acquisition Corp., dated September 13, 2022 (filed as exhibit 3.1 to the Form 8-K filed September 15, 2022).

 3.4

 Bylaws (incorporated by reference to exhibit 3.4 of the registrant's Form S-1 (file no. 333-249677).

 3.5

 Amendment to Amended and Restated Certificate of
Incorporation of Breeze Holdings Acquisition Corp., dated December 23, 2024
(filed as exhibit 3.1 to the Form 8-K filed December 30, 2024).

 4.1

 Warrant Agreement, dated November 23, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent. (1)

 4.2

 Rights Agreement, dated November 23, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. (1)

 4.3

 Description of Registrant's Securities (filed as exhibit 4.3 to the Form 10-K filed March 31, 2021).

 4.4

 Amended and Restated Rights Agreement, dated as of January 26, 2022, between Breeze Holdings Acquisition Corp. and Continental Stock Transfer & Trust Company.

 10.1

 Letter Agreement, dated November 23, 2020, by and among the Company, Breeze Sponsor, LLC and each of the officers and directors of the Company. (1)

 10.2

 Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant. (1)

 10.3

 Registration Rights Agreement, dated November 23, 2020, by and among the Company and certain holders party thereto. (1)

 10.4

 Administrative Services Agreement, dated November 23, 2020, by and between the Company and Breeze Sponsor, LLC. (1)

 10.5

 Securities Escrow Agreement, by and among the Company, Breeze Sponsor, LLC and each of the officers and directors of the Company. (incorporated by reference to exhibit 10.9 of the registrant's Form S-1 (file no. 333-249677).

 10.6

 Termination Agreement, dated August 12, 2022, by and among Breeze Holdings Acquisition Corp., D-Orbit S.p. A., D-Orbit S.A., Lift-Off Merger Sub, Inc., Seraphim Space (Manager) LLP and Breeze Sponsor, LLC (filed as exhibit 10.1 to the Form 8-K filed August 15, 2022).

 10.7

 Termination Notification Letter, dated August 5, 2024, from TV Ammo to Breeze Holdings Acquisition Corp. (filed as Item 1.02 to the Form 8-K filed August 9, 2024).

 10.8

 Sponsor Support Agreement dated as of September 24,2024 (filed as exhibit 10.1 to the Form 8-K filed September 25, 2024).

 10.9

 Shareholder Support Agreement dated as of September 24,2024 (filed as exhibit 10.2 to the Form 8-K filed September 25, 2024).

 10.10

 Lock-Up Agreement dated as of September 24,2024 (filed as exhibit 10.3 to the Form 8-K filed September 25, 2024).

 Exhibit No.

 Description

 Code of Ethics (incorporated by reference to exhibit 14 of the registrant's Form S-1 (file no. 333-249677).

 31.1

 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 32.1

 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 97.1

 Breeze Holdings Acquisition Corp. Dodd-Frank Restatement Recoupment Policy (filed as exhibit 97.1 to the form 10-K/A filed April 24, 2024)

 101.INS

 101.CAL

 101.SCH

 101.DEF

 101.LAB

 101.PRE

 *

 Filed herewith.

 **

 Furnished herewith.

 (1)

 Incorporated by reference to the registrant's Current Report on Form 8-K, filed with the SEC on November 27, 2020.

 Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.

 ITEM 16.

 FORM 10-K SUMMARY

 Not applicable.

 SIGNATURES

 Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

 /s/ J. Douglas Ramsey

 Name: J. Douglas Ramsey

 Title: Chief Executive Officer

 Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 Name

 Position

 Date

 /s/ J. Douglas Ramsey

 Chairman, Chief Executive Officer and Chief

 J. Douglas Ramsey

 Financial Officer

 ( Principal Executive, Financial and Accounting Officer)

 /s/ Russell D. Griffin

 President and Director

 Russell D. Griffin

 /s/ James L. Williams

 Director

 James L. Williams

 /s/ Albert McLelland

 Director

 Albert McLelland

 /s/ Bill Stark

 Director

 Bill Stark

 /s/ Robert L. Thomas

 Director

 Robert L. Thomas

 INDEX TO FINANCIAL STATEMENTS

 Report of Independent Registered Public Accounting Firm (Marcum LLP; New York, NY; PCAOB ID# 688)

 Financial Statements:

 Consolidated Balance Sheets as of December 31, 2024 and 2023

 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023

 Consolidated Statements of Changes in Stockholders' Deficit for the years ended December 31, 2024 and 2023

 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023

 Notes to Financial Statements

 Report of Independent Registered Public Accounting Firm

 To the Shareholders and Board of
Directors of

 Breeze Holdings Acquisition Corp.

 Opinion on the Financial Statements

 We have
audited the accompanying consolidated balance sheet s of Breeze Holdings Acquisition Corp. (the "Company") as of December
31, 2024 and 2023, the related consolidated statements of operations,
stockholders' deficit and cash flows for each of the two years in the period ended December 31, 2024, and the related
notes (collectively referred to as the "financial statements"). In our opinion, based on our audits, the
financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024 and 2023, and the results of
its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity
with accounting principles generally accepted in the United States of America.

 Explanatory Paragraph
– Going Concern

 The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As
described in Note 1 to the financial statements, the Company is a Special
Purpose Acquisition Corporation that was formed for the purpose of completing a
merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination with one or more businesses on
or before June 26, 2025. The Company entered into a Merger Agreement and Plan
of Reorganization with a business combination target on September 24, 2024;
however, the completion of this transaction is subject to the approval of the
Company's stockholders among other conditions. There is no assurance that the
Company will obtain the necessary approvals, satisfy the required closing
conditions, raise the additional capital it needs to fund its operations, and
complete the transaction prior to June 26, 2025, if at all. The Company also
has no approved plan in place to extend the business combination deadline and
fund operations for any period of time after June 26, 2025, in the event
that it is unable to complete a business combination by that date. These
matters raise substantial doubt about the Company's ability to continue as a
going concern. Management's plans with regard to these matters are also
described in Note 1. The financial statements do not include any adjustments
that may be necessary should the Company be unable to continue as a going
concern.

 Basis for Opinion

 These financial statements are
the responsibility of the Company's management. Our responsibility is to
express an opinion on the Company's financial statements based on our audit s. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States)
("PCAOB") and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit s in accordance with the standards of
the PCAOB. Those standards require that we plan and perform the audit s to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due
to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of
our audit s we are required to
obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit s included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audit s
also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable
basis for our opinion.

 /s/ Marcum LLP

 Marcum LLP

 We have served as the Company's auditor since 2020.

 New York, NY

 CONSOLIDATED BALANCE SHEETS

 December 31,

 December 31,

 2024

 2023

 ASSETS

 Current assets

 Cash

 $

 101,674

 $

 4,228

 Due from Sponsor

 53,905

 18,672

 Prepaid expenses

 55,305

 148,953

 Prepaid franchise taxes

 —

 57,550

 Prepaid income taxes

 36,689

 36,742

 Total Current Assets

 247,573

 266,145

 Cash held in Trust Account

 10,532,045

 12,977,528

 Total Assets

 $

 10,779,618

 $

 13,243,673

 LIABILITIES AND STOCKHOLDERS' DEFICIT

 Current liabilities

 Accounts payable and accrued expenses

 $

 632,533

 $

 206,639

 Trust amount payable to redeeming stockholders

 7,353,424

 —

 Franchise tax payable

 50,450

 —

 Excise tax payable

 160,441

 56,270

 Due to Sponsor

 9,583,457

 7,814,506

 Total Current Liabilities

 17,780,305

 8,077,415

 Warrant liabilities

 2,877,250

 2,200,250

 Total Liabilities

 20,657,555

 10,277,665

 Commitments

 Common stock subject to possible redemption, 893,712 and 1,159,276 shares at redemption value as of December 31, 2024 and 2023, respectively

 3,078,621

 12,647,701

 Stockholders' Deficit

 Preferred stock, $ 0.0001 par value; 1,000,000 authorized; none issued and outstanding

 —

 —

 Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 3,140,000 shares and 3,140,000 shares issued and outstanding as of December 31, 2024 and 2023, respectively (excluding 893,712 and 1,159,276 shares subject to possible redemption, respectively)

 Additional paid-in capital

 —

 —

 Accumulated deficit

 ( 12,956,873

)

 ( 9,682,008

)

 Total Stockholders' Deficit

 ( 12,956,558

)

 ( 9,681,693

)

 TOTAL LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' DEFICIT

 $

 10,779,618

 $

 13,243,673

 The accompanying notes are an integral part of the consolidated financial statements.

 CONSOLIDATED STATEMENTS OF OPERATIONS

 December 31, 2024

 December 31, 2023

 Operating and formation costs

 $

 2,225,820

 $

 2,070,143

 Loss from operations

 ( 2,225,820

)

 ( 2,070,143

)

 Other (expenses) income:

 Interest income

 598,182

 554,701

 Change in fair value of warrant liabilities

 ( 677,000

)

 ( 1,015,500

)

 Total other expenses, net

 ( 78,818

)

 ( 460,799

)

 Loss before income taxes

)

 ( 2,530,942

)

 Income tax expense

 —

 ( 18,169

)

 $

)

 $

)

 Basic and diluted weighted average shares outstanding

 4,145,884

 4,427,788

 Basic and diluted net loss per share of Common Stock

 $

 ( 0.56

)

 $

 ( 0.58

)

 The accompanying notes are an integral part of the consolidated financial statements.

 CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

 FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

 Common Stock

 Shares

 Amount

 Additional

 Paid-in

 Capital

 Accumulated

 Deficit

 Total

 Stockholders'

 Deficit

 December 31, 2022

 3,140,000

 $

 $

 —

 $

 ( 6,532,077

)

 $

 ( 6,531,762

)

 Re-measurement of Common Stock to redemption value

 —

 —

 —

 ( 544,550

)

 ( 544,550

)

 Excise taxes payable

 —

 —

 —

 ( 56,270

)

 ( 56,270

)

 —

 —

 —

)

)

 December 31, 2023

 3,140,000

 $

 $

 —

 $

 ( 9,682,008

)

 $

 ( 9,681,693

)

 Re-measurement of Common Stock to redemption value

 —

 —

 —

 ( 866,056

)

 ( 866,056

)

 Excise taxes payable

 —

 —

 —

 ( 104,171

)

 ( 104,171

)

 —

 —

 —

)

)

 December 31, 2024

 3,140,000

 $

 $

 —

 $

 ( 12,956,873

)

 $

 ( 12,956,558

)

 The accompanying notes are an integral part of the consolidated financial statements.

 CONSOLIDATED STATEMENTS OF CASH FLOWS

 December 31, 2024

 December 31, 2023

 Cash Flows from Operating Activities:

 $

)

 $

)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Interest income held in Trust Account

 ( 598,182

)

 ( 554,701

)

 Change in fair value of warrant liabilities

 677,000

 1,015,500

 Changes in operating assets and liabilities:

 Prepaid expenses

 58,415

 10,951

 Prepaid franchise taxes

 57,550

 ( 47,550

)

 Prepaid income taxes

 ( 36,742

)

 Accounts payable and accrued expenses

 449,877

 139,139

 Franchise tax payable

 50,450

 —

 Income tax payable

 —

 ( 2,089

)

 Net cash used in operating activities

 ( 1,609,475

)

 ( 2,024,603

)

 Cash Flows from Investing Activities:

 Investment of cash in Trust Account

 ( 359,273

)

 ( 528,514

)

 Cash withdrawn from Trust Account to redeeming stockholders

 3,081,712

 5,627,005

 Cash withdrawn from Trust Account to pay franchise and income taxes

 321,226

 209,650

 Net cash provided by investing activities

 3,043,665

 5,308,141

 Cash Flows from Financing Activities:

 Proceeds from working capital loan - related party

 1,385,695

 1,811,900

 Proceeds from promissory note for extensions– related party

 359,273

 521,666

 Redemptions of common stock

 ( 3,081,712

)

 ( 5,627,005

)

 Net cash used in financing activities

 ( 1,336,744

)

 ( 3,293,439

)

 Net Change in Cash

 97,446

 ( 9,901

)

 Cash – Beginning of year

 4,228

 14,129

 Cash – End of year

 $

 101,674

 $

 4,228

 Supplemental disclosure of non-cash financing activities:

 Excise taxes payable

 $

 160,441

 $

 56,270

 Re-measurement of common stock to redemption value

 $

 866,056

 $

 544,550

 Trust amount payable to redeeming stockholders

 $

 7,353,424

 $

 —

 The accompanying notes are an integral part of the consolidated financial statements.

 BREEZE HOLDINGS ACQUISITON CORP.

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 December 31, 2024 and 2023

 Note 1 — Description of Organization and Business Operations

 Breeze Holdings Acquisition Corp. (the "Company") is a blank check company incorporated in Delaware on June 11, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the "Business Combination").

 The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

 As of December 31, 2024, the Company had not commenced any operations. All activity for the period from June 11, 2020 (inception) through December 31, 2024, relate to the Company's formation, the Initial Public Offering ("Initial Public Offering"), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering and from changes in the fair value of its warrant liability.

 The registration statement for the Company's Initial Public Offering was declared effective on November 23, 2020. On November 25, 2020, the Company consummated the Initial Public Offering of 11,500,000 units (the "Units" and, with respect to the shares of common stock included in the Units sold, the "Public Shares"), generating gross proceeds of $ 115,000,000, which is described in Note 3.

 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,425,000 warrants (the "Private Placement Warrants") at a price of $ 1.00 per Private Placement Warrant in a private placement to Breeze Sponsor, LLC, a Delaware limited liability company (the "Sponsor") and I-Bankers Securities, Inc. ("I-Bankers"), generating gross proceeds of $ 5,425,000, which is described in Note 4.

 Following the closing of the Initial Public Offering on November 25, 2020, an amount of $ 115,000,000 ($ 10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and $ 1,725,000 from the sale of the Private Placement Warrants was placed in a trust account (the "Trust Account") and invested in U.S. government securities, within the meaning set forth in Section 2 (a)( 16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2 a- 7 of the Investment Company Act of 1940, as amended (the "Investment Company Act"), as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account to the Company's stockholders, as described below. As of December 31, 2024 and 2023 all funds in the trust account were held in cash in an interest-bearing account.

 Transaction costs incurred in connection with the Initial Public Offering amounted to $ 4,099,907, consisting of $ 2,300,000 of underwriting fees, $ 1,322,350 of representative share offering costs, and $ 477,557 of other offering costs. As of December 31, 2024, cash of $ 101,674 was held outside of the Trust Account and was available for working capital purposes.

 The Company's management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete an initial Business Combination having an aggregate fair market value of at least 80 % of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable) at the time of the agreement to enter into the initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50 % or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the "Investment Company Act").

 The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then in the Trust Account (initially $ 10.15 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company's warrants.

 Unless a stockholder proposal to approve amendment to the Company's Amended and Restated Certificate of Incorporation ("A&R COI") to eliminate the limitation is approved, the Company will proceed with a Business Combination only if the Company has net tangible assets of at least $ 5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If a stockholder vote is not required and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its A&R COI, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission ("SEC") and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks stockholder approval in connection with a Business Combination, the Company's Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased by it during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares, regardless of whether they vote for or against a Business Combination.

 If the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company's A&R COI provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a "group" (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), will be restricted from seeking redemption rights with respect to 10 % or more of the Public Shares, without the Company's prior written consent.

 The Sponsor has agreed (a) to waive its
redemption rights with respect to any Founder Shares and Public Shares held by
it in connection with the completion of a Business Combination, (b) to
waive its liquidation rights with respect to the Founder Shares and
(c) not to propose an amendment to the A&R COI (i) to modify the substance or timing of the Company's
obligation to allow redemption in connection with the Company's initial
Business Combination or to redeem 100 % of its
Public Shares if the Company does not complete a Business Combination or
(ii) with respect to any other provision relating to stockholders' rights
or pre-initial business combination activity, unless the Company provides the
public stockholders with the opportunity to redeem their Public Shares in
conjunction with any such amendment. However, if the Sponsor acquires Public
Shares in or after the Initial Public Offering, such Public Shares will be
entitled to liquidating distributions from the Trust Account if the Company
fails to complete a Business Combination within the approved time period
through June 26, 2025, (the "Combination Period").

 The Company held a meeting of its stockholders on March 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of March 26, 2023, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as September 26, 2023), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company.

 The Company held a meeting of its stockholders on September 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of September 26, 2023, up to nine ( 9) times for an additional one ( 1) month each time (ultimately until as late as June 26, 2024), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. On September 27, 2023 Breeze executed the thirteenth one -month extension through October 26, 2023. On October 25, 2023, November 27, 2023, December 27, 2023, January 26, 2024, February 27, 2024, March 26, 2024, May 7, 2024 and June 3, 2024 Breeze executed the fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty -first one -month extensions through June 26, 2024.

 The
Company held a meeting of its stockholders on June 21, 2024 where the Company's
stockholders approved (i) a proposal to amend the Company's A&R COI to
authorize the Company to extend the date of June 26, 2024, up to six (6) times for an additional one (1) month each time (ultimately until as late as
December 26, 2024), and (ii) a proposal to amend the Trust Agreement to
authorize the Extension and its implementation by the Company. For each one-month extension the Company deposited $ 31,280 ($ 0.035 per
share) into the Trust Account. On June 26, 2024 and August 1, 2024, Breeze
executed the twenty-second and twenty-third extensions, and on November 22,
2024, Breeze executed (including accrued interest) the twenty-fourth,
twenty-fifth and twenty-sixth one-month extensions for the period from
September 26, 2024 through November 26, 2024. On January 2, 2025, the Company executed the
twenty-seventh and twenty-eighth one-month extensions for the period from
November 26, 2024 to January 26, 2025.

 On December 23, 2024, the Company held a meeting of its stockholders where they approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of December 26, 2024, up to six (6) times for an additional one (1) month each time (ultimately until as late as June 26, 2025), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. As of December 31, 2024, the first one-month extension payment of $ 9,523, has been deposited in the Trust Account. The
Company, as with all previous extensions, provided its stockholders with the
opportunity to redeem all or a portion of their Public Shares at the time of
this stockholders' meeting. The public stockholders will continue to have the
opportunity to redeem all or a portion of their Public Shares upon the
completion of an initial business combination at a per share price, payable in cash,
equal to the aggregate amount on deposit in the Trust Account as of two
business days prior to the consummation of the initial business combination,
including interest (which interest shall be net of taxes payable) divided by
the number of then outstanding public shares, subject to the limitations
described herein.

 If the Company executes all six ( 6) extensions, it will have until June 26, 2025 (unless the Company's shareholders approve a proposal to amend the A&R COI to permit an extension of up to six additional one -month periods) to complete a Business Combination (the "Combination Period"). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $ 100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining stockholders and the Company's board of directors, dissolve and liquidate, subject in each case to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

 In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below ( 1) $ 11.505 per Public Share or ( 2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and will not apply to any claims under the Company's indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company's independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 On October 31, 2022, Breeze entered into the Original Merger Agreement, by and among Breeze, BH Velocity Merger Sub, Inc. ("Company Merger Sub"), and TV Ammo, Inc., an advanced technology manufacturing and licensing company focused on revolutionizing the global ammunition and weapons industry through the introduction of its composite-cased ammunition, innovative weapons systems and advanced manufacturing technology ("TV Ammo"). On February 14, 2024, Breeze entered into an Amended and Restated Merger Agreement and Plan of Reorganization (the "A&R Merger Agreement"), by and among Breeze, True Velocity, Inc. ("True Velocity"), Breeze Merger Sub, Inc. ("Parent Merger Sub"), Company Merger Sub, and TV Ammo, which amended and restated the Original Merger Agreement in its entirety.

 On August 5, 2024, the A&R Merger Agreement was terminated by written notice from TV Ammo. As a result of the termination, the Company is no longer pursuing a business Combination with TV Ammo.

 On September 24, 2024, Breeze Holdings Acquisition
Corp., a Delaware corporation ("Breeze" or "Parent"), entered into a
Merger Agreement and Plan of Reorganization (the "Merger Agreement"), by and
among (i) Breeze, (ii) a Cayman Islands exempted company and wholly-owned
subsidiary of Parent named "YD Bio Limited," (f/k/a True Velocity, Inc., a
wholly-owned subsidiary of Breeze) which name was changed to YD Bio Limited on
November 18, 2024, which will enter into a joinder to the Merger Agreement ("Pubco"),
(iii) Breeze Merger Sub, Inc., a Delaware corporation and which is a
direct, wholly-owned subsidiary of Pubco ("Parent Merger Sub"), (iv) a Cayman
Islands exempted company which will be a wholly-owned subsidiary of Pubco,
expected to be named "BH Biopharma Merger Sub Limited," and once formed, will
enter into a joinder to the Merger Agreement ("Company Merger Sub," with
Company Merger Sub and Parent Merger Sub together referred to herein as the
"Merger Subs"), and (v) YD Biopharma Limited, a Cayman Islands exempted company
("YD Biopharma"). YD Biopharma is the operating company of the target.
Capitalized terms used herein and not defined shall have the meaning attributed
to them in the Merger Agreement.

 The Merger Agreement and the transactions contemplated thereby were approved by the boards of directors of each of Breeze and YD Biopharma.

 Pursuant to and in accordance with the terms set forth in the Merger Agreement, (a) Parent Merger Sub will merge with and into Breeze, with Breeze continuing as the surviving entity (the "Parent Merger"), as a result of which, (i) Breeze will become a wholly-owned subsidiary of Pubco, and (ii) each issued and outstanding security of Breeze immediately prior to the effective time of the Parent Merger (the "Parent Merger Effective Time") (other than shares of Breeze common stock that have been redeemed or are owned by Breeze or any of its direct or indirect subsidiaries as treasury shares and any Dissenting Parent Shares (as defined in the Merger Agreement)) shall no longer be outstanding and shall automatically be cancelled in exchange for the issuance to the holder thereof of a substantially equivalent security of Pubco (other than the Parent Rights, which shall be automatically converted into ordinary shares of Pubco), and, (b) immediately following the consummation of the Parent Merger but on the same day, Company Merger Sub will merge with and into YD Biopharma, with YD Biopharma continuing as the surviving entity (the "Company Merger" and, together with the Parent Merger, the "Mergers"), as a result of which, (i) YD Biopharma will become a wholly-owned subsidiary of Pubco, and (ii) each issued and outstanding security of YD Biopharma immediately prior to the effective time of the Company Merger (the "Company Merger Effective Time") (other than any Cancelled Shares or Dissenting Shares) shall no longer be outstanding and shall automatically be cancelled in exchange for the issuance to the holder thereof of a substantially equivalent security of Pubco. The Mergers and the other transactions contemplated by the Merger Agreement are hereinafter referred to as the "Business Combination."

 The Business Combination is expected to close in April 2025, subject to customary closing conditions, the receipt of certain governmental approvals and the required approval by the stockholders of Breeze and YD Biopharma.

 Pursuant to and in accordance with the terms set forth in the Merger Agreement, at the Parent Merger Effective Time, (a) each share of Breeze common stock, par value $ 0.0001 per share ("Breeze Common Stock") outstanding immediately prior to the Parent Merger Effective Time that has not been redeemed, is not owned by Breeze or any of its direct or indirect subsidiaries as treasury shares and is not a Dissenting Parent Share will automatically convert into one ordinary share of Pubco (each, a "Pubco Ordinary Share"), (b) each Breeze Warrant shall automatically convert into one warrant to purchase a Pubco Ordinary Share (each, a "Pubco Warrant") on substantially the same terms and conditions; and (c) each Breeze Right will be automatically converted into the number of Pubco Ordinary Shares that would have been received by the holder of such Breeze Right if it had been converted upon the consummation of a business combination in accordance with Breeze's organizational documents.

 T he aggregate consideration to be received by the equity holders of YD Biopharma is based on a pre-transaction equity value of $ 647,304,110. In accordance with the terms and subject to the conditions of the Merger Agreement, at the Company Merger Effective Time, each issued and outstanding ordinary share of YD Biopharma shall be cancelled and converted into a number of Pubco Ordinary Shares based on that Exchange Ratio described below. The Exchange Ratio will be equal to (i) $ 647,304,110, divided by (ii) the number of fully-diluted shares of YD Biopharma Common Stock outstanding as of the Closing, further divided by (iii) an assumed value of Pubco Ordinary Shares of 10.00 per share.

 The parties have agreed to take actions such that, effective immediately after the Closing of the Business Combination, Pubco's board of directors shall consist of seven directors, consisting of two Breeze designees (at least one of whom shall be an "independent director"), four YD Biopharma designees (at least three of whom shall be "independent directors"). Additionally, certain current YD Biopharma management personnel will become officers of Pubco. To qualify as an "independent director" under the Merger Agreement, a designee shall qualify as "independent" under the rules of the Nasdaq Stock Market.

 The Merger Agreement contains representations, warranties and covenants of each of the parties thereto that are customary for transactions of this type, including, among others, covenants providing for (i) certain limitations on the operation of the parties' respective businesses prior to consummation of the Business Combination, (ii) the parties' efforts to satisfy conditions to consummation of the Business Combination, including by obtaining any necessary approvals from governmental agencies (including U.S. federal antitrust authorities and under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act")), (iii) prohibitions on the parties soliciting alternative transactions, (iv) Pubco preparing and filing a registration statement on Form F- 4 with the Securities and Exchange Commission (the "SEC") and taking certain other actions to obtain the requisite approval of Breeze's stockholders to vote in favor of certain matters, including the adoption of the Merger Agreement and approval of the Business Combination, at a special meeting to be called for the approval of such matters, and (v) the protection of, and access to, confidential information of the parties.

 The representations, warranties and covenants in the Merger Agreement were made solely for the benefit of the parties to the Merger Agreement and are subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made the parties to the Merger Agreement which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. Breeze does not believe that these schedules contain information that is material to an investment decision.

 In addition, Pubco has agreed to adopt an equity incentive plan, as described in the Merger Agreement.

 The obligations of Breeze, Pubco, Parent Merger Sub and Company Merger Sub (the "Breeze Parties") and YD Biopharma to consummate the Business Combination are subject to certain closing conditions, including, but not limited to, (i) the approval of Breeze's stockholders, (ii) the approval of YD Biopharma's stockholders, and (iii) Pubco's Form F- 4 registration statement becoming effective.

 In addition, the obligations of the Breeze Parties to consummate the Business Combination are also subject to the fulfillment (or waiver) of other closing conditions, including, but not limited to, (i) the representations and warranties of YD Biopharma being true and correct to the standards applicable to such representations and warranties and each of the covenants of YD Biopharma having been performed or complied with in all material respects, (ii) delivery of certain ancillary agreements required to be executed and delivered in connection with the Business Combination, and (iii) no Material Adverse Effect having occurred.

 The obligation of YD Biopharma to consummate the Business Combination is also subject to the fulfillment (or waiver) of other closing conditions, including, but not limited to, (i) the representations and warranties of the Breeze Parties being true and correct to the standards applicable to such representations and warranties and each of the covenants of the Breeze Parties having been performed or complied with in all material respects, and (ii) the shares of Pubco Common Stock issuable in connection with the Business Combination being listed on the Nasdaq Stock Market.

 The Merger Agreement may be terminated under certain customary and limited circumstances prior to the Closing of the Business Combination, including, but not limited to, (i) by mutual written consent of Breeze and YD Biopharma, (ii) by Breeze, on the one hand, or YD Biopharma, on the other hand, if there is any breach of the representations, warranties, covenant or agreement of the other party as set forth in the Merger Agreement, in each case, such that certain conditions to closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods, (iii) by either Breeze or YD Biopharma if the Business Combination is not consummated by April 30, 2025 (which date may be extended by mutual agreement of the parties to the Merger Agreement), (iv) by either Breeze or YD Biopharma if a meeting of Breeze's stockholders is held to vote on proposals relating to the Business Combination and the stockholders do not approve the proposals, and (v) by Breeze if the YD Biopharma stockholders do not approve the Merger Agreement.

 Under certain circumstances as described further in the Merger Agreement, if the Merger Agreement is validly terminated by Breeze, YD Biopharma will pay Breeze a fee equal to the actual documented expenses incurred by Breeze in connection with the Business Combination of up to $ 150,000.

 The Merger Agreement contemplates that Breeze, Pubco and YD Biopharma shall use their commercially reasonable efforts to enter into and consummate a subscription with investors related to a private placement of shares in the Company, Breeze and/or Pubco (the "PIPE Investment").

 Concurrently with the execution of the Merger Agreement, Breeze, Pubco, YD Biopharma and the Parent Initial Stockholders (as defined in the Merger Agreement) entered into an Sponsor Support Agreement (the "Sponsor Support Agreement"), pursuant to which, among other things, the Parent Initial Stockholders: (a) agreed to vote all of their shares of Breeze Common Stock in favor of the Parent Proposals, including the adoption of the Merger Agreement and the approval of the Transactions; (b) agreed to vote against any other matter, action, agreement, transaction or proposal that would reasonably be expected to result in (i) a breach of any of the Breeze Parties' representations, warranties, covenants, agreements or obligations under the Merger Agreement or (ii) any of the mutual or YD Biopharma conditions to the Closing in the Merger Agreement not being satisfied; (c) (i) waived, subject to and conditioned upon the Closing and to the fullest extent permitted by applicable law and the Breeze organizational documents, and (ii) agreed not to assert or perfect, any rights to adjustment or other anti-dilution protections to which such Breeze Initial Stockholder may be entitled in connection with the Mergers or the other Transactions; (d) agreed to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable laws to consummate the Mergers and the other Transactions on the terms and subject to the conditions set forth in the Merger Agreement prior to any valid termination of the Merger Agreement; (e) agreed not to transfer or pledge any of their shares of Breeze Common Stock, or enter into any arrangement with respect thereto, after the execution of the Merger Agreement and prior to the Closing Date, subject to certain customary conditions and exceptions; and (f) waived their rights to redeem any of their shares of Breeze Common Stock in connection with the approval of the Parent Proposals.

 The foregoing description of the Sponsor Support Agreement is subject to and qualified in its entirety by reference to the full text of the Sponsor Support Agreement, and the terms of which are incorporated herein by reference. Any capitalized terms used in this section entitled " Sponsor Support Agreement " and not otherwise defined herein shall have the meanings assigned to them in the Sponsor Support Agreement.

 Concurrently with the execution of the Merger Agreement, Breeze, Pubco, YD Biopharma, and certain shareholders of YD Biopharma representing the requisite votes necessary to approve the Merger Agreement (the "YD Biopharma Equity Holders") entered into Shareholder Support Agreements (the "Shareholder Support Agreement"), pursuant to which the YD Biopharma Equity Holders: (a) agreed to vote in favor of the adoption of the Merger Agreement and approve the Mergers and the other Transactions to which YD Biopharma is a party; (b) agreed to waive any appraisal or similar rights they may have pursuant to Cayman law with respect to the Mergers and the other Transactions; (d) agreed to vote against any other matter, action, agreement, transaction or proposal that would reasonably be expected to result in (i) a breach of any of YD Biopharma's representations, warranties, covenants, agreements or obligations under the Merger Agreement or (ii) any of the mutual or the Breeze Parties' conditions to the Closing in the Merger Agreement not being satisfied; and (e) agreed not to sell, assign, transfer or pledge any of their YD Biopharma ordinary shares (or enter into any arrangement with respect thereto) after the execution of the Merger Agreement and prior to the Closing Date, subject to certain customary conditions and exceptions.

 Concurrently with the execution of the Merger Agreement, Breeze, Pubco, YD Biopharma, the Parent Initial Stockholders and certain YD Biopharma Equity Holders entered into a Lock-Up Agreement (the "Lock-Up Agreement"), pursuant to which the Parent Initial Stockholders and such YD Biopharma Equity Holders agreed, among other things, to refrain from selling or transferring their shares of Pubco Common Stock for a period of eight ( 8) months following the Closing, subject to early release (a) of 10 % of their shares of Pubco Common Stock if the daily volume weighted average closing sale price of Pubco Common Stock quoted on the Nasdaq for any 20 trading days within any 30 consecutive trading day period beginning on the four -month anniversary of the Closing exceeds $ 12.50 per share, (b) of an additional 10 % of their shares of Pubco Common Stock if the daily volume weighted average closing sale price of Pubco Common Stock quoted on the Nasdaq for any 20 trading days within any 30 consecutive trading day period beginning on the four -month anniversary of the Closing exceeds $ 15.00 per share; (c) of all of their shares of Pubco Common Stock upon the occurrence of a Subsequent Transaction; and (d) upon the determination of the Pubco board of directors (including a majority of the independent directors) following the six month anniversary of the Closing Date.

 In accordance with the Merger Agreement, within thirty ( 30) days after the execution of the Merger Agreement, Breeze, the Parent Initial Stockholders, Pubco, and certain YD Biopharma Equity Holders are expected to enter into a registration rights agreement (the "Registration Rights Agreement"), pursuant to which Pubco will, among other things, be obligated to file a registration statement to register the resale of certain securities of Pubco held by the Parent Initial Stockholders and such YD Biopharma Equity Holders. The Registration Rights Agreement will also provide the Parent Initial Stockholders and such YD Biopharma Equity Holders with "piggy-back" registration rights, subject to certain requirements and customary conditions.

 Going concern

 As of December 31, 2024, the Company had $ 101,674 in cash held outside of the Trust Account and a working capital deficit of $ 17,358,530 (excluding prepaid income tax, franchise tax payable and excise tax payable).

 In connection with the Company's assessment of going concern
considerations in accordance with the authoritative guidance in Financial
Accounting Standard Board ("FASB") Accounting Standards Update ("ASU") Topic
2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as
a Going Concern," management has determined that the Company currently lacks
the liquidity it needs to sustain operations for a reasonable period of time,
which is considered to be at least one year from the date that the consolidated financial
statements are issued.

 The Company's liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the proceeds of $ 25,000 from the sale of the Founder Shares, and a loan of $ 300,000 under an unsecured and non-interest bearing promissory note (see Note 5). Subsequent to the consummation of the Initial Public Offering, the Company's liquidity needs have been satisfied from the net proceeds from the private placement held outside of the Trust Account.

 The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a business combination. In addition, in order to finance transaction costs in connection with an intended initial business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors may, but are not obligated to, loan the Company funds as may be required. There is no assurance that the Company's plans to consummate a business combination or obtain loans will be successful or successful within the Combination Period.

 The Company has until June 26, 2025 to consummate a business combination, and we intend to do so within this time period.

 We believe we will need to raise additional funds in order to meet the expenditures required for operating our business. If our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a business combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our business combination. Moreover, we may need to obtain additional financing either to complete our business combination or because we become obligated to redeem a significant number of our public shares upon consummation of our business combination, in which case we may issue additional securities or incur debt in connection with such business combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our business combination. If we are unable to complete our business combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. In addition, following our business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are available to be issued. The Company's business plan is dependent on the completion of a business combination and the Company's cash and working capital as of December 31, 2024 are not sufficient to complete its planned activities. These conditions raise a substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recovery of the recorded assets or the
classification of the liabilities that might be necessary should we be unable
to continue as a going concern.

 Risks and uncertainties

 With rising tensions around the world based on
the current conflict between Israel and Hamas and the current conflict between
Ukraine and Russia, we may be unable to complete a business combination if
concerns related to this and other potential conflicts impact global capital
markets, the ability to transfer money, currency exchange rates, cyber attacks
and infrastructure including power generation and transmission, communications,
and travel. Escalating conflicts could also have an impact on global demands
for health care, international trade including vendor supply chains, and
energy. In addition, there have been recent threats to infrastructure and
equipment including cyber attacks, physical facility destruction and equipment
destruction.

 Our operations and financial performance may also be subject to significant risks arising from geopolitical tensions, particularly in relation to China, South Korea and Taiwan. As a major global economic power, China's political policies, trade practices, and regulatory environment may directly impact our business. Additionally, rising political tensions and potential conflicts in the Asia-Pacific region, such as territorial disputes, trade disagreements, or military confrontations, could disrupt supply chains, increase costs, or adversely affect market demand. These risks are compounded by the potential for government interventions, such as trade restrictions, tariffs, sanctions, export controls or blockades, which may affect our ability to operate or source products from Taiwan and/or other affected regions. Moreover, changes in laws and regulations, including those relating to technology, intellectual property, labor practices, and environmental regulations, may also introduce additional uncertainty and operational challenges.

 The outcome of these conflicts or their impact cannot be predicted and may have an adverse impact in a material way on our ability to consummate a business combination, or to operate a target business with which we ultimately consummate a business combination.

 On August 16, 2022, the Inflation Reduction Act of 2022 (the "Inflation Reduction Act") was signed into law, which, among other things, imposes a 1 % excise tax on the fair market value of stock repurchased by a domestic corporation beginning in 2023, with certain exceptions. Because the Company is a Delaware corporation and its securities trade on the Nasdaq Stock Market, the Company is a "covered corporation" within the meaning of the Inflation Reduction Act, and while not free from doubt, it is possible that the excise tax will apply to any redemptions of its common stock after December 31, 2022, including redemptions in connection with an initial Business Combination and any amendment to its certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. Consequently, the value of an investment in the Company's securities may decrease as a result of the excise tax. In addition, the excise tax may make a transaction with the Company less appealing to potential Business Combination targets, and thus, potentially hinder the Company's ability to enter into and consummate an initial Business Combination. Further, the application of the excise tax in the event of a liquidation is uncertain absent further guidance.

 On March 29, 2023, the Company redeemed 509,712 shares of its common stock subject to redemption at $ 10.56 per share for $ 5.4 million. On September 26, 2023, the Company redeemed 21,208 shares of its common stock subject to redemption at $ 10.77 per share for approximately $ 231,000. On June 21, 2024, the Company redeemed 265,564 shares of its common stock subject to redemption at $ 11.60 per share for approximately $ 2.9 million. On December 23, 2024, the Company redeemed 621,609 shares of its common stock subject to redemption at $ 11.83 per share for approximately $ 7.4 million, which was paid on January 2, 2025. Management evaluated the classification of the stock redemption under Accounting Standards Codification ("ASC") 450, "Contingencies". ASC 450 states that when a loss contingency exists the likelihood that the future event(s) will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. Management determined that it should recognize a 1 % excise tax on the redemption amount paid. As of December 31, 2024, the Company recorded $ 160,441 of excise tax liability calculated as 1 % of shares redeemed on March 29, 2023, September 26, 2023, June 21, 2024 and December 23, 2024. Any reduction to this liability resulting from either a subsequent stock issuance or an event giving rise to an exception that occurs within this tax year, will be recognized in the period (including an interim period) that such stock issuance or event giving rise to an exception occurs.

 We may maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation (the "FDIC") insurance limit. The FDIC took control and was appointed receiver of Silicon Valley Bank and New York Signature Bank on March 10, 2023 and March 12, 2023, respectively. The Company does not have any direct exposure to Silicon Valley Bank or New York Signature Bank. However, if other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.

 Note 2 — Summary of Significant Accounting Policies

 Basis of presentation

 The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the SEC.

 Emerging growth company

 The Company is an "emerging growth company," as defined in Section 2 (a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 Further, Section 102 (b)( 1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 Principles of Consolidation

 The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiaries, YD Bio Limited (f/k/a True Velocity, Inc.), Parent Merger Sub, and Company Merger Sub. From the inception of each operating subsidiary through December 31, 2024, the subsidiaries had no activity after elimination of all intercompany transactions and balances as of December 31, 2024 and 2023.

 Use of estimates

 The preparation of the consolidated financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

 Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 Cash and cash equivalents

 The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no t have any cash equivalents as of December 31, 2024 and 2023.

 Cash held in Trust Account

 At December 31, 2024 and 2023, all of the assets held in the Trust Account were held as cash in an interest-bearing bank demand deposit account.

 Common stock subject to possible redemption

 All of the 11,500,000 shares of common stock sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company's liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company's A&R COI. In accordance with SEC and its staff's guidance on redeemable equity instruments, which has been codified in ASC 480 -10-S 99, redemption provisions not solely within the control of the Company require common stock subject to possible redemption to be classified outside of permanent equity. Therefore, all of the shares of common stock sold as part of the Units in the Initial Public offering have been classified outside of permanent equity.

 On September 13, 2022, the Company held its annual stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to March 26, 2023 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.35 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 3,076,817 shares of the Company's common stock were redeemed.

 On March 22, 2023, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to September 26, 2023 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.56 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 509,712 shares of the Company's common stock were redeemed.

 On September 22, 2023, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to June 26, 2024 was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 10.77 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 21,208 shares of the Company's common stock were redeemed.

 On June 21, 2024, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to December 26, 2024 and was approved. The stockholders who elected to redeem their shares did so for a pro rata portion of the amount then in the Trust Account ($ 11.085 per share), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. In connection with the extension proposal, 265,564 shares of the Company's common stock were redeemed, representing 6.2 % of Breeze's total outstanding shares at the time of the vote.

 On December 23, 2024, the Company held a stockholders' meeting at which a proposal to approve the extension of time to consummate the closing of a Business Combination Agreement to June 26, 2025 and was approved. The Company, as with all previous extensions, provided
its stockholders with the opportunity to redeem all or a portion of their
Public Shares at the time of this stockholders' meeting. The stockholders who elected to redeem 621,609 of their shares for a pro rata portion of the amount then in the Trust Account ($ 11.83 per share), which included any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The Company recorded a liability of approximately $ 7.4 million as of December 31, 2024 for the payment of its obligation for the share redemption. On January, 2, 2025, 621,609 shares of the Company's common stock were redeemed. The 893,712 shares and 1,159,276 shares of common stock remaining from the Initial Public Offering at December 31, 2024 and 2023, respectively, were classified outside of permanent equity.

 The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are recorded as charges or credits to additional paid-in capital and, if necessary, accumulated deficit. Stockholders who elect to redeem their shares do so for a pro rata portion of the amount then in the Trust Account, and also receive any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $ 100,000 of interest to pay dissolution expenses).

 As of December 31, 2024, the common stock reflected in the consolidated balance sheet are reconciled in the following table:

 Common stock subject to possible redemption – December 31, 2023

 $

 12,647,701

 Plus:

 Re-measurement of common stock to redemption value

 866,056

 Less:

 Common stock redeemed

 ( 10,435,136

)

 Common stock subject to possible redemption – December 31, 2024

 $

 3,078,621

 Warrant Liabilities

 The Company accounts for the Public Warrants and Private Placement Warrants (collectively, "Warrants", see Note 7 issued in connection with the Initial Public Offering) in accordance with ASC 815 - 40, "Derivatives and Hedging — Contracts in Entity's Own Equity". Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be classified as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability is adjusted to fair value, with the change in fair value recognized in the Company's consolidated statements of operations.

 Income Taxes

 The Company follows the asset and liability method of accounting for income taxes under ASC 740, "Income Taxes". Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 ASC 740-270 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2024 and 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 Net loss per share

 The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, "Earnings Per Share". Net loss per share of common stock is computed by dividing net loss by the weighted-average number of common stock outstanding during the period. As the Public Shares are considered to be redeemable at fair value, and a redemption at fair value does not amount to a distribution different than other shareholders, redeemable and non-redeemable shares of common stock are presented as one class of shares in calculating net loss per share of common stock. As a result, the calculated net loss per share is the same for redeemable and non-redeemable shares of common stock. At December 31, 2024 and 2023, the Company did no t have any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented.

 The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):

 For the Year Ended December 31, 2024

 For the Year Ended December 31, 2023

 Numerator:

 $

)

 $

)

 Denominator:

 Weighted average shares of Common Stock

 4,145,884

 4,427,788

 Basic and diluted net loss per share of Common Stock

 $

 ( 0.56

)

 $

 ( 0.58

)

 Concentration of credit risk

 Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporate coverage of $ 250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 Fair value of financial instruments

 The Company applies ASC 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

 The carrying amounts reflected in the balance sheet for cash, prepaid expenses and accrued offering costs approximate fair value due to their short-term nature.

 The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

 Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

 Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

 See Note 10 for additional information on assets and liabilities measured at fair value.

 Segment Reporting

 The Company complies with ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07),
which improves reportable segment disclosure requirements, primarily through
enhanced disclosures about significant segment expenses among other disclosure
requirements. The Company adopted ASU 2023-07 on January 1, 2024. The amendments
will be applied retrospectively to all prior periods presented in the financial
statements (see Note 11).

 Recently Issued Accounting Standards

 December 14, 2023, the Financial Accounting Standards Board (FASB or Board) issued Accounting Standards Update (ASU) 2023 - 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023 - 09). The ASU focuses on income tax disclosures around effective tax rates and cash income taxes paid. ASU 2023 - 09 is effective for public business entities for annual periods beginning after December 15, 2024 (generally, calendar year 2025) and effective for all other business entities one year later. Entities should adopt this guidance on a prospective basis, though retrospective application is permitted. The Company's management does not believe the adoption of ASU 2023 - 09 will have a material impact on its financial statements and disclosures.

 Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's consolidated financial statements.

 Note 3 — Initial Public Offering

 Pursuant to the Initial Public Offering, the Company sold 10,000,000 Units at a purchase price of $ 10.00 per Unit on November 23, 2020, for an aggregate purchase price of $ 100,000,000. Each Unit consists of one share of common stock, $0.0001 par value, one Right to receive one-twentieth (1/20) of one share of common stock upon the consummation of an initial business combination and one redeemable warrant ("Public Warrant"). In connection with the underwriters' exercise of the over-allotment option on November 25, 2020, the Company sold an additional 1,500,000 Units at a price of $ 10.00 per Unit. Each whole Public Warrant entitles the holder to purchase one share of common stock at an exercise price of $ 11.50 per whole share (see Note 7). Each Warrant will become exercisable on the later of 30 days after the completion of the Company's initial Business Combination or 18 months from the closing of the Initial Public Offering and will expire five years after the completion of the Company's initial Business Combination or earlier upon redemption or liquidation. However, if the Company does not complete its initial Business Combination on or prior to June 26, 2025, assuming all remaining one -month extensions are utilized, the Warrants will expire worthless at the end of such period.

 Note 4 — Private Placement

 Simultaneously with the closing of the Initial Public Offering, the Sponsor and I-Bankers purchased an aggregate of 5,425,000 Private Placement Warrants at a price of $ 1.00 per Private Placement Warrant, for an aggregate purchase price of $ 5,425,000. Each Private Placement Warrant is exercisable to purchase one share of common stock at a price of $ 11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, certain of the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.

 Note 5 — Related Party Transactions

 Founder Shares

 In June 2020, the Sponsor purchased 100 shares of common stock (the "Founder Shares") for an aggregate purchase price of $ 25,000. On July 15, 2020, the Sponsor effected a 28,750 -for- 1 forward stock split and, as a result, our initial shareholders held 2,875,000 Founder Shares as of the date of our initial public offering.

 The 2,875,000 Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters' over-allotment option was not exercised in full or in part, so that the Sponsor will own, on an as-converted basis, 20 % of the Company's issued and outstanding shares after the Initial Public Offering (assuming the Sponsor does not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters' election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture. The Founder Shares will automatically convert into shares of common stock upon consummation of a Business Combination on a one-for-one basis, subject to certain adjustments, as described in Note 6.

 The Sponsor and each holder of Founder Shares have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination or (B) subsequent to a Business Combination, (x) if the last sale price of the Company's common stock equals or exceeds $ 12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 -trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company's stockholders having the right to exchange their shares of common stock for cash, securities or other property.

 The Company had agreed with each of its four independent directors (the "Directors") subsequent to incorporation of the Company to provide them the right to each purchase 25,000 Founder Shares with a par value of $ 0.0001 of the Company from Breeze Sponsor, LLC (the "Sponsor"). The Directors each exercised their right in full on July 6, 2021 and purchased 100,000 shares ( 25,000 per each Director) of the Founder Shares from Sponsor for a total of $ 10 in the aggregate. Sponsor has agreed to transfer 15,000 Founder Shares to each of the Directors upon the closing of a Business Combination by the Company, with such shares currently beneficially owned by Sponsor.

 The Sponsor and I-Bankers purchased an aggregate of 5,425,000
Private Placement Warrants at a price of $ 1.00 per warrant in a private
placement that occurred simultaneously with the closing of Breeze's IPO. Of
such amount, 4,325,000 Private Placement Warrants were purchased by the Sponsor,
and an aggregate of 1,100,000 Private Placement Warrants were purchased by I-Bankers
and Northland. The Private Placement Warrants (including the common stock
issuable upon exercise of the private placement warrants) may not, subject to certain
limited exceptions, be transferred, assigned or sold by the holder until 30
days after the completion of Breeze's initial business combination.

 If any of Breeze's officers or directors becomes aware
of a business combination opportunity that falls within the line of business of
any entity to which he or she has then-current fiduciary or contractual obligations,
he or she may be required to present such business combination opportunity to
such entity prior to presenting such business combination opportunity to us.
Breeze's executive officers and directors currently have certain relevant
fiduciary duties or contractual obligations that may take priority over their
duties to us.

 The Sponsor, executive officers and directors, or any of
their respective affiliates, will be reimbursed for any out-of-pocket expenses
incurred in connection with activities on Breeze's behalf such as identifying
potential target businesses and performing due diligence on suitable business
combinations. Breeze's audit committee will review on a quarterly basis all
payments that were made to the Sponsor, officers, directors or Breeze's or
their affiliates and will determine which expenses and the amount of expenses
that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket
expenses incurred by such persons in connection with activities on Breeze's behalf.

 Administrative Support Agreement

 The Company entered into an agreement whereby, commencing on November 23, 2020 through the earlier of the Company's consummation of a Business Combination and its liquidation, the Company will pay an affiliate of the Sponsor a total of $5,000 per month for office space, utilities and secretarial and administrative support services. For each of the years ended December 31, 2024 and 2023, the Company incurred $ 60,000 in fees for these services, of which such amounts are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.

 Related Party Loans

 In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors may, but are not obligated to, loan the Company funds as may be required. Such loans would be evidenced by promissory notes. The notes would be repaid upon consummation of a Business Combination, without interest. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the loans, but no proceeds held in the Trust Account would be used to repay the loans.

 On November 19, 2021 (as amended), the Sponsor loaned Breeze an aggregate of $ 1,150,000 pursuant
 to an unsecured promissory note to extend the date by which Breeze has
to consummate a business combination from November 25, 2021 to February 25, 2022. This unsecured promissory note is non-interest bearing and payable
 on the earlier of (i) the
consummation of an initial Business Combination, or (ii) June 26, 2025. On February 18, 2022 (as amended), the Sponsor loaned the
Company an aggregate of $ 1,150,000 pursuant to an
unsecured promissory note to extend the date by which the Company had to
consummate a business combination from February 25, 2022 to May 25, 2022. This
unsecured promissory note is non-interest bearing and payable on the earlier of
(i) the consummation of an initial Business Combination, or (ii) June 26,
2025.

 On February 1, 2022 (as amended), the Company signed a Promissory Note for working capital with Sponsor, with a Maturity Date of March 26, 2023, for a total of up to $ 1,500,000. On October 1, 2022, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 4,000,000. On April 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of September 26, 2023 for a total of up to $ 5,000,000. On October 1, 2023, the Company signed an Amended Promissory Note with Sponsor, with a Maturity Date of June 26, 2024 for a total of up to $ 6,000,000. On March 1, 2024, the Company signed an Amended
Promissory Note with Sponsor, with a Maturity Date of June
26, 2024 for a total of up to $ 7,000,000.
On July 1, 2024, the Company signed an Amended Promissory Note with Sponsor,
with a Maturity Date of December 26, 2024 for a
total of up to $ 7,500,000. On December 26, 2024,
the Company signed an Amended Promissory Note with Sponsor, with a Maturity
Date of June 26, 2025 for a total of up to $ 7,500,000. As of December 31, 2024, the amount outstanding under this Promissory Note was $ 5,997,804 for direct working capital, and $ 1,083,097 for monthly SPAC extension funds for the month of September 2022 through December 2024 for a total of $ 7,080,901 from Sponsor. The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of an initial Business Combination, or (ii) June 26, 2024. The
Company additionally owes Sponsor $ 202,556 for expenses paid by Sponsor on
behalf of the Company. The total amount owed Sponsor as of December 31, 2024
is $ 9,583,457.
 The Company had 12 months from the closing of the Initial Public Offering to consummate its initial Business Combination. However, by resolution of its board, requested by the Sponsor, the Company extended the period of time to consummate a Business Combination two times, each by an additional three months (for a total of up to 18 months to complete a Business Combination). The Sponsor deposited additional funds into the Trust Account in order to extend the time available for the Company to consummate its initial Business Combination. The Sponsor deposited into the Trust Account for each three-month extension, $ 1,150,000 ($ 0.10 per share) on or prior to the date of the applicable deadline.

 On September 13, 2022, the Company held its annual stockholders' meeting and approved the Company to extend the date of September 26, 2022, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as March 26, 2023). For each one-month extension on September 26, October 26, November 26, December 26, 2022, January 25, 2023 and February 23, 2023 $ 59,157 ($ 0.035 per share) per extension, up to an aggregate of $ 354,942, or approximately $ 0.21 per share. The Company held a meeting of its stockholders on March 22, 2023 where the Company's stockholders approved the Company to extend the date of March 26, 2023, up to six ( 6) times for an additional one ( 1) month each time (ultimately until as late as September 26, 2023). For each one-month extension through September 26, 2023, the Sponsor deposited into the Trust Account $ 41,317 ($ 0.035 per share) on March 30, 2023, April 25, 2023, May 25, 2023, June 26, 2023, August 2, 2023 and August 28, 2023.

 The Company held a meeting of its stockholders on September 22, 2023 where the Company's stockholders approved (i) a proposal to amend the Company's A&R COI to authorize the Company to extend the date of September 26, 2023, up to nine ( 9) times for an additional one ( 1) month each time (ultimately until as late as June 26, 2024), and (ii) a proposal to amend the Trust Agreement to authorize the Extension and its implementation by the Company. For each one-mo n th extension the Company deposited ($ 0.035 per share) into the Trust Account. On September 27, 2023 Breeze executed the thirteenth one - month extension through October 26, 2023. On October 24, 2023, November 26, 2023, December 27, 2023, January 26, 2024, February 27, 2024, March 26, 2024, May 7, 2024 and June 3, 2024 Breeze executed the fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty-first one -month extensions through June 26, 2024.

 The Company held a meeting of its stockholders
on June 21, 2024 where the Company's stockholders approved (i) a proposal
to amend the Company's A&R COI to authorize the Company to extend the date
of June 26, 2024, up to six (6) times for an additional one (1) month
each time (ultimately until as late as December 26, 2024), and (ii) a proposal
to amend the Trust Agreement to authorize the Extension and its implementation
by the Company. For each one-month extension the Company deposited ($ 0.035 per share) into the Trust Account. On June 26, 2024 and August 1, 2024, Breeze
executed the twenty-second and twenty-third extensions, and on November 22,
2024, Breeze executed (including accrued interest) the twenty-fourth,
twenty-fifth and twenty-sixth one-month extensions for the period from
September 26, 2024 through November 26, 2024. On December 31, 2024 the
company executed the twenty-seventh and twenty-eighth one-month extension for
the period from November 26, 2024 to January 26, 2025.

 On December 23, 2024, the Company held a stockholders' meeting
at which a proposal to approve the extension of time to consummate the closing
of a Business Combination Agreement to June 26, 2025 was approved. For each one-month extension the Company will deposit ($ 0.035 per share) into the Trust Account.

 Extension payments are funded in the form of a loan from Sponsor. The loans are non-interest bearing and payable upon the consummation of the Company's initial Business Combination. If the Company completes an initial Business Combination, it will repay such loaned amounts out of the proceeds of the Trust Account released to it. If the Company does not complete a Business Combination, it will not repay such loans. Furthermore, the letter agreement with the Company's initial stockholders contains a provision pursuant to which the Sponsor has agreed to waive its right to be repaid for such loans out of the funds held in the Trust Account in the event that the Company does not complete a Business Combination.

 Representative and Consultant Shares

 Pursuant to the underwriting agreement (the "Underwriting Agreement") between the Company and I-Bankers Securities (the "Representative"), on November 23, 2020, the Company issued to the Representative and its designee 250,000 shares of common stock and separately agreed to issue the Company's Consultant 15,000 shares of common stock for nominal consideration in a private placement intended to be exempt from registration under Section 4 (a)( 2) of the Act. In August 2021, the Company issued to the Consultant such Consultant Shares. The Company accounted for the Representative
Shares and Consultant Shares as a deferred offering cost of the Initial Public
Offering. Accordingly, the offering cost was allocated to the separable
financial instruments issued in the Initial Public Offering based on a relative
fair value basis, compared to total proceeds received. Offering costs allocated
to the Warrants were expensed immediately in the statement of operations, while
offering costs allocated to the redeemable Public Shares were deferred and subsequently
charged to temporary stockholders' equity following the completion of the
Initial Public Offering.

 In 2020, the Company estimated and recorded the fair value of the Representative Shares and Consultant Shares to be $1,322,350 based upon the price of the common stock issued ($4.99 per share) to the Representative and Consultant. The holders of the Representative Shares and Consultant Shares have agreed not to transfer, assign or sell any such shares until the later of (i) 30 days after the completion of a Business Combination and 180 days pursuant to FINRA Conduct Rule 5110(e)(1) following the effective date of the Registration Statement to anyone other than (i) the Representative or an underwriter or selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such underwriter or selected dealer. Additionally, pursuant to FINRA Conduct Rule 5110(e), the Representative Shares and Consultant Shares will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the Registration Statement.

 In addition, the holders of Representative Shares and Consultant Shares have agreed (i) to waive their redemption rights with respect to such shares in connection with the completion of a Business Combination and (ii) to waive their rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete a Business Combination within the time specified in the certificate of incorporation.

 Note 6 — Commitments

 Registration and Stockholder Rights

 Pursuant to a registration rights and stockholder agreement entered into on November 23, 2020, the holders of the Founder Shares and Private Placement Warrants (and any shares of common stock issuable upon the exercise of the Private Placement Warrants and upon conversion of the Founder Shares) will be entitled to registration and stockholder rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company's common stock). The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain "piggy-back" registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. In the case of the private placement warrants and representative shares issued to I-Bankers Securities, the demand registration rights provided will not be exercisable for longer than five years from the effective date of the registration statement in compliance with FINRA Rule 5110 (g)( 8)(C) and the piggyback registration right provided will not be exercisable for longer than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110 (g)( 8)(D). The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 Business Combination Marketing Agreement

 The Company has engaged I-Bankers on November 23, 2020, as an advisor in connection with a Business Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target business' attributes, introduce the Company to potential investors that are interested in purchasing the Company's securities in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay I-Bankers a cash fee for such services upon the consummation of a Business Combination in an amount equal to 2.75 % of the gross proceeds of Initial Public Offering, or $ 3,162,500. As of December 31, 2024, there were no unbilled
or accrued amounts for services that had been performed pursuant to this
agreement.

 Strategic Legal Advisory Services

 On March 24, 2021, as
supplemented on August 30, 2022, the Company signed a Legal Services Engagement
Letter with Woolery & Co. ("Woolery") for services in connection
with completing a business combination or a similar transaction. Services include, but are not limited to, strategic legal advice on a
business combination and associated corporate matters, introductions to
financial institutions to facilitate business combination financing
requirements, domestic and international transaction structuring, and
preparation of any required Nasdaq listing application. As of December 31, 2024, there were no unbilled
or accrued amounts for services that had been performed pursuant to this
agreement. Pursuant to the engagement letter, Breeze paid a non-refundable retainer of $ 100,00, and upon the completion of a business
combination or similar transaction, Breeze is obligated to pay Woolery a fee of
$ 2.0 million, however, Sponsor has agreed to assume $ 1.2 million of the obligation, and a discretionary performance fee, if warranted, and mutually
and reasonably agreed upon by Breeze and Woolery. At the closing of a business combination, Breeze will pay Woolery the balance of $ 800,000.

 Merger Proxy/Business Combination Rate Agreement

 On October 30, 2024, the Company signed a Merger Proxy/Business Combination Rate Agreement with Edgar Agents LLC, for SEC document preparation, printing and filing for the merger with YD Biopharma. As of December 31, 2024, there were no unbilled or pending amounts for services that had been performed through December 31, 2024, pursuant to this
agreement. The agreement includes an obligation to pay a Transaction Success Fee of $ 50,000 upon successful completion and filing of the documents with the SEC.

 Proxy Solicitation Services Agreement

 On October 17, 2024, the Company signed a Proxy Solicitation Services Agreement with D.F. King & Co., Inc.("D.F. King"), for proxy solicitation services associated with the business combination with YD Biopharma. As of December 31, 2024, D.F. King has not provided
the Company with any services pursuant to this agreement. The agreement includes an obligation to pay a Service Fee of $ 25,000 and a discretionary fee, if warranted, at the sole discretion of Breeze, based upon the campaign and D.F. King's performance.

 Public Relations Agreement

 On February 29, 2024, the Company signed a Public
Relations Agreement with Gateway Group, Inc. ("Gateway"), for public relations services for the
business combination with YD Biopharma. As of December 31, 2024, Gateway has not provided the
Company with any services pursuant to this agreement. The agreement includes an obligation to pay
a Transaction Success Fee of $ 100,000 upon the successful completion of the
business combination with YD Biopharma.

 Note 7 — Warrants

 As of December 31, 2024 and 2023, there were 11,500,000 Public Warrants and 5,425,000 Private Placement Warrants outstanding. The Company classifies the outstanding Public Warrants and Private Placement Warrants as warrant liabilities on the balance sheet in accordance with the guidance contained in ASC 815 - 40. Under the guidance in ASC 815-40, certain warrants do
not meet the criteria for equity treatment. These warrants include a clause
whereby the warrant holder may be entitled to receive a net cash settlement
upon the acceptance by the holders of the Company's common stock of a tender, exchange
or redemption offer. Upon such a qualifying tender cash offer (an event which
could be outside the control of the Company), all Warrant holders would be
entitled to cash. This factor precludes
the Company from applying equity accounting as the warrant holder could receive
a net cash settlement value that is greater than a holder of the Company's
common stock. Accordingly, the Company has concluded that liability accounting
is required. As such, these warrants are recorded at fair value as of each
reporting date with the change in fair value reported within other income in
the accompanying consolidated statements of operations as "Change in fair value
of warrant liability" until the warrants are exercised, expired or other facts
and circumstances lead the warrant liability to be reclassified to
stockholders' equity. For 2023 and certain periods in 2024, the Company utilized a Modified Black Scholes Model to
estimate the fair values of the warrants, which incorporates significant inputs
that are not observable in the market, and thus represents a Level 3
measurement as defined in ASC 820. The unobservable inputs utilized for
measuring the fair value of the contingent consideration reflect management's
own assumptions about the assumptions that market participants would use in
valuing the contingent consideration. The Company determined the fair value by
using the below key inputs to the Modified Black Scholes Model.

 Public Warrants may only be exercised for a whole number of shares. No fractional shares are issued upon exercise of the Public Warrants. The Public Warrants are exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.

 The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant will be exercisable for cash, and we will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within a specified period following the consummation of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3 (a)( 9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

 The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of its initial business combination, we will use our reasonable best efforts to file, and within 60 business days after the closing of its initial business combination, to have declared effective, a registration statement relating to the shares of common stock issuable upon exercise of the warrants and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Company's common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a "covered security" under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of public warrants who exercise their warrants to do so on a "cashless basis" in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its best efforts to qualify the shares under applicable blue sky laws to the extent an exemption is not available.

 Once the warrants become exercisable, the Company may call the warrants for redemption:

 •

 in whole and not in part;

 •

 at a price of $ 0.01 per warrant;

 •

 upon not less than 30 days' prior written notice of redemption (the " 30 -day redemption period") to each warrant holder; and

 •

 if, and only if, the reported last sale price of the common stock equals or exceeds $ 18.00 per share for any 20 trading days within a 30 -trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders.

 The Company may not redeem the warrants when a holder may not exercise such warrants.

 In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $ 9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company's board of directors and, in the case of any such issuance to our initial stockholders or their affiliates, without taking into account any founder shares held by its initial stockholders or such affiliates, as applicable, prior to such issuance), (the "Newly Issued Price") (y) the aggregate gross proceeds from such issuances represent more than 60 % of the total equity proceeds, and interest thereon, available for the funding of its initial business combination on the date of the consummation of its initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company's common stock during the 20 trading day period starting on the trading day after the day on which the Company consummates its initial business combination (such price, the "Market Value") is below $ 9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115 % of the higher of the Market Value and the Newly Issued Price, and the $ 18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180 % of the higher of the Market Value and the Newly Issued Price.

 The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

 No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number of shares of common stock to be issued to the warrant holder.

 The Private Placement Warrants (including the common stock issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will be non-redeemable so long as they are held by the original holders or their permitted transferees. If the Private Placement Warrants are held by someone other than the original holders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Warrants included in the Units being sold in the Initial Public Offering. Otherwise, the Private Placement Warrants have terms and provisions that are substantially identical to those of the Warrants being sold as part of the Units in the Initial Public Offering.

 The Sponsor and I-Bankers purchased from the Company an aggregate of 5,425,000 Warrants at a price of $ 1.00 per Warrant (a purchase price of $ 5,425,000), in a private placement that occurred simultaneously with the completion of the Initial Public Offering (the "Private Placement Warrants"). Each Private Placement Warrant entitles the holder to purchase one share of common stock at $ 11.50. The purchase price of the Private Placement Warrants were added to the proceeds from the Initial Public Offering to be held in the Trust Account pending completion of the Company's initial Business Combination.

 If the Company does not complete a Business Combination, then the proceeds will be part of the liquidating distributions to the public stockholders and the Warrants issued to the Sponsor and I-Bankers will expire worthless.

 At December 31, 2023, the fair value of the Company's Private Placement
Warrants was based on a Modified Black-Scholes model, and the Public
Warrants utilized the trading price of the Company's Public Warrants. At
December 31, 2024, the fair value of both the Company's Private Placement
Warrants and Public Warrants utilized the Company's trading price of the Public
Warrants. As of December 31, 2024, the Company determined that utilizing the
Modified Black-Scholes model to value the Private Placement Warrants deviated
too far from what would be expected if the Private Placement Warrants were
publicly traded as the terms of the Public Warrants and Private Placement
Warrants are similar.
 The Public Warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value. The Company recognized a loss in connection with changes in the fair value of warrant liabilities of $ 677,000 and $ 1,015,500 for the years ended December 31, 2024 and 2023, respectively.

 Note 8 — Stockholders' Deficit

 Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $ 0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company's board of directors. Pursuant to the Company's A&R COI, our board of directors has the express authority to the full extent provided by law to adopt any such resolution or resolutions with respect to the unissued shares of preferred stock, if any, without stockholder approval. At December 31, 2024 and 2023, there were no shares of preferred stock issued or outstanding.

 Common Stock — The Company is authorized to issue 100,000,000 shares of common stock with a par value of $ 0.0001 per share. Holders of common stock are entitled to one vote for each share. Holders of shares of our common stock are entitled to one vote per share owned on each matter properly submitted to the stockholders on which the holders of the common stock are entitled to vote. The holders of shares of our common stock shall be entitled to receive dividends and other distributions (payable in cash, property or capital stock of the Company) when, as and if declared thereon by our board of directors from time to time out of any assets for funds of the Company legally available therefor and shall share equally on a per share basis in such dividends and distributions. At December 31, 2024 and 2023, there were 3,140,000 shares of common stock issued and outstanding, respectively, excluding 893,712 and 1,159,276 shares of common stock subject to possible redemption.

 Rights — Except in cases where the Company is not the surviving company in a Business Combination, each holder of a Right will automatically receive one -twentieth ( 1/20) of a share of common stock upon consummation of the Business Combination, even if the holder of a Right converted all shares held by him, her or it in connection with the Business Combination or an amendment to the Company's certificate of incorporation with respect to its pre-business combination activities. In the event that the Company will not be the surviving company upon completion of the Business Combination, each holder of a Right will be required to affirmatively convert his, her or its Rights in order to receive the one -twentieth ( 1/20) of a share of common stock underlying each Right upon consummation of the Business Combination. No additional consideration will be required to be paid by a holder of Rights in order to receive his, her or its additional share of common stock upon consummation of the Business Combination. The shares issuable upon exchange of the Rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of Rights to receive the same per share consideration the holders of shares of common stock will receive in the transaction on an as-converted into common stock basis.

 The Company will not issue fractional shares in connection with an exchange of Rights. As a result, the holders of the Rights must hold Rights in multiples of 20 in order to receive shares for all of the holders' Rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of Rights will not receive any of such funds with respect to their Rights, nor will they receive any distribution from the Company's assets held outside of the Trust Account with respect to such Rights, and the Rights will expire worthless. Additionally, in no event will the Company be required to net cash settle the Rights. Accordingly, the Rights may expire worthless.

 Note 9 — Income Taxes

 The Company's net deferred tax assets are as follows:

 2024

 2023

 Deferred tax assets:

 Net operating loss carryforwards

 $

 495,712

 $

 71,824

 Capitalized start-up costs

 1,148,526

 777,461

 Total deferred tax assets

 1,644,238

 849,285

 Valuation allowance

 ( 1,644,238

)

 ( 849,285

)

 Deferred tax assets, net of valuation allowance

 $

 —

 $

 —

 The income tax provisions for the year ended December 31, 2024 and 2023 consists of the following:

 For the Year Ended December 31, 2024

 For the Year Ended December 31, 2023

 Federal

 Current

 $

 —

 $

 18,169

 Deferred

 ( 794,953

)

 ( 226,958

)

 State

 Current

 —

 —

 Deferred

 —

 —

 Change in valuation allowance

 794,953

 226,958

 Income tax provision

 $

 —

 $

 18,169

 As of December 31, 2024, and 2023, the Company had available a U.S. federal operating loss carry forward of approximately $ 2,360,533 and $ 342,018, respectively, that may be carried forward indefinitely.

 In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. As of December 31, 2024 and 2023, the valuation allowance was $ 1,644,238 and $ 849,285, respectively.

 A reconciliation of the U.S. federal income tax rate to the Company's effective tax rate at December 31, 2024 and 2023 is as follows:

 2024

 2023

 Statutory U.S. Federal income tax rate

 21.00

 %

 21.00

 %

 Change in fair market value of warrant liabilities

 ( 6.17)

 %

 ( 8.43)

 %

 Previous tax year adjustment

 —

 %

 4.19

 %

 Non-deductible transaction costs

 19.67

 %

 ( 8.26)

 %

 Change in valuation allowance

 ( 34.49)

 %

 ( 8.97)

 %

 Other

 ( 0.01)

 %

 ( 0.25)

 %

 Income tax provision

 0.00

 %

 ( 0.72)

 %

 The Company's effective tax rates for the periods presented differ from the expected (statutory) rates due to changes in fair value of warrants, non-deductible transaction costs and the change in the valuation allowance on deferred tax assets. The Company files income tax returns in the U.S. federal and Texas jurisdictions, both of which remain open and subject to examination.

 Note 10 — Fair Value Measurements

 The following table presents information about the Company's financial assets that are measured at fair value on a recurring basis at December 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 Description

 Level 1

 Level 2

 Level 3

 Liabilities

 Warrant liability – Public Warrants

 $

 1,955,000

 $

 —

 $

 —

 Warrant liability – Private Placement Warrants

 $

 —

 $

 922,250

 $

 —

 The following table presents information about the Company's financial assets that are measured at fair value on a recurring basis at December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 Description

 Level 1

 Level 2

 Level 3

 Liabilities

 Warrant liability - Public Warrants

 $

 1,495,000

 $

 —

 $

 —

 Warrant liability - Private Placement Warrants

 $

 —

 $

 —

 $

 705,250

 Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. The value of the Public Warrants was transferred from Level 1 to Level 3 during the three months ended June 30, 2024, and transferred from Level 3 to Level 1 during the three months ended September 30, 2024, and there were no transfers during the year ended December 31, 2023. The value of the Private Warrants was transferred from Level 3 to Level 2 during the three months ended December 31, 2024, and there were no transfers during the year ended December 31, 2023.

 The following table presents information about the Company's financial assets that were transferred from Level 3 to Level 1:

 Level 3 roll forward of Warrant Liability - Public Warrants

 For The Year Ended December 31, 2024

 Beginning balance

 $

 —

 Transfer in

 3,795,000

 Transfer out

 ( 2,415,000

)

 Unrealized gain

 ( 1,380,000

)

 Ending balance

 $

 —

 Amount of unrealized gain for the period included in income relating to assets held at the end of the reporting period

 $

 ( 1,380,000

)

 The Company utilized a back-solve lattice model for the initial valuation of the Public Warrants. The subsequent measurement of the Public Warrants as of December 31, 2024 and 2023 is classified as Level 1 due to the use of an observable market quote in an active market under the ticker BRZHW and BREZW, respectively. The quoted price of the Public Warrants was $ 0.17 and $ 0.13 per warrant as of December 31, 2024 and 2023, respectively.

 The Company utilized a Modified Black-Scholes model to value the Private Placement Warrants as of December 31, 2023, with changes in fair value recognized in the consolidated statement of operations. The estimated fair value of the Private Placement warrant liability is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The risk-free interest rate is based on the U.S. Treasury zero -coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The probability of completing the business combination is derived by taking a sample of other special purpose acquisition companies and calculating the implied probability of completion for each company in the sample set. The average and 1 st and 3 rd quartiles of the implied probability of completion then formulates the basis for the probability utilized for the Company in the models. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.

 As of December 31, 2024, the Company determined that utilizing the Modified Black-Scholes model to value the Private Placement Warrants deviated too far from what would be expected if the Private Placement Warrants were publicly traded as the terms of the Public Warrants and Private Placement Warrants are similar. Consequently, the Company used the quoted price of the Public Warrants of $ 0.17 per warrant as of December 31, 2024 as a proxy for the fair value of the Private Placement Warrant. Pursuant to ASC 820, since the fair value is being based on the market price of the Public Warrants (which are similar but not identical to the Private Placement Warrants), this is considered a Level 2 input as it is observable, either directly or indirectly, for the Public Warrants but is not a quoted price in an active market for identical items.

 The following table presents information about the Company's financial assets that were transferred from Level 3 to Level 2:

 Level 3 roll forward of Warrant Liability - Private Warrants

 For The Year Ended December 31, 2024

 Beginning balance

 $

 705,250

 Transfer in

 —

 Transfer out

 ( 922,250

)

 Unrealized loss

 217,000

 Ending balance

 $

 —

 Amount of unrealized loss for the period included in income relating to assets held at the end of the reporting period

 $

 217,000

 The aforementioned warrant liabilities are not subject to qualified hedge accounting.

 The following table provides the significant inputs to the Modified Black-Scholes model for the fair value of the Private Placement Warrants:

 As of December 31, 2023

 Stock price

 $

 11.03

 Strike price

 $

 11.50

 Probability of completing a Business Combination

 6.50

 %

 Dividend yield

 —

 Term (in years)

 5.25

 Volatility

 11.30

 %

 Risk-free rate

 3.84

 %

 Fair value of warrants

 $

 0.13

 The following table presents the changes in the fair value of warrant liabilities:

 Private

 Placement

 Public

 Warrant

 Liabilities

 Fair value as of December 31, 2023

 $

 705,250

 $

 1,495,000

 $

 2,200,250

 Change in valuation inputs or other assumptions

 217,000

 460,000

 677,000

 Fair value as of December 31, 2024

 $

 922,250

 $

 1,955,000

 $

 2,877,250

 Note 11 — Segment Information

 ASC Topic 280, "Segment Reporting," establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company's chief operating decision maker ("CODM"), or group, in deciding how to allocate resources and assess performance.

 The Company is a blank check company formed for the purpose of effecting a Business Combination. As of December 31, 2024, the Company had not commenced any operations. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash from the proceeds derived from the Initial Public Offering, and non-operating income or expense from the changes in the fair value of warrant liability.

 The Company's CODM has been identified as the Chief Executive Officer, who reviews the consolidated operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 When evaluating the Company's primary measure of performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, which include the following:

 For the Year Ended December 31, 2024

 For the Year Ended December 31, 2023

 Operating and formation costs

 $

 2,225,820

 $

 2,070,143

 Loss from operations

 ( 2,225,820

)

 ( 2,070,143

)

 Total other expenses, net

 ( 78,818

)

 ( 460,799

)

 Loss before income taxes

 $

)

 $

 ( 2,530,942

)

 $

)

 $

)

 Operating and formation costs are reviewed and
monitored by the CODM to manage and forecast cash to ensure enough capital is
available to complete a business combination within the business combination
period. The CODM also reviews operating and formation costs to manage, maintain
and enforce all contractual agreements to ensure costs are aligned with all
agreements and budget.

 Note 12 — Subsequent Events

 The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, the Company did not, except as described in these consolidated financial statements and below, identify any other subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

 On March 3, 2025, YD Bio Limited entered into Subscription Agreements with certain investors for the private placement of an aggregate of 1,250,000 shares of YD Bio Limited's ordinary shares, par value $ 0.0001 per share, at a purchase price of $ 8.00 per share, for an aggregate purchase price of $ 9.0 million. This PIPE financing is contingent upon the successful completion of the Merger Agreement at which time the shares will be issued. The funds raised from this PIPE financing will be used to support the business combination and related transaction costs.